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Abstract 
 
Macrophages play a key role in maintaining the balance and efficiency of the immune 
response. TH2 cytokines IL-4 & IL-13, through shared IL-4Rα signalling, trigger a state 
of alternative activation in macrophages and also drive their proliferation. Alternatively 
activated macrophages (AAMΦ) are involved in the control of helminth infections and 
have also been implicated in tissue repair. However, TH2 weighted imbalance can result 
in inflammatory disorders such as asthma and fibrosis. Hence, macrophage responses 
must be tightly regulated. MicroRNAs, a short (~22nt) class of non-coding RNA, are one 
such immunomodulatory feedback mechanism that can regulate gene expression by 
targeting the 3’ UTR of mRNA resulting in destabilisation of the mRNA and/or inhibition 
of translation. With their ability for vast gene regulation, it was hypothesised that 
microRNAs could play a crucial role in the regulation of AAMΦ by targeting genes and 
pathways critical for their induction, maintenance & proliferation.  
Previously generated microarrays in the lab have allowed us to identify microRNAs 
differentially expressed in AAMΦ. In an effort to determine which microRNAs are 
genuinely associated with alternative activation, the first part of this project examined the 
expression profiles of ten shortlisted microRNA candidates under varying conditions of 
alternative activation, ranging from a reductionist in vitro IL-4/13 stimulation of 
macrophage cell lines to a complex in vivo TH2 mouse model of filarial infection. 
Profiling of microRNA expression under these conditions revealed that the expression of 
two IL-4Rα dependent microRNAs, namely miR-199b-5p and miR-378, along with 
another microRNA, miR-146, was highly regulated and consistently associated with 
alternative activation. The subsequent chapters of this thesis investigated the contribution 
of these microRNAs in regulating AAMΦ responses.  
Interestingly, we identified miR-199b-5p as being highly expressed in AAMΦ in vivo but 
not in vitro. Pathway analysis identified insulin signalling and other proliferative 
pathways such as PI3K/AKT as being highly targeted by miR-199b-5p. Overexpression 
of miR-199b-5p in RAW 264.7 cells resulted in a reduction in the rate of proliferation and 
a change in the levels of Insulin Receptor Substrate -1 (IRS-1), suggesting that miR-199b-
5p might regulate macrophage proliferation via insulin signalling. An alteration in the 
 
  xiv 
expression of YM-1 and RELM-α, markers characteristic of alternative activation, was 
also observed. MiR-199b-5p was successfully delivered to the lung and overexpressed in 
alternatively activated alveolar macrophages. No effect was observed on IL-4 induced 
proliferation, potentially due to the lack of significant insulin receptor and IRS-1 
expression in alveolar macrophages. However, secreted levels of YM-1, but not RELM-α, 
were significantly reduced.  
MiR-378 is a microRNA that has previously been shown to be associated with AAMΦ 
through targeting of AKT-1; however, a direct influence of this microRNA on the 
regulation of this phenotype is yet to be determined. In this thesis, we have provided 
direct evidence of the impact of miR-378 deficiency on the regulation of AAMΦ and their 
responses using miR-378 KO mice. The ability of macrophages isolated from WT and 
KO animals to alternatively activate was studied in various systems both in vitro and in 
vivo. The influence of miR-378 deficiency on IL-4 induced proliferation was also 
addressed in vivo. Although the lack of miR-378 had no significant effect on IL-4 driven 
macrophage proliferation, results from this chapter support a role for miR-378 in the 
regulation of alternative activation through regulation of YM-1 and RELM-α expression. 
Lastly, to determine whether this regulation by miR-378 had functional consequences, we 
also utilised Litomosoides sigmodontis, a murine model of filarial infection. Due to 
experimental limitations, a concrete role for miR-378 in the context of infection could not 
be established.  
The final chapter of this thesis focuses on examining the role of miR-146 in the regulation 
of AAMΦ. MiR-146a is a highly studied microRNA that has previously been linked 
strongly to TH1 immune responses, especially classical activation of macrophages. 
However, a role for this microRNA in regulating AAMΦ is yet to be determined. 
Expression levels of miR-146a and miR-146b, the two isoforms of miR-146, were found 
to be differentially regulated upon alternative activation, with a decrease in miR-146a and 
increase in miR-146b expression in response to IL-4 both in vitro and in vivo. Based on 
this difference in expression and their known functions in suppressing excessive 
proinflammatory responses, it was hypothesised that miR-146a/b serve to regulate 
proinflammatory molecules (and signals) in a fine balance to allow efficient alternative 
activation to occur. However, the high sequence similarity between these two isoforms 
proved to be a hindrance to test this hypothesis in terms of shared targets. Therefore, the 
 
  xv 
latter half of this chapter was devoted to the generation and optimisation of a stable cell 
line for the identification of microRNA targets using CLASH (cross-linking, ligation and 
sequencing of hybrids).  
In summary, the results from this thesis provide an important foundation for further 
studies of the functional role of microRNAs in the regulation of AAMΦ. Firstly, it 
characterises the expression profiles of ten different microRNAs differentially expressed 
during alternative activation. Secondly, for the first time, it identifies a role for miR-199b-
5p in the regulation of macrophage proliferation and activation. Thirdly, this thesis has 
provided direct evidence for the effect of miR-378 deficiency on AAMΦ responses. 
Lastly, it identifies and demonstrates the robust differential expression of two separate 
isoforms of the same microRNA (miR-146) under varying conditions of alternative 
activation, whose functional properties as regulators of the AAMΦ phenotype await 
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Chapter 1: Introduction 
 
1.1 The immune system and the T helper cell paradigm 
The immune system has evolved to protect the host against a plethora of pathogens 
that range from microscopic organisms such as bacteria and viruses to far larger 
multicellular parasites such as helminths. Different pathogens utilise distinct methods 
of growth, survival and immune evasion resulting in insult and injury to the host. 
This necessitates the employment and activation of diverse effector mechanisms by 
the host to mount a response effective enough to contain and/or eliminate the foreign 
pathogen, whilst at the same time maintaining tolerance to self and limiting collateral 
damage (Parkin and Cohen, 2001, Graham et al., 2005a). The immune system has 
been classified into the innate and adaptive immune systems. The innate immune 
system initially detects foreign invasion through the recognition of common 
components/molecular patterns of pathogens and provides the first line of defence in 
a relatively non-specific manner. However, innate immunity is not always sufficient 
to recognise and eliminate all infectious agents. To deal with organisms that survive 
and/or escape this initial response, the adaptive immune system comprising B and T 
lymphocytes has evolved to provide a more versatile means of defence involving 
pathogen recognition in an antigen specific manner, but is still reliant on innate 
effectors (Dempsey et al., 2003, Paul, 2011). 
T lymphocytes play a central role in immunostimulation and immunomodulation. T 
helper (TH) cells, which express the cell surface marker CD4, orchestrate the 
employment of an appropriate immune response by differentiating into discrete 
subsets and secreting distinct cytokines. Based upon their cytokine profiles, these 
CD4+ helper T cells were initially classified into one of two subsets by Mosmann and 
Coffman (Mosmann et al., 1986). Subsequently, transcriptional regulators were 
identified that verified this subset distinction. T helper type 1 (TH1) cells are 
characterised by the transcription factor T-bet and expression of Interferon-γ (IFN- γ) 
and Tumour Necrosis Factors (TNFs) and considered to be mediators of immunity 
against intracellular pathogens. In contrast, TH2 cells are distinguished by their 
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expression of the transcription factor GATA-3 and production of the cytokines IL-4, 
IL-5 and IL-13 (Romagnani, 1997, Kidd, 2003, Kaiko et al., 2008) among others. 
This original TH1/ TH2 paradigm has now developed into the TH1/ TH2/ TH17 
paradigm with the addition of the third TH17 subset that requires the transcription 
factors ROR and STAT3 and an extensive network of cytokines such as the 
differentiation factors TGF-β, IL-6 and IL-21, and IL-23 for growth and stability 
(Steinman, 2007, Korn et al., 2009, Peck and Mellins, 2010).  TH17 cells mediate 
host defensive mechanisms to various infections, especially extracellular bacterial 
infections, and are characterised by their preferential production of IL-17, IL-21 and 
IL-22 (Ouyang et al., 2008, Korn et al., 2009). TH17 cells are also involved in the 
pathogenesis of many autoimmune diseases (Waite and Skokos, 2012, Noack and 
Miossec, 2014, Yang et al., 2014). Another distinct lineage of CD4+ T cells whose 
differentiation is also induced by TGF-β are T regulatory (Treg) cells, identified 
according to their high expression of CD25 and the transcription factor Foxp3, and 
their ability to negatively regulate excessive and aberrant immune responses (Vignali 
et al., 2008, Saito et al., 2010, Josefowicz et al., 2012).  
In addition to recognition mechanisms that have evolved to overcome the constraints 
faced by the innate immune system, adaptive immunity also provides increased 
protection against subsequent reinfection with a pathogen previously encountered by 
the host. However, the cells of the innate immune system play a crucial role in the 
initiation and subsequent direction of these adaptive immune responses, besides 
participating in the removal of pathogens targeted by the adaptive immune response. 
Mounting of an effective immune response thus depends on careful interplay 
between the innate and adaptive immune arms.  
 
1.2 Macrophages 
Macrophages sit at the interface of innate and adaptive immunity and are crucial for 
maintaining the balance and efficiency of the immune response. Macrophages are 
mononuclear phagocytes essential for the maintenance of homeostasis and are also 
involved in both the initiation and resolution of inflammatory responses. 
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Macrophages are present in essentially all tissues of the body. Until recently, the 
majority of the tissue resident macrophages were believed to originate from bone 
marrow derived blood monocytes (Davies et al., 2013a). However, recent evidence 
suggests that adult tissue macrophages in most tissues originate during development 
and not from circulating monocytes (Hashimoto et al., 2013, Epelman et al., 2014).  
Work from the Geissmann lab has shown that populations of tissue resident 
macrophages can arise from embryonic yolk sac precursors (Schulz et al., 2012, 
Gomez Perdiguero et al., 2015) and others have shown that they can also be foetal 
monocyte derived (Guilliams et al., 2013). Macrophages are dependent on either 
Colony-Stimulating Factor 1 (CSF-1, M-CSF) (Cecchini et al., 1994, Pixley and 
Stanley, 2004) or IL-34 (Wang et al., 2012), both of which signal via the CSF-1 
receptor (CSF1R, Csf1r, CD115) (Hume and MacDonald, 2012) and are essential for 
macrophage development and survival. However, it has been shown that alveolar 
macrophages self-maintain via Granulocyte Macrophage Colony Stimulating Factor 
instead (GM-CSF, CSF-2) (Guilliams et al., 2013, Hashimoto et al., 2013). Besides 
differences in their origin, it has now also been demonstrated that the tissue 
environment in itself is a major controller of macrophage phenotype and can be a key 
determinant influencing the expression of several genes regardless of origin (Davies 
and Taylor, 2015).  
Since macrophages are so widely distributed in various tissues throughout the body, 
they provide a first line of defence against invading pathogens. As part of the innate 
immune system, macrophages have the ability to recognise, engulf and kill potential 
pathogens (Gordon, 2007, Zhang and Mosser, 2008). At the same time, through their 
function as Antigen Presenting Cells (APC), macrophages bridge the gap between 
innate and adaptive immunity (Unanue, 1984). Heterogeneity and plasticity are 
hallmarks of macrophages. With such diverse characteristics, it is not surprising that 
macrophages display a range of functional phenotypes depending on the 
environmental cues and stimuli that they encounter (Mosser and Edwards, 2008).  
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1.2.1 Classical activation of macrophages  
Also referred as M1 activation, classical activation is the best-documented mode of 
macrophage activation. Classically activated macrophages (CAMΦ) are the major 
effector cells of the TH1 response and their prime functional focus is microbial 
destruction. CAMΦ are induced by exposure to a combination of two signals, the 
cytokine IFN-γ in concert with microbial products such as lipopolysaccharide (LPS) 
(Nathan, 1991, Wherry et al., 1991, Dalton et al., 1993, Mantovani et al., 2005). 
Signalling via IFN-γ is often termed the “priming step” that activates the 
transcription factor STAT1, which binds to Gamma-Activated Sequences (GAS) 
found in several immune effector genes. The second stimulus is ligation of one of the 
Toll Like Receptors (TLRs) with ligands typically expressed on pathogens termed 
Pathogen Associated Molecular Patterns (PAMPs). Activation of TLRs induces the 
MyD88 dependent production of Tumour Necrosis Factor (TNF-α), a cytokine that 
co-operates with IFN-γ and acts in an autocrine manner to stimulate macrophages 
(Mosser and Edwards, 2008, Mosser and Zhang, 2008). Whilst IFN receptor ligation 
activates STAT molecules, Nuclear Factor κB (NFκB) and Mitogen Activated 
Protein Kinases (MAPKs) are activated in response to TLR or TNF receptor 
ligation. Of note, TLR signalling through the adaptor molecule Toll IL-1 Receptor 
domain-containing adaptor-inducing IFN-beta (TRIF) can induce the production of 
IFNβ. This IFNβ can replace IFN-γ, thereby overcoming the need for two signals 
for activation (Mosser and Zhang, 2008).  
CAMΦ are identified by virtue of their generation of a wide variety of oxygen 
and nitrogen derived radicals with antimicrobial properties, such as hydrogen 
peroxide (H2O2), superoxide (O2-) anions and hydroxyl (OH) radicals (Nathan et 
al., 1983, Ding et al., 1988). Inducible nitric oxide synthase (iNOS, Nos2) is 
responsible for the production of the primary reactive nitrogen intermediate, 
nitric oxide (NO)(MacMicking et al., 1997, Mori and Gotoh, 2000). These 
reactive radical based cytotoxic pathways are triggered as a result of 
proinflammatory cytokine production (Parameswaran and Patial, 2010), which 
are generally the result of TLR ligation (Mosser and Zhang, 2008). TLR ligation 
also results in the production of other pro-inflammatory cytokines that are an 
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important component of host defence, but can also cause extensive damage to 
host physiology. For example, CAMΦ produce IL-1, IL-6 (Figure 1.1) and IL-23 
(Mosser and Edwards, 2008) that have been associated with the development 
and expansion of TH17 cells (Bettelli et al., 2006, Veldhoen et al., 2006), which 
have implicated roles in several autoimmune disorders (Langrish et al., 2005, 
Waite and Skokos, 2012). 
 
1.2.2 Alternative activation of macrophages  
Similar to the TH1/TH2 paradigm, an M1/M2 activation paradigm has been proposed 
for macrophages [reviewed in (Martinez and Gordon, 2014)]. However, the 
differentiation of macrophages into the M1 and M2 phenotypes is presumed to be 
more flexible than the differentiation of T helper cell subsets. Although M1/classical 
activation has a fairly clearly defined effector role and phenotype, the M2 activation 
phenotype of macrophages is less clear-cut. As such, M2 cells have been further sub-
categorised into three polarised populations (Mantovani et al., 2004): 
 M2a: induced by the cytokines IL-4 and IL-13 (hereafter referred to as 
“alternatively activated macrophages” in this thesis) 
  M2b: induced by exposure to immune complexes and agonists of TLRs or 
IL-I receptor (IL-1R) 
  M2c: induced by IL-10 and glucocorticoid (GC) hormones 
 
Due to the complex nature of terminology utilised with regards to mediators involved 
in the generation of different polarised macrophage populations, Murray et al (2014) 
proposed the adoption of a uniform nomenclature that is linked to the activating 
stimulus concerned (Murray et al., 2014). In line with this, the M2a-c states of 
macrophage activation are addressed as M(IL-4), M(Ig)/M(LPS)/M(IFN-γ) and 
M(IL10)/ M(GC) respectively instead.  
The Allen lab follows Siamon Gordon’s description of alternative activation of 
macrophages and defines alternative activation [M(IL-4)] as a state of activation 
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induced by the TH2 cytokines IL-4 and IL-13 (Gordon and Martinez, 
2010).Therefore, for the purpose of this thesis, all references made to alternative 
activation refer to the M(IL-4) or M2a state of activation.  
In contrast to CAMΦ being elicited in response to TH1 stimuli, alternatively activated 
macrophages (AAMΦ) are potently induced during TH2 responses. Macrophage 
function in large part is determined by stimuli they encounter from the local 
environment. Of utmost importance are cytokine signals from cells that are also 
recruited or present at the site of insult and injury. IL-4 and IL-13 signal through a 
shared IL-4 receptor (IL-4Rα) chain (Heller et al., 2008) that is absolutely required 
for the induction of AAMΦ. The IL-4Rα forms heterodimers with either the gamma 
chain (γC subunit) to form the Type I receptor or the IL-13Rα1 subunit to form the 
Type II receptor (Gordon, 2003, Heller et al., 2008, Gordon and Martinez, 2010).  
Thus, IL-4 has the ability to activate both Type I & II receptors whereas IL-13 
activates Type II receptors only. In addition, the IL-21 receptor has been shown to 
augment the AAMΦ phenotype, mainly by increasing IL-4Rα and IL-13Rα 
expression (Pesce et al., 2006). Furthermore, IL-33 (ST2) is also known to contribute 
to the polarisation of AAMΦ by upregulating the expression IL-4Rα and promoting 
type 2 chemokine production (CCL24 and CCL17) (Kurowska-Stolarska et al., 
2009). A role for the IL-33 receptor has also been implicated in IL-13 production that 
induces alternative activation of macrophages (Yang et al., 2013, Piehler et al., 
2015).  
Signalling via either IL-4 or IL-13 promotes phosphorylation of the IL-4Rα subunit, 
resulting in the activation of the transcription factor Signal Transducer and Activator 
of Transcription 6 (STAT6) (Hou et al., 1994, Goenka and Kaplan, 2011). 
Phosphorylation and subsequent activation of STAT6 drives alternative activation 
through the upregulation of several genes including Arginase-1 (Arg-1), Chi3l3 
(Chitinase 3 like 3, YM-1) and Retnla (Resistin like alpha, RELM-α), considered to 
be hallmarks of AAMΦ (Modolell et al., 1995, Munder et al., 1999, Loke et al., 
2002, Stutz et al., 2003). AAMΦ can be derived from both tissue resident 
macrophages and from recruited inflammatory monocytes. However, Gundra et al 
showed that these different sources generate AAMΦ that are transcriptionally distinct 
Chapter 1: Introduction 
  7 
(Gundra et al., 2014). Whilst Arg-1, YM-1 and RELM-α are expressed in AAMΦ 
regardless of origin, molecules such as the Mannose Receptor (MR, CD206) (Stein et 
al., 1992), Retinal Dehydrogenase 2 (Raldh2) (Broadhurst et al., 2012) and 
Programmed Death Ligand 2 (PD-L2) (Huber et al., 2010) that are also potently 
enhanced in response to IL-4 and strongly associated with AAMΦ have now been 
shown to be highly upregulated predominantly by AAMΦ of blood monocyte origin 
(Gundra et al., 2014). 
 
1.2.2.1 Markers characteristic of alternatively activated macrophages 
YM-1 and RELM-α were initially found to be major targets of IL-4 action and 
abundantly expressed in AAMΦ isolated from Brugia malayi infection in mice (Loke 
et al., 2002, Nair et al., 2003). Both YM-1 and RELM-α can also be induced in 
response to IL-4 and IL-13 in vitro (Raes et al., 2002, Nair et al., 2003, Edwards et 
al., 2006). YM-1 is an enzymatically inactive chitinase-like lectin found in mice that 
belongs to the chitinase-like protein (CLP) family (Jin et al., 1998, Chang et al., 
2001). CLPs are amongst the most abundant proteins found under conditions of TH2 
activation but their functions are still poorly understood. In agreement with this, YM-
1 expression is enhanced during a wide range of pathologies and it has previously 
been identified as a mediator of TH2 inflammation in allergy (Webb et al., 2001, 
Welch et al., 2002). More recently, our lab has shown that YM-1 promotes IL-17 
mediated neutrophilia that is essential for limiting parasite survival during 
Nippostrongylus brasiliensis infection in the lung (Sutherland et al., 2014). YM-1 
was first described as an eosinophil chemotactic factor produced by CD8 
lymphocytes (Owhashi et al., 1998). However, this finding has not been subsequently 
verified. 
RELM-α is a member of the secreted cysteine-rich resistin-like molecules (RELM) 
family of proteins that was first identified in the lavage fluid of mice with 
experimentally induced asthma (Holcomb et al., 2000). Like YM-1, RELM-α has 
also been strongly associated with type 2 immune responses. However, the functions 
of RELM-α in TH2 mediated settings such as helminth infection still remain to be 
Chapter 1: Introduction 
  8 
elucidated. During type 2 inflammation, a role for RELM-α has been implicated as a 
negative regulator by limiting pathogenesis of TH2 cytokine mediated pulmonary 
inflammation (Nair et al., 2009).  Additionally, recombinant RELM-α has also been 
reported to antagonise the effects of nerve growth factor (NGF), a protein associated 
with the exacerbation of allergic pulmonary responses (Holcomb et al., 2000). In 
contrast, RELM-α also exhibits various pro-fibrotic functions. These are discussed 
more in depth later on along with other effector functions of AAMΦ.  
AAMΦ and their responses are widely considered to be “anti-inflammatory” in 
contrast to the pro-inflammatory CAMΦ (Martinez and Gordon, 2014). The 
induction of Arginase-1 (Arg-1) by AAMΦ, another marker characteristic of 
alternative activation, exemplifies this functional antagonism between the two 
phenotypes (Modolell et al., 1995). Whereas AAMΦ produce Arg-1, CAMΦ 
synthesise inducible nitric oxide synthase (iNOS). The induction of either Arg-1 or 
iNOS is usually coupled with suppression of the opposing enzyme, indicating a 
competitive nature in these alternative states of macrophage metabolism (Modolell et 
al., 1995). Both Arg-1 and iNOS compete for a common substrate, L-arginine 
(Figure 1.1). Whilst CAMΦ utilise this L-arginine to produce nitrosative 
intermediates crucial for microbial killing, the same is converted to L-Ornithine and 
urea by AAMΦ (Munder et al., 1998, Munder, 2009). This L-Ornithine produced by 
AAMΦ is the substrate for two additional enzymes, namely ornithine decarboxylase 
(ODC) and ornithine aminotransferase (OAT). These enzymes further metabolise L-
Ornithine to polyamines and proline respectively, which are vital for cell 
proliferation and collagen production (Albina et al., 1993, Igarashi and Kashiwagi, 
2000, Bronte and Zanovello, 2005, Yeramian et al., 2006). Consistent with this 
function of Arginase-1, a role for AAMΦ has been implicated in wound repair and 
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Figure 1.1 Differential metabolism of L-arginine during classical and alternative 
macrophage activation. 
 
1.3 Macrophage proliferation 
In addition to inducing a state of alternative activation, IL-4 (and also IL-13) also 
drives the proliferation of AAMΦ. IL-4 driven proliferation of macrophages was first 
discovered by the Allen lab in a study involving the filarial nematode Litomosoides 
sigmodontis (Jenkins et al., 2011), which resides in the pleural cavity of infected 
mice. In this study, a time course assessment over the first 10 days of infection 
demonstrated that although there was a steady increase in macrophage numbers in 
the pleural cavity, their overall profile, as determined by flow cytometry, remained 
identical to that of naïve mice. Further, depletion of blood monocytes did not alter 
expansion of the F4/80hi population. This suggested that the resident F4/80hi 
macrophage population in the pleural cavity was expanding by means other than 
blood monocyte recruitment. Using Ki67 and BrdU staining as measures of 
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proliferation, it was found that the resident macrophage population was actively 
proliferating (Jenkins et al., 2011). This nematode-induced macrophage proliferation 
was found to be significantly reduced in IL-4-/- mice.  Prior to this, the survival and 
expansion of macrophages in the serous cavities had been associated with CSF1R 
signalling (Hume et al., 1988, MacDonald et al., 2010, Tagliani et al., 2011). In the 
study by Jenkins et al, IL-4 complex (IL-4c), which is a combination of recombinant 
IL-4 complexed to an anti-IL-4 antibody, was injected in the peritoneal cavity of 
mice resulting in a significant increase in macrophage proliferation. Remarkably, 
proliferation of macrophages was not restricted to the serous cavities, but also 
observed in other organs such as the liver and spleen. In a subsequent study from our 
lab, it was revealed that macrophage expansion following IL-4c delivery was 
independent of the adaptive immune system (using RAG-/- mice). However, the same 
result could not be achieved in mice deficient in either STAT6 or IL-4Rα (Jenkins et 
al., 2011, Jenkins et al., 2013). Additionally, using macrophage intrinsic bone 
marrow chimeras that included reconstitution of WT Ly5.1+ mice with a 1:1 mix of 
Ly5.1+ WT and Ly5.2+ IL-4Rα-/- cells, Jenkins and colleagues demonstrated that IL-4 
acts directly on macrophages and that IL-4Rα is essential to drive proliferation. 
However, it was identified that as opposed to IL-4Rα-/- cells that failed to incorporate 
BrdU following IL-4c injection, these IL-4Rα-/- cells during early stages of L. 
sigmodontis infection did in fact incorporate BrdU, but at levels lower than WT cells 
(Jenkins et al., 2013). This led to the finding that this residual proliferation observed 
in IL-4Rα-/- cells during L. sigmodontis infection was driven by the canonical 
macrophage mitogen CSF-1. Since IL-13 also signals through a shared IL-4Rα chain, 
Jenkins et al also tested the ability of IL-13 to drive macrophage proliferation. 
Delivery of IL-13 complex to the peritoneal cavity in a manner similar to IL-4c 
resulted in IL-13 driving macrophage proliferation comparable to IL-4 (Jenkins et al., 
2013).  
In addition to IL-4 induced macrophage proliferation being STAT6 dependent, 
another study from our lab has demonstrated that intact PI3K/AKT signalling is also 
essential (Ruckerl et al., 2012). Ruckerl et al showed that chemical inhibition of 
AKT completely abrogates IL-4 induced macrophage proliferation. Notably, 
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proliferation of macrophages in vitro in response to IL-4 or IL-13 is very limited, 
suggesting that IL-4Rα signalling alone is not sufficient to induce macrophage 
proliferation and that a secondary factor may be needed.   
This process of IL-4 (and IL-13) induced proliferation is of particular importance in 
scenarios of infection wherein recruitment of inflammatory macrophages can be 
detrimental to host pathology.  The proliferation and local expansion of tissue 
resident macrophages in response to IL-4 may negate the need for coincident 
accumulation of inflammatory cells recruited from the blood – a key contributory 
factor to excessive inflammation and tissue damage.  
 
1.4 Functions of alternatively activated macrophages 
1.4.1 Helminth Infections 
The importance of AAMΦ in a TH2 environment is strongly suggested by their 
prevalence in chronic TH2 settings like multicellular helminth infections. Helminths 
are a group of metazoan parasites comprising nematodes, trematodes and cestodes 
that elicit broadly similar immune responses in mammalian hosts (Jenkins and Allen, 
2010, Allen and Maizels, 2011). Increasing evidence points to a role for 
macrophages during helminth infections in imposing slow death by compromising 
worm vitality and fecundity. For example, during infection with the gut dwelling 
nematode Heligmosoides polygyrus, AAMΦ are involved in impairment of the larval 
parasite health and mobility, thereby contributing to the expulsion of adult worms 
(Anthony et al., 2006). In this study, macrophages were depleted in mice during H. 
polygyrus infection using clodronate-loaded liposomes. These mice had impaired 
worm expulsion and also significantly greater larvae in comparison to mice treated 
with PBS-loaded liposomes. Moreover, inhibition of Arginase also yielded high 
parasite burdens and enhanced larval recovery suggesting an essential role for 
AAMΦ in the development of a protective immune response against H. polygyrus 
(Anthony et al., 2006). In a recent study, expression of AAMΦ markers Arginase-1, 
YM-1 and RELM-α also strongly correlated with the elimination of H. polygyrus. In 
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the same study, macrophage depletion by clodronate also compromised resistance to 
infection in BALB/c mice and slowed down worm expulsion (Filbey et al., 2014). A 
role for arginase was directly implicated in nematode killing during secondary H. 
polygyrus infection by Esser-von Bieren and colleagues (2013). In this study, using 
mice lacking antibodies or activating Fc receptors, the authors demonstrated that 
antibodies activate macrophages to trap and immobilise infective larvae. Although 
the ability of antibodies to induce Arginase expression for worm killing was found to 
be IL-4Rα independent, the lack of IL-4Rα resulted in a failure of macrophages to 
accumulate at the site of infection suggesting that certain processes may require 
macrophage expansion independent of IL-4Rα dependent molecular functions 
(Esser-von Bieren et al., 2013). Esser-von Bieren and colleagues also showed that L-
ornithine and polyamines, which are products derived from arginine catabolism by 
Arginase-1, reduce the migratory capacity of H. polygyrus larvae in vitro. In line 
with these findings, inhibition of Arginase-1 has also been associated with reduced 
retention and trapping of Nippostrongylus brasiliensis larvae in the skin of infected 
mice (Obata-Ninomiya et al., 2013). Proline, another byproduct of arginine 
metabolism and the building block of collagen (and thus, extracellular matrix), is 
found in abundance in Schistosoma mansoni induced liver granulomas and 
considered to be potentially important in restricting larval migration (Morris, 2007).  
Delivery of IL-4 and/or IL-13 alone has been reported to trigger mucous production, 
smooth muscle contraction and epithelial cell turnover, all of which are sufficient to 
mediate worm expulsion from the gut (Finkelman et al., 2004). AAMΦ have also 
been implicated in expulsion of parasites by increasing the hypercontractility of 
intestinal smooth muscles in primary Nippostrongylus brasiliensis infection (Zhao et 
al., 2008). Roles for both IL-4Rα and STAT6 have been implicated in this expulsion 
(Urban et al., 1998). Eosinophilia is a distinct protective feature of helminth 
infections (Behm and Ovington, 2000) and mice implanted with the filarial nematode 
Brugia malayi and deficient in AAMΦ display reduced recruitment of eosinophils 
(Loke et al., 2007).  Consistent with these findings, Thomas et al have showed that 
AAMΦ produce CCL24, CCL8 and TxA2 (a bioactive precursor of TxB2), all of 
which are eosinophil chemoattractants, following B. malayi implant in the peritoneal 
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cavity of mice (Thomas et al., 2012). Interference with macrophage function through 
injection of carbon particles or carrageenan also enhances the survival of B. malayi 
and B. pahangi larvae in the peritoneal cavity of mice (Nakanishi et al., 1989, Rao et 
al., 1992).  
Multinucleated giant cell formation is a feature of AAMΦ that has previously been 
described (Gordon, 2003). It is thought that fusion of macrophages and giant cell 
formation may be vital for worm encapsulation and granuloma formation and that 
this entrapment might be important for allowing the immune system enough time to 
deploy additional defence mechanisms. Additionally, these fused macrophages are 
considered to create restricted environments for the secretion of effective killing 
molecules and/or for the removal of essential nutrients to starve the parasite, thereby 
limiting parasite survival [reviewed in (Ruckerl and Allen, 2014). In support of this, 
RNAseq data generated in our lab using B. malayi implant has shown that a dramatic 
change in metabolic pathways utilised by macrophages occurs post infection. This 
data identified pathways linked with the degradation and processing of many amino 
acids, thereby suggesting that AAMΦ may withhold essential nutrients from the 
surrounding environment. Furthermore, upregulation of transporters for amino acid 
uptake by IL-4Rα was also reported (Thomas et al., 2012). However, it is still 




It is estimated that one third of the global human population is infected by helminths, 
with the most common helminthiases being caused by infection with intestinal 
helminths such as hookworms (Hotez et al., 2008). Beyond the abundant soil-
transmitted infections, helminths are also the causative agents of vector-borne 
diseases such as Elephantiasis (lymphatic filariasis) (Evans et al., 1993), river 
blindness (Onchocherciasis) (Davies, 1994) and schistosomiasis (Chitsulo et al., 
2000). Filariasis is an infectious disease of the lymphatics and subcutaneous tissues 
caused by nematodes (roundworms) or filariae that belong to the Filarioidea 
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superfamily and are transmitted by blood-feeding black flies and mosquitoes. 
Filariasis is further classified into groups depending on the niche that the parasites 
inhabit within the body: 
1. Lymphatic filariasis – This is caused by parasites that occupy the lymphatic 
system such as Wuchereria bancrofti and Brugia malayi.  
2. Subcutaneous filariasis – This includes parasites that inhabit the subcutaneous 
layer of the skin such as Onchocerca volvulus and Loa loa.  
3. Serous cavity filariasis – Includes worms that dwell in the serous cavity of the 
abdomen such as some Mansonella species.  
 
Lymphatic filariasis is an endemic disease estimated to affect approximately 83 
countries around the world and ~1.3 billion people are projected to be at risk of 
developing this disease. The infected patients have a high risk of developing chronic 
symptoms such as lymphedema, elephantiasis and/or blindness that can result in 
decreased productivity, quality of life and in some cases also lead to life threatening 
infections (Mendoza et al., 2009, Ruckerl and Allen, 2014). The life cycles of all 
filariae are similar, beginning with infective larvae that are transmitted by the 
relevant vector through a blood meal. The larvae then migrate to the specific niches 
in the host where they develop into adults and mate. Microfilariae are then released 
into the blood stream or the skin by female worms, depending on the parasite 
involved. The transmission vector then takes up the microfilariae during a 
subsequent blood meal, where they progress onto infective larval stages [reviewed in 
(Mendoza et al., 2009)].  
Models of lymphatic filariasis were utilised in this project and data from these 
infection models has been discussed in this thesis.  The first of these is modelled by 
the human parasite Brugia malayi (McSorley and Maizels, 2012). However, the 
infective L3 larval stage of B. malayi, which is transmitted from the arthropod vector 
to the mammalian host, does not readily progress to the adult worm stage in mice. 
Instead, the Mongolian Jird (Meriones unguiculatus) serves as an intermediary and 
adult worms are extracted from the peritoneal cavity of the jird and subsequently 
implanted surgically into the peritoneal cavity of mice (MacDonald et al., 1998). 
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Although not the natural host or route of infection, this has served as an effective tool 
to study TH2 immune responses mounted against the adult worms.  
 
1.4.1.1.1 Litomosoides sigmodontis model of filarial infection 
Despite the existence of the B. malayi implant model, work in filariasis was 
constrained by the absence of a model that allows the investigation of both the 
immunology and natural migration of filarial parasites. In recent years, rodent 
adapted models have been developed to represent filarial models of human infection. 
Reflecting lymphatic filariasis and Onchocerciasis (river blindness), Litomosoides 
sigmodontis, developed by Odile Bain’s group in Paris, is a mouse model of filarial 
infection that has also been used in this thesis. This natural parasite of the cotton rat 
has the added advantage of completing developmental progression from the infective 
L3 larvae to adult worms (and microfilariae) within mice (Hubner et al., 2009). 
Depending on the strain of mice used, this model provides the opportunity to 
elucidate the mechanisms, immunological and otherwise, that determine whether this 
nematode can establish a successful infection or is rejected by the host. Whilst 
C57BL/6 mice are largely resistant to infection, BALB/c mice are susceptible 
allowing the development of patent infection (Le Goff et al., 2002, Babayan et al., 
2003b). This patent infection is characterised by the presence of circulating 
microfilariae in the bloodstream (Hoffmann et al., 2000). The lifecycle of L. 
sigmodontis in mice involves subcutaneous infection with infective L3 larvae (Figure 
1.2). These larvae migrate through the lymphatic system to the pleural cavity 
between 4 to 6 days and induce a strong TH2 response. Following migration, 
moulting to the L4 larval stage occurs and by day 28, development progresses to the 
adult worm stage. In the resistant C57BL/6 mice, these adult worms are killed prior 
to the onset of sexual maturation (~ day 50 post infection). In comparison, patency is 
established in the susceptible BALB/c mice with the onset of microfilariae 
production around day 55 post infection (Hoffmann et al., 2000, Le Goff et al., 2002, 
Babayan et al., 2003b). In both C57BL/6 and BALB/c mice, alternative activation of 
macrophages, as characterised by YM-1 and RELM-α production, and IL-4 induced 
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macrophage proliferation are both observed during infection (Babayan et al., 2003a, 
Jenkins et al., 2011).   
 
Figure 1.2 Lifecycle of the filarial nematode Litomosoides sigmodontis in resistant 
C57BL/6 and susceptible BALB/c mice (adapted from http://www.oncholab-
sokode.de/forsch.htm). 
The direct contribution of AAMΦ during L. sigmodontis infection still remains 
unclear. However, the importance of IL-4 in this model of infection was established 
by Le Goff et al. (2002) using IL-4 knockout animals on the resistant C57BL/6 
background. The major finding from this study was that two months post infection, 
adult worm recovery and the percentage of microfilaraemic mice in infected IL-4 
deficient C57BL/6 groups were comparable with those of the susceptible BALB/c 
mice (Le Goff et al., 2002). In another study, using susceptible BALB/c mice, 
Volkmann et al (2001) showed that mice lacking IL-4 exhibited up to a 100 fold 
higher and significantly prolonged microfilaraemia compared to wild type BALB/c 
mice. Whilst adult worm development and persistence were unaffected, the fertility 
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and length of adult female worms in mice deficient in IL-4 was clearly enhanced 
(Volkmann et al., 2001). Data from our lab has provided some evidence for IL-4Rα 
mediated macrophage activation during L. sigmodontis infection. Infected LysMCre 
IL-4Rαflox/- mice exhibit increased numbers of circulating microfilariae during late 
stages of infection suggestive of a role for AAMΦ in hampering circulating 
microfilariae or impairing female worm fecundity. However, the relatively inefficient 
deletion of the floxed IL-4Rα gene and lack of differences in activation markers at 
later stages of infection, presumably due to chronic IL-4 exposure and increase in IL-
4Rα expression, made interpretation of results challenging (Ruckerl and Allen, 
2014).  
 
1.4.2 Wound healing and tissue repair 
The type 2 response is host protective in part because it results in the reduction of 
parasites either through direct killing or expulsion. However, during the progression 
of infection, damage to the host also occurs as these parasites migrate through the 
body. Thus, an essential function of type 2 immunity is to also protect the host 
against damage mediated by these large multicellular parasites through resolution of 
inflammation and wound repair. Macrophages are present in every stage of repair 
following tissue injury – from the initial inflammatory phase, proliferation and 
angiogenesis to matrix deposition and tissue remodelling (Lucas et al., 2010, 
Sindrilaru and Scharffetter-Kochanek, 2013). In the initial stages of repair, 
macrophages produce pro-fibrotic mediators such as Transforming Growth Factor β 
(TGF-β) and Platelet-Derived Growth Factor (PD-GF) that recruit and activate 
myofibroblasts. AAMΦ also secrete Insulin-Like Growth Factor 1 (IGF-1), which 
stimulates the proliferation and survival of myofibroblasts (Wynn and Barron, 2010). 
The importance of IGF-1 and AAMΦ in tissue repair was illustrated by a study that 
showed IGF-1 producing AAMΦ are needed to repair the damage caused by N. 
brasiliensis larvae in the lung (Chen et al., 2012a). In addition, AAMΦ are also 
known to produce matrix metalloproteases (MMPs) and tissue inhibitors of matrix 
metalloproteases (TIMPs) that control extracellular matrix (ECM) turnover. As 
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professional phagocytes, macrophages also terminate inflammation through uptake 
of debris and dead cells.  
Parasite killing and tissue repair (as a consequence of worm damage) are flip sides of 
the same coin (Allen and Sutherland, 2014). For example, arginase is involved in 
both parasite killing and wound repair. As described earlier, L-arginine metabolism 
via Arginase-1 activity results in the production of proline and polayamines that are 
involved in collagen production and cell proliferation (Figure 1.1). These properties 
of AAMΦ originally led to the hypothesis that wound healing is a function of this 
phenotype (Hesse et al., 2001, Wynn, 2004). Alternative activation by IL-4 and IL-
13 has been described as an innate and rapid response to tissue injury that takes place 
even in the absence of an infectious agent (Loke et al., 2007). IL-13, in particular has 
been described as being potently pro-fibrotic (Wynn, 2004). Increasing evidence 
supports the involvement of AAMΦ in host protection, wound healing and tissue 
remodelling (Sandler et al., 2003, Wynn, 2004, Loke et al., 2007). For example, 
AAMΦ in schistosomiasis are essential for protection against organ injury.  IL-
4Rα−/− and LysMCreIL-4Rα−/flox mice infected with S. mansoni are unable to survive 
acute schistosomiasis and die from overwhelming inflammatory responses in the 
intestine and leakage of bacteria into the blood (Herbert et al., 2004). In this model, 
TH2 progression confers AAMΦ dependent protection and their absence results in a 
TH1 response instead. Moreover, this data shows that in the absence of  AAMΦ, the 
host is unable to repair damage caused by egg migration through the intestinal wall. 
The association of AAMΦ with egg-induced liver granulomas during Schistosoma 
mansoni in mice also suggests an effector function for this phenotype (Herbert et al., 
2004). During schistosomiasis, AAMΦ account for 20-30% of egg induced liver 
granulomas, and are thought to contribute to hepatic fibrosis. Infected mice treated 
with IL-12, a cytokine that results in classical activation of macrophages and NO 
production, exhibit much less fibrosis (Hesse et al., 2001). In a different model of 
silica-induced lung fibrosis, AAMΦ were found to be critical for the induction and 
maintenance of CD4+ TH2 response necessary to trigger fibrosis (Migliaccio et al., 
2008, Wynn and Barron, 2010).  
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1.4.3 Alternative activation proteins in tissue repair and fibrosis 
The anti-inflammatory properties of AAMΦ combined with their pro-angiogenic and 
tissue remodelling abilities that are predicted to facilitate wound repair and tissue 
regeneration (Martinez et al., 2009, Wynn and Barron, 2010, Allen and Wynn, 2011). 
The specific contribution of IL-4Rα signalling in repair and wound healing processes 
still remains elusive. However, there is growing evidence that IL-4Rα signalling in 
macrophages has an important contribution in tissue repair through the elucidation of 
the potential functional roles of the three most abundant proteins produced by 
AAMΦ, namely Arginase-1, YM-1 and RELMα. However, it is important to note 
that a current hurdle in delineating the direct effector functions (and otherwise) of 
AAMΦ is that many of the molecular signatures associated with AAMΦ are not 
restricted to macrophages.  
Proline, an amino acid essential for collagen synthesis, is produced in abundance by 
AAMΦ in an Arginase-1 dependent mechanism; because Arginase-1 is 
predominantly expressed by macrophages, this pathway has been singled out as 
central to their putative role in wound healing and tissue repair. (Wynn and Barron, 
2010, Hesse et al., 2001). The process of tissue remodelling is dependent on the 
timely removal and remodelling of pre-existing collagen scaffolds. Madsen et al 
showed collagen uptake through the mannose receptor and its subsequent 
degradation by AAMΦ (Madsen et al., 2013). Suppression of inflammatory 
responses is one of the key functions of Arginase-1, and an essential part of tissue 
repair. Suppressive effects of Arginase-1 are mediated through competition with 
iNOS but also direct effects on T cells. T cells are extremely sensitive to arginine 
concentration and AAMΦ deplete arginine in the surrounding environment through 
the activation of Arginase-1, thereby impairing T cell function (Zhu et al., 2014). 
Due to the conversion of arginine to polyamines and proline by Arginase-1, it has 
frequently been associated with the progression of fibrosis and it is believed to 
contribute to pathological tissue remodelling, particularly in asthma (Maarsingh et 
al., 2009). Although Arginase-1 is considered to be mostly pro-fibrotic, it can also 
suppress repair. Dysregulated and extensive repair results in fibrosis and AAMΦ 
have been reported to compete for extracellular arginine with fibroblasts during 
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inflammatory processes, thereby limiting fibrosis by restricting proline availability 
(Pesce et al., 2009a).  
No specific function for YM-1 has been defined in tissue remodelling yet, however, 
CLPs including YM-1 are known to bind to extracellular matrix (Hung et al., 2002) 
and are often expressed in injury environments. Although a functional role of YM-1 
is yet to be elucidated in tissue repair, other members of the chitinase family such as 
Acidic Mammalian Chitinase (AMCase) that are also expressed by AAMΦ, have 
been shown to ameliorate airway remodelling through inactivation of the 
downstream processes of IL-13 in an aeroallergen asthma model (Zhu et al., 2004). 
AMCase and BRP-39, also members of the CLP family, are also increased in livers 
of mice embedded with S. mansoni eggs, suggesting a potential involvement in the 
development of IL-13 dependent fibrosis in the context of infection [reviewed in 
(Wynn and Barron, 2010)].  
In contrast, there is considerably more evidence for a pro-repair role for RELM-α 
with its well-established angiogenic and mitogenic properties (Teng et al., 2003). 
However, since RELM-α is a known negative regulator of TH2 responses, delineating 
its contribution in wound healing and tissue repair is contradictory to its role in 
controlling fibrosis (Nair et al., 2009, Pesce et al., 2009b).  Unpublished data from 
our lab suggests that the amount of RELM-α together with the extent of damage may 
determine whether RELM-α promotes or inhibits fibrosis. Both RELM-α and YM-1 
are transiently but abundantly expressed in response to wounding (Loke et al., 2007). 
Circumstantial evidence suggests that RELM-α might be involved in fibrogenesis by 
promoting the differentiation and survival of myofibroblasts. For example, RELM-α 
is highly induced in the lung in the bleomycin model of fibrosis during fibrogenesis 
and RELM-α expressing cells activate Type I collagen and actin expression in 
fibroblasts (Liu et al., 2004b, Liu et al., 2009b). Furthermore, instillation of RELM-α 
in the lungs of mice induces a phenotype that is similar to that seen following a 
pneumonectomy with increased epithelial cell proliferation and hyperplasia (Li et al., 
2005).  Ablation of RELM-α in mice also exacerbates IL-13 mediated liver fibrosis 
in response to S. mansoni eggs (Pesce et al., 2009b), suggesting a protective function. 
This is in line with its function as a negative regulator of the TH2 response (Nair et 
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al., 2009). More recently, Knipper et al provided the first direct evidence for the 
involvement of IL-4Rα dependent macrophage activation in controlling collagen 
assembly important for effective repair at the cost of pro-fibrotic side effects. It was 
found that following mechanical skin injury, macrophages switched from an 
inflammatory to a resolution phenotype in an IL-4Rα dependent manner. IL-4Rαfl/- 
Lyz2-Cre mice failed to initiate essential repair programmes. The study identified 
RELM-α as a key player for the induction of LH2 in fibroblasts, an enzyme 
responsible for directing collagen cross links (Knipper et al., 2015).  
 
1.5 Macrophage plasticity  
Classical and alternative activation of macrophages are two extremes of a wide 
spectrum of overlapping activation phenotypes. In a reflection of dynamic changes 
and complex tissue-derived signals, the existence of macrophage plasticity and 
coexistence of cells in different activation states has been suggested. A growing body 
of evidence supports the theory that macrophages are highly plastic and rarely adopt 
a fixed phenotype (Biswas and Mantovani, 2010, Sica and Mantovani, 2012, 
Mantovani et al., 2013). Macrophages have been suggested to readily adapt and 
reprogram to changing microenvironments (Stout and Suttles, 2004, Stout et al., 
2009). The lack of a concrete phenotype is evidenced by data showing that once the 
stimulating agent driving a particular macrophage phenotype is removed, 
macrophages tend to rapidly lose their activation status (Ruckerl and Allen, 2014). 
This is further supported by the fact that macrophages isolated from one environment 
when subject to an opposing stimulus readily adopt activation features of the new 
stimulus (Stout et al., 2009). For example, macrophages isolated from mice 
implanted with the TH2-inducing nematode B. malayi if subject to stimulation with 
LPS and IFNγ begin to express a pro-inflammatory cytokine profile that includes IL-
6 and TNF (Mylonas et al., 2009). In a related study, it was shown that macrophages 
isolated from B. malayi infected mice expressed a different cytokine profile 
depending on the stage that they were isolated at. Whilst early isolation was 
associated with a TH2 profile, macrophages isolated at later stages exhibited 
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increased proinflammatory cytokine production (Whyte et al., 2011). Of note, even 
though plasticity between macrophage phenotypes exists, studies have reported that 
in certain cases the switch between phenotypes is not always absolute. For example, 
in the study by Mylonas et al, it was observed that despite production of iNOS and 
other proinflammatory cytokines by B. malayi isolated macrophages following 
stimulation with LPS/IFNγ, they were unable to detect the release of IL-12, a 
hallmark of classically activated macrophages (Mylonas et al., 2009). This may, in 
part, be explained by recent reports of macrophage regulation by epigenetic 
mechanisms that can also govern macrophage phenotype and are induced early on 
during development, thereby restricting the extent of macrophage plasticity (Ishii et 
al., 2009, Satoh et al., 2010).  
From existing literature it is evident that AAMΦ have the potential to exert both 
beneficial and detrimental effects on host physiology. It is also clear that macrophage 
function and diversity of phenotypes seem to be regulated by extremely complicated 
networks and factors that are capable of acting individually or in conjunction. 
Therefore, it is essential to understand the molecular mechanisms underlying the 
regulation of these different macrophage phenotypes that govern their overall 
function. Although there has been striking progress in understanding the underlying 
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1.6 MicroRNAs 
MicroRNAs have gained importance over the last decade as regulators of immune 
cells and their responses and as such are prime candidates for involvement in 
macrophage function. MicroRNAs are a class of short (~19-24nt), single stranded, 
non-coding RNA that are known to negatively regulate gene expression at the post 
transcriptional level. This is achieved typically by binding to the 3’ untranslated 
region (UTR) of target messenger RNAs (mRNAs) resulting in translational 
repression and/or destabilisation of the mRNA (Bartel, 2004, Wilczynska and 
Bushell, 2015). Back in 1993, the first evidence for the existence of microRNAs was 
obtained from the labs of Victor Ambros and Gary Ruvkun with discovery of the 
small endogenous RNA lin-4 in the nematode Caenorhabditis elegans. They showed 
that the lin-4 gene did not encode a protein; instead it gave rise to two small RNA 
transcripts of 22nt and 61nt respectively that were complementary to the 3’ UTR of 
lin-14 mRNA, a transcription factor critical for larval stage progression in C. 
elegans, and also bound to lin-14 mRNA in an antisense manner (Lee et al., 1993, 
Wightman et al., 1993). Later in 2000, Reinhart et al discovered let-7, a 21nt long 
microRNA that controls the L4 to adult transition of larval development in C. 
elegans via the regulation of lin-41 (Reinhart et al., 2000).  It was also discovered 
that this microRNA is conserved in other animals, including mammals (Pasquinelli et 
al., 2000), resulting in the assumption that more such small RNAs were likely to 
exist. Subsequently, hundreds of microRNAs have been identified in animals, plants 
and also viruses (Griffiths-Jones et al., 2008) and mirBase (http://www.mirbase.org), 
an online database was established to facilitate classification of microRNAs 
(Griffiths-Jones et al., 2008, Kozomara and Griffiths-Jones, 2011, Kozomara and 
Griffiths-Jones, 2014). As of June 2014, version 21 of mirBase describes 28,645 
microRNA loci expressing 35,828 mature microRNAs spanning across 223 species. 
Typically, microRNAs do not require perfect complementarity with their targets and 
each microRNA is, therefore, predicted to bind several hundreds of targets (Bartel, 
2009, Friedman et al., 2009), making microRNAs complex regulators of cellular 
gene expression. Furthermore, different cell types express different microRNA 
signatures and thus, different combinations of microRNAs may be important in 
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different contexts (Krek et al., 2005). Taking together the gene regulatory capacity of 
microRNAs along with their diversity, microRNAs are involved in nearly all 
developmental and pathological processes and it is difficult to find a cellular pathway 
that is not regulated by microRNAs at some level. 
 
1.7 Biogenesis of microRNAs 
Approximately 50% of the genes encoding microRNAs in mammals are localised in 
intergenic spaces. Of the remaining microRNA-coding genes, ~40% are found within 
introns and ~10% are encoded within exons of protein coding genes (O'Carroll and 
Schaefer, 2013). Most of the intergenic microRNAs are autonomously expressed and 
possess their own enhancer and promoter elements whereas transcription of intronic 
microRNAs and those found within exons (if encoded in the sense direction) is 
thought to be tightly co-ordinated with the transcription of the protein-coding parent 
genes [(Corcoran et al., 2009), reviewed in (O'Carroll and Schaefer, 2013, Ha and 
Kim, 2014)]. Furthermore, microRNAs with highly related sequences (termed 
isoforms) and consequently, similar targets, are classified into the same microRNA 
families. Of note, microRNAs are often redundant in function with isoforms of the 
same microRNA located on different chromosomes. These relationships are 
annotated by alphanumeric descriptions. For example, in mice, the microRNA let-7 
family comprises members ranging from let-7a to let-7k located on different 
chromosomes. Some of these family members are also redundant in function. For 
instance, mature let-7a can be derived from two separate chromosomal locations and 
is termed let-7a-1 or let-7a-2 depending on its origin. In addition to the individual 
loci, microRNA genes can also be organised in clusters giving rise to dicistronic or 
polycistronic microRNAs that can either be co-expressed/co-transcribed or expressed 
independently of each other (Altuvia et al., 2005, Baskerville and Bartel, 2005, Song 
and Wang, 2008, Ramalingam et al., 2014). The mir-125a/let-7e/99a, miR-125b-
1/let-7a-2/miR-100 and miR-99a/let-7c/miR-125b-2 clusters exemplify these 
complex microRNA cluster relationships. Regardless of their genomic localisation, 
the canonical biogenesis of mature microRNAs occurs in a highly conserved process 
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comprising processing of the primary microRNA transcript in the nucleus followed 
by further processing of the precursor microRNA in the cytoplasm (Figure 1.3).  
 
1.7.1 MicroRNA transcription in the nucleus 
The majority of the microRNAs are transcribed in the nucleus by RNA polymerase II 
(Lee et al., 2004, Schanen and Li, 2011), with a small subset being transcribed by 
RNA polymerase III (Cai et al., 2004, Pfeffer et al., 2005, Borchert et al., 2006, 
Canella et al., 2010). Transcription by RNA polymerase II results in the generation 
of a long primary transcript, usually several kilobases in length, which forms a local 
hairpin structure within which the microRNA sequences are embedded. A typical 
primary microRNA (pri-miRNA) consists of a 33-35bp stem, a terminal loop and 
flanking single stranded RNA segments on 5’ and 3’ ends. When clustered, pri-
miRNA transcripts can form highly complex structures containing several sequential 
multiple stem loops (O'Carroll and Schaefer, 2013). The pri-miRNAs generated via 
RNA Polymerase II have a 7-methylguanosine cap (m7Gppp) at the 5’ end and a 
poly(A) tail at the 3’ end (Cai et al., 2004).  The pri-miRNA is recognised by the 
nuclear microprocessor complex encompassing two core proteins, namely Drosha 
and DiGeorge syndrome Critical Region 8 (DGCR8, referred to as PASH-1 in 
C.elegans and Pasha in Drosophila melanogaster) (Lee et al., 2003, Denli et al., 
2004, Gregory et al., 2004, Han et al., 2004, Landthaler et al., 2004, Wang et al., 
2007). DGCR8 recognises and binds to the stem region of the pri-miRNA followed 
by the recruitment the nuclear RNase III Drosha, which initiates the processing of the 
pri-miRNA by cropping the stem-loop to release a small hairpin RNA termed the 
precursor microRNA (pre-miRNA). The pre-miRNAs are generally ~65-70nt in 
length and possess a 5’ phosphate and 3’ –OH with a 2-3nt overhang (Lee et al., 
2003, Zeng et al., 2005). In addition to the canonical microRNA biogenesis 
involving the microprocessor complex (Drosha/DGCR8), a non-canonical pathway 
for pre-miRNA generation termed the “Mirtron pathway” has also been described. 
Mirtrons are short intronic hairpins found in protein coding genes with the ability to 
debranch and become pre-miRNAs independent of Drosha and DGCR8 (Berezikov 
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et al., 2007, Babiarz et al., 2011). The nascent pre-miRNAs (including mirtrons) are 
then exported to the cytoplasm in a GTP-dependent manner by Exportin-5 (EXP5). 
EXP5 is a karyopherin protein family member that forms a transport complex with 
the nuclear protein RAN-GTP and recognises the 2-3nt 3’ overhang left by Drosha at 
the base of the pre-miRNA stem (Bohnsack et al., 2004, Lund et al., 2004, Tomari 
and Zamore, 2005). The maturation of the exported pre-miRNA is then completed in 
the cytosol.  
 
1.7.2 MicroRNA maturation and RISC assembly in the cytoplasm 
Upon export to the cytoplasm, the pre-miRNA is cleaved by the RNase III enzyme 
Dicer, which binds to the pre-miRNA with a preference for the 3’ overhang 
generated by Drosha, resulting in the liberation of a small (~22nt) 
microRNA:microRNA* duplex (Bernstein et al., 2001, Grishok et al., 2001, 
Hutvagner et al., 2001, Ketting et al., 2001). Like Drosha is a component of the 
microprocessor complex, Dicer also functions as part of a large complex called the 
RISC (RNA Induced Silencing Complex) Loading Complex (RLC) and interacts 
with Transactivation Response RNA-Binding Protein (TRBP) and Protein Activator 
of PKR (PACT) (Chendrimada et al., 2005, Haase et al., 2005, Lee et al., 2006). 
Although not essential for Dicer-mediated cleavage, TRBP facilitates the stability of 
Dicer and acts as a sensor for thermodynamic asymmetry within a microRNA 
duplex. Additionally, both TRBP and PACT participate in the recruitment of an 
Argonaute protein to the RLC (Chendrimada et al., 2005, Lee et al., 2006). 
Following cleavage by Dicer, the double stranded microRNA:microRNA* duplex is 
separated into the functional “guide” strand and the “passenger (*)” strand. The 
guide or lead strand is preferentially loaded on to the Argonaute protein, which forms 
part of the RISC complex, whereas the passenger (*) strand is usually degraded 
(Khvorova et al., 2003, Schwarz et al., 2003, Bartel, 2004, Castilla-Llorente et al., 
2013) [reviewed in (Winter et al., 2009)]. According to current nomenclature, the 
mature microRNA originating from the 5’ arm of the pre-miRNA stem is termed the 
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5p microRNA and that arising from the 3’ arm of the stem is referred to as the 3p 
microRNA.  
Argonaute proteins are central components of RISC and essential for microRNA 
mediated gene silencing. In mammals, the prevalence of four Argonaute (1-4) 
proteins has been reported with no obvious affinity or bias for specific microRNAs 
(Burroughs et al., 2011, Czech and Hannon, 2011), although some reports suggest 
specificity in the microRNAs associated with differents Agos (Li et al., 2014). 
Shared N-terminal, Piwi-Argonaute-Zwille (PAZ), C-terminal love containing MID 
domain and P-element Induced WImpy estis (PIWI) domains are hallmarks of all 
Argonaute proteins (Song et al., 2004, Elkayam et al., 2012, Schirle and MacRae, 
2012). Whilst the N domain mediates loading and unwinding of the 
microRNA:microRNA* duplex, the PAZ and MID domain anchor the 3’ and 5’ ends 
of the microRNA respectively (Jinek and Doudna, 2009).  Although all four 
Argonaute proteins function in a similar manner, only Argonaute 2 possesses 
endonucleolytic activity such that it can cleave target mRNAs with perfect 
complementarity to the mature microRNA (Diederichs and Haber, 2007, Hutvagner 
and Simard, 2008).  
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Figure 1.3 Biogenesis of microRNAs [adapted from Winter et al. (2009)].  
Primary microRNAs (pri-miRNAs) containing a 7-methylguanosine cap (m7Gppp) and a 3’ 
poly(A) tail are transcribed by RNA polymerase II in the nucleus. The pri-miRNAs are 
cleaved by the microprocessor complex comprising the endonuclease Drosha and its partner 
DGCR8 into ~70nt long precursor microRNAs (pre-miRNA). Exportin-5 exports the pre-
miRNAs to the cytoplasm in a GTP dependent manner, where they are further cleaved by a 
complex consisting of the endonuclease Dicer and its interacting partners TRBP and PACT. 
This generates a ~22nt long microRNA:microRNA* duplex, which is incorporated into the 
RISC complex containing Argonaute protein. The guide/lead strand of the duplex remains 
associated with Argonaute, whereas the passenger strand (microRNA*) dissociates from the 
RISC and is subsequently degraded.  
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1.8 Mechanism of action 
The targeting specificity of microRNAs is largely dictated by the “seed region” 
found between nucleotides 2 and 8 from the 5’ end of the mature microRNA (Bartel, 
2009). Perfect complementarity between the seed sequence of a microRNA and its 
target mRNA is the most common form of microRNA mediated target repression. 
Although the main mechanism of action for most microRNAs is based on their 
binding to the 3’UTR of the target mRNA, interactions between microRNAs and the 
5’ UTR or coding sequence (CDS) of mRNAs have also been reported (Zhou et al., 
2009, Hausser et al., 2013). Other than complementarity with the seed region, pairing 
between the 3’ UTR and microRNA at nucleotides 13 to 16 can reduce the off rate of 
RISC from the target mRNA and has been referred to as “supplementary” base 
pairing, which is suggested to improve target inhibition. Additionally, 
“compensatory” pairing between the 3’ end of the microRNA and the 3’ UTR of the 
mRNA can also compensate for mismatches within the seed region (Brennecke et al., 
2005, Grimson et al., 2007, Shin et al., 2010). Furthermore, other features such as the 
presence of adenosine residues across from the first base of a microRNA, the 
position of the target site within 3’ UTR and/or sequence motifs within microRNAs 
can affect the overall binding affinity of a microRNA to its target (Grimson et al., 
2007, Obernosterer et al., 2008, Tafer et al., 2008). The interaction between a 
microRNA and its target mRNA within the RISC complex results in destabilisation 
of the mRNA and/or inhibition of translation. Although many studies have shown 
that microRNAs are capable of regulating gene expression post-transcriptionally, the 
exact mechanisms of microRNA mediated repression of targets still remain 
controversial. Several mechanisms have been proposed to be involved in 
translational inhibition at the initiation and elongation steps and mRNA 
destabilization and/or degradation [reviewed in (Huntzinger and Izaurralde, 2011, 
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1.8.1 MicroRNA directed degradation of target mRNA 
It is widely accepted that microRNA directed endonucleolytic cleavage of target 
mRNAs by Argonaute occurs in plants. This occurs at the site in the mRNA that 
pairs to nucleotides 10 and 11 in the microRNA and requires complete 
complementarity between the microRNA and its target (Llave et al., 2002, Rhoades 
et al., 2002, Yekta et al., 2004). However, in animals, microRNAs are only partially 
complementary to the binding sites within target mRNAs. In this case, the 
microRNA mediated mRNA degradation occurs via the 5’ to 3’ mRNA decay 
pathway (Figure 1.4). In this pathway, the target mRNA first undergoes 
deadenylation by the CAF1-CCR4-NOT deadenylase complex. The PAN2 and 
PAN3 deadenylase complexes are also required, although to a lesser extent 
[reviewed in (Wilczynska and Bushell, 2015)]. All these complexes are recruited by 
GW182, a protein characterized by the presence of glycine and tryptophan repeats 
(GW repeats) and essential for microRNA mediated target repression (Rehwinkel et 
al., 2005, Behm-Ansmant et al., 2006, Kuzuoglu-Ozturk et al., 2012). GW182, when 
physically associated with AGO, interacts with the Poly(A) Binding Protein 
(PABPC). PABPC binds the poly(A) tail of the target mRNA and recruits the CCR4-
NOT deadenylase complex resulting in mRNA deadenylation (Behm-Ansmant et al., 
2006, Chekulaeva et al., 2011).  Following deadenlyation, the target mRNA is then 
decapped. The decapping enzyme DCP2, which further requires association with 
decapping activators and enhancers (DCP1, DDX6 and EDC4) for complete activity 
and stability, catalyses this removal of the 5’ cap of the mRNA (Rehwinkel et al., 
2005, Eulalio et al., 2007, Nishihara et al., 2013). This capping process has been 
shown to be independent of the deadenylation process (Fabian and Sonenberg, 2012). 
Subsequently, the 5’-3’ exonuclease XRN1 degrades the deadenylated and decapped 
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Figure 1.4 MicroRNA mediated mRNA decay [figure adapted from Huntzinger & 
Izaurralde (2011)].  
The eIF4F complex (eIF4G, eIF4E and eIF4F) binds to the 5’ cap of the mRNA. eIF4G also 
interacts with PABPC, which binds to the poly(A) tail forming a closed mRNA loop for 
translation. MicroRNAs contained within the RISC complex bind to partially complementary 
sites within the 3’ UTR of target mRNA. GW182 associated Argonaute (AGO) interacts 
with PABPC resulting in the recruitment of the CCR4-NOT complex, which deadenylates 
the target mRNA. Following deadenylation, the mRNA undergoes decapping through the 
recruitment and activity of DCP2 bound to various co-factors (DDX6, DCP1 and EDC4). 
Subsequently, the target mRNA is further degraded by the 5’-3’ exonuclease XRN1.  
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1.8.2 MicroRNA mediated translational repression 
Translational repression is a key feature of microRNA directed gene regulation. 
Previously, next-generation sequencing and ribosome profiling data have revealed 
that the decrease in protein level observed in microRNA-mediated regulation of 
target mRNAs is primarily due to mRNA decay and only in some (11-16%) cases 
derived from translational inhibition (Guo et al., 2010). However, accumulating 
evidence in recent years suggests that translational repression of microRNA targets is 
the primary event and recent studies have suggested that repression can occur 
without the necessity for mRNA degradation (Mathonnet et al., 2007, Fabian et al., 
2009, Bazzini et al., 2012, Bethune et al., 2012, Djuranovic et al., 2012, Meijer et al., 
2013). Studies have also investigated whether these mechanisms of regulation are 
mutually exclusive and if mRNA degradation is a consequence of translational 
repression. mRNA translation consists of three distinct steps: initiation, elongation 
and termination. Different studies suggest that microRNAs can repress translation at 
both the initiation and post initiation steps in four distinct ways: inhibition of 
translation initiation, inhibition of translation elongation, co-translational protein 
degradation and premature termination of translation  [reviewed in (Huntzinger and 
Izaurralde, 2011, Wilczynska and Bushell, 2015).  
Translation requires numerous factors that are involved in the recruitment of the 
ribosomal subunits to the mRNA and that ensure initiation at the correct initiation 
codon, and subsequently proper elongation and termination. Initiation of translation 
involves the recognition of the 5’ terminal m7G cap by the eIF4F (eukaryotic 
translation initiation factor) complex comprising eIF4E, eIF4G and eIF4A. Whilst 
eIF4A is a helicase, eIF4E binds the mRNA cap and eIF4G provides a scaffold for 
the assembly of the entire complex. eIF4G, together with eIF3, facilitates the 
recruitment of the 40S ribosomal subunit (Kapp and Lorsch, 2004). Additionally, 
eIF4G also interacts with PABP1 [Poly(A) binding protein 1], which binds the 
poly(A) tail of the mRNA, resulting in the circularization of mRNA that is efficiently 
translated and protected from degradation (Derry et al., 2006). Initiation of 
translation occurs at the AUG (methionine) codon, with assembly of the 60S 
ribosomal subunit and progression on to the elongation phase.  
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Several studies have demonstrated that microRNAs interfere with the functioning of 
the eIF4F complex and PABPC during translation. For example, studies involving 
repression of lin-14 and lin-28 by the lin-4 microRNA reported the detection of these 
mRNAs in polysomes suggesting that repression occurred after the initiation of 
translation (Olsen and Ambros, 1999, Seggerson et al., 2002). These findings were 
further supported by the fact that upon sucrose gradient sedimentation, microRNAs 
and their targets were found to be associated with polysomes. These appeared in the 
actively translated fraction, however, the corresponding protein was undetectable 
(Maroney et al., 2006, Nottrott et al., 2006, Petersen et al., 2006). These findings 
were explained via different hypotheses including degradation of the nascent 
polypeptide chain co-translationally (Nottrott et al., 2006) and premature dissociation 
of ribosomes (Petersen et al., 2006). The study carried out by Petersen et al also 
showed that microRNA-associated polysomes, when treated with a translational 
inhibitor, dissociated more rapidly in comparison to polysomes associated with a 
control unrepressed mRNA. Furthermore, Petersen and colleagues observed an 
ability for microRNAs to silence translation initiated independently of the cap 
structure via an Internal Ribosome Entry Site (IRES) (Petersen et al., 2006), thus 
providing further evidence for translational repression by microRNAs post initiation.  
At the same time, a conflicting study reported that in the presence of cognate 
microRNAs, target mRNAs do not co-sediment with the polysomal fraction during 
sucrose gradient sedimentation; instead they are found in lighter fractions that 
contain fewer ribosomes (Pillai et al., 2005). Pillai et al and other related studies 
stated that mRNAs translated through an IRES were refractory to repression by 
microRNAs, suggesting that the mechanism for microRNA inhibition involved cap 
dependent translation initiation (Humphreys et al., 2005, Pillai et al., 2005). 
Consistent with this finding, studies involving cell free extracts demonstrated that 
microRNAs silenced m7Gppp-capped mRNAs but not mRNAs with artificial Appp 
caps and failed to silence transcripts in IRES driven translation (Mathonnet et al., 
2007, Wakiyama et al., 2007). In further agreement with these results, target 
silencing was suppressed with increasing concentrations of purified eIF4F in extracts 
from mouse tumour cells (Wakiyama et al., 2007).  The idea that microRNAs 
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interfere with the functioning of the cap binding complex, thereby repressing 
initiation, was also supported by a bioinformatic analysis that revealed that mRNAs 
containing miRNA target sites are more likely to have highly structured 5’ UTRs 
(Meijer et al., 2013).  
 
1.8.3 Evidence for microRNA mediated mRNA degradation 
Evidence for the finding that microRNAs can induce target degradation comes from 
transcriptomic studies showing that the levels of mRNA targets correlate inversely 
with microRNA abundance [reviewed in (Huntzinger and Izaurralde, 2011)]. These 
transcriptomic profiles reveal that cells transfected with specific microRNAs show a 
reduction in transcripts containing complementary binding sites for these 
microRNAs. The finding that the levels of microRNA targets increase when these 
factors are depleted supports a role for mRNA decay factors in microRNA mediated 
mRNA destabilisation. For example, depletion of components of the CAF1-CCR4-
NOT deadenylase complex results in the upregulation of most microRNA targets 
suggesting that deadenylation is a widespread consequence of microRNA regulation 
(Behm-Ansmant et al., 2006, Eulalio et al., 2007). Additionally, Guo et al showed 
that reduction of protein in a microRNA-mediated fashion is a result of mRNA 
degradation. In this study, ribosomal profiling was carried out that involves 
sequencing of ribosome-protected mRNA fragments (RPFs) to evaluate the effects of 
microRNAs on protein production along with simultaneous measurement of mRNA 
levels. The effect of a specific microRNA on protein production was calculated as a 
ratio of RPFs and mRNA levels. It was found that the decrease in mRNA levels 
accounted for more than 84% of the decrease in protein production, suggesting that 
microRNA mediated destabilisation/degradation of mRNAs may be accountable for 
the protein reduction (Guo et al., 2010). 
Although mechanisms of microRNA action remain controversial, the most wide-
spread current opinion is that microRNA-mediated translational repression is a 
prerequisite for target mRNA degradation (Wilczynska and Bushell, 2015). In light 
of this, kinetic studies in Drosophila melanogaster and mammalian cells have 
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demonstrated that microRNAs function through initial repression of target translation 
prior to triggering mRNA decay (Bethune et al., 2012, Djuranovic et al., 2012). 
Furthermore, in Zebrafish, inhibition of translation has been shown to cause mRNA 
degradation. Using ribosomal profiling it was found that miR-430 reduced the 
ribosomal occupancy on target mRNAs with subsequent mRNA decay (Bazzini et 
al., 2012).  
 
1.8.4 Novel functions of microRNAs 
Normally, an anti-correlation in expression would be expected for a true miRNA–
mRNA pair. However, besides translational repression and mRNA destabilisation, 
microRNAs have also been linked to translational activation in specific 
circumstances. For example, upon cell cycle arrest in serum starved cells, AU-rich 
elements (AREs), present specifically in TNFα mRNA are transformed into an 
activation signal for translation. This results in the recruitment of AGO and miR-
369-3 directs its association with the AREs to activate translation (Vasudevan et al., 
2007). Vasudevan et al also showed that whilst let-7 represses translation in 
proliferating cells, it could also induce translational activation in a similar manner 
during cell cycle arrest. In another study, miR-373 has been reported to induce the 
expression of E-cadherin by targeting a site in the promoter. In the same study, 
expression of Cold-Shock Domain-Containing protein C2 (CSDC2) was also induced 
in response to miR-373 (Place et al., 2008).  However the exact mechanisms of how 
microRNAs result in translational activation are still unknown.  
Additionally, Eiring et al have suggested a novel function for microRNAs as decoys 
for regulatory RNA-binding proteins. They showed that miR-328 is bound by 
hnRNP E2 and sequesters it away from its mRNA targets. This interaction with 
hnRNP E2 is independent of the microRNA seed sequence and results in the release 
of the key myeloid differentiation factor CEBPA mRNA from hnRNP E2 mediated 
translational inhibition. Patients with chronic myeloid leukaemia were found to have 
decreased expression of miR-328, meaning that there is less competition for hnRNP 
E2. As a result, hnRNP E2 is free to induce the translational inhibition of CEBPA 
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(Eiring et al., 2010). Another study by Balkhi et al also showed a similar relationship 
between HuR and miR-29, which prevents the protein from repressing the mRNA of 
tumour suppressor A20 by acting as a decoy (Balkhi et al., 2013). At the same time, 
recent works propose that mRNA targets can also act as competitive inhibitors 
(“sponges”) of microRNAs and therefore, affect the concentration of microRNAs 
(Ebert et al., 2007, Ebert and Sharp, 2010, Hansen et al., 2013). This adds another 
layer of complexity to the already existing complex microRNA networks mediating 
posttranscriptional gene regulation. 
Although the varied mechanisms of microRNA-mediated gene regulation are still 
being elucidated, based on their wide-spread functions in the regulation of gene 
expression microRNAs are important fine tuners of a variety of cellular processes, 
including immune responses.  
 
1.9 MicroRNAs in immune responses 
In the past decade, there has been great insight into the intersection between the 
fields of immunology and microRNA biology. The contribution of microRNAs in the 
regulation of the immune system is highlighted by their importance in various 
processes such as haematopoietic development (Bissels et al., 2012, Undi et al., 
2013, Montagner et al., 2014), maintenance of immune homeostasis (Lian et al., 
2012, Runtsch et al., 2014, Pauley et al., 2009), cancer (Hayes et al., 2014, Lee and 
Dutta, 2009, Jansson and Lund, 2012, Lin and Gregory, 2015)  and autoimmunity 
(Pauley et al., 2009, Ceribelli et al., 2012, Singh et al., 2013, Qu et al., 2014, 
Simpson and Ansel, 2015). The earliest studies involving microRNAs focused on 
their impact on the functioning of the immune system as a whole. More recently, 
advancement in profiling methods has allowed for the identification and contribution 
of specific microRNAs in the regulation of distinct immune cell populations and 
their responses.  
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Knocking out of Dicer, which is essential for microRNA biogenesis, is 
embryonically lethal, with Dicer1 null embryos depleted of stem cells entirely 
(Bernstein et al., 2003). In addition, Homeobox (HOX) genes are critical in 
regulating haematopoietic stem cell (HSC) homeostasis (Argiropoulos and 
Humphries, 2007). MicroRNAs belonging to the miR-196 and miR-10 families are 
not only located in the HOX loci, but also have the capacity to directly repress HOX 
family expression (Yekta et al., 2004, Garzon et al., 2008). MiR-196b is specially 
expressed in mouse HSCs and modulates HSC homeostasis and lineage commitment 
(Popovic et al., 2009), whereas miR-126 regulates the expression of HOXA9 and 
PLK2 and is involved in the production of downstream progenitors by HSCs (Li et 
al., 2008). MiR-221 and miR-222, on the other hand inhibit KIT expression of stem 
cells resulting in impaired cell proliferation (Felli et al., 2005). 
Since mice lacking Dicer do not survive, follow on studies utilised conditional Dicer 
knockout systems. Specific deletion of Dicer in the T cell lineage results not only in 
defective T cell development, but also irregular TH cell differentiation and cytokine 
production (Cobb et al., 2005, Muljo et al., 2005, Seo et al., 2010, Zhang and Bevan, 
2010, Podshivalova and Salomon, 2013). Whilst Dicer deletion in mature CD8 T 
cells results in enhanced activation but defective survival and migration to peripheral 
tissues (Zhang and Bevan, 2010), global microRNA knockout (Dicer -/-) in CD4 T 
cells deletion leads to reduced proliferation and abnormal TH1 cytokine production 
(Muljo et al., 2005, Chong et al., 2008). Despite these aberrations, Dicer appears to 
be dispensable for CD4 and CD8 lineage commitment in the thymus (Cobb et al., 
2005). Additionally, regulatory T cells lacking Drosha or Dicer lose their suppressor 
function and fail to prevent autoimmunity in mice and this fatal autoimmunity is 
indistinguishable from that caused by deficiency in Foxp3, the master regulator of 
Treg differentiation (Chong et al., 2008, Liston et al., 2008, Zhou et al., 2008).  
T cells are one of the most widely studied cell type in the context of regulation by 
specific microRNAs. MiR-181a has been shown to positively regulate the T cell 
receptor (TCR) mediated response to antigen in CD4+ T cells through the 
amplification of signal strength and subsequent cytokine release (Li et al., 2007). In 
the same study, Li and colleagues showed that miR-181a acts like a rheostat through 
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the coordinated downregulation of multiple phosphatases downstream of this surface 
receptor and was thus implicated in the regulation of positive and negative selection 
of T cells during thymic development (Li et al., 2007, Ebert et al., 2009). Unwanted 
T cell clones are commonly disposed of via apoptosis. The miR-17 to miR-92 cluster 
of microRNAs is involved in the regulation of T cell survival through the repression 
of BIM and PTEN, factors involved in the potentiation of cell death. At the same 
time, overexpression of this microRNA cluster in transgenic mice results in T cell 
populations that are hyperproliferative and resistant to cell death (Xiao et al., 2008). 
Interestingly, CD4 T cell display mRNA with shorter 3’ UTRs upon activation 
(Sandberg et al., 2008). Sandberg et al showed that truncation of the UTR results in 
loss of specific microRNA binding sites, thus protecting transcripts from microRNA 
mediated degradation and implicating a role for microRNAs in T cell activation. 
Activated CD4+ T cells express miR-155 and deficiency of this microRNA results in 
a TH2 bias under neutral conditions in vitro (Rodriguez et al., 2007, Thai et al., 
2007). Mice lacking miR-155 are also defective in their capacity to produce TH1 and 
TH17 cells in mouse models of autoimmune inflammation such as Experimental 
Autoimmune Encephalomyelitis (EAE) (O'Connell et al., 2010), colitis (Oertli et al., 
2011) and Collagen Induced Arthritis (CIA) (Kurowska-Stolarska et al., 2011). MiR-
326 is also a promoter of TH17 responses and EAE development through targeting of 
the transcription factor Ets1, an established repressor of TH17 development (Du et 
al., 2009). Furthermore, the clonal expansion of T cells is repressed by the 
suppression of Foxo1 by miR-182, a microRNA that is induced in response to IL-2, a 
cytokine produced by activated T cells (Stittrich et al., 2010). In contrast to miR-182, 
miR-214 is a microRNA that promotes T cell proliferation through the repression of 
PTEN, an established inhibitor of the PI3K pathway (Jindra et al., 2010). Absence of 
the microRNA miR-146a in T cells leads to the elevated expression of STAT1 and 
an uncontrolled TH1 response. Moreover, miR-146a
-/- mice succumb to a chronic 
inflammatory disorder with a reduced life span (Lu et al., 2010). These studies are 
only a few selected examples from the extensive literature describing the functional 
role of microRNAs in T cells.  
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A deficiency in microRNAs also affects B cell development, as first reported by the 
conditional deletion of AGO2 in haematopoietic cells. This resulted in a partial 
deficiency in microRNA function and compromised the development of B and 
erythroid cells (O'Carroll et al., 2007). Furthermore, a B cell lineage specific deletion 
of Dicer hampers B cell development and an almost complete block at the pro to pre-
B cell transition due to apoptosis of Dicer-/- pre-B cells (Koralov et al., 2008). The 
miR-17~92 cluster was shown to peak in these pre-B cells and was also accountable 
for the inhibition of cell death through downregulation of the proapoptotic protein 
Bim. This block in B cell development could be overcome by transgenic expression 
of BCL-2, but the mature B cells still had abnormal distributions of VDJ 
rearrangements, suggesting that there was a considerable defect in the regulation of B 
cell selection. Significantly, mice lacking the miR-17~92 microRNA cluster are also 
non viable at birth with severe defects in the lung and heart (Ventura et al., 2008). 
Dicer ablation in mature B cells also skews the cells towards transitional and 
marginal zone phenotypes in the spleen with a concomitant reduction in follicular B 
cells (Koralov et al., 2008). MiR-155 is induced during LPS activation of B cells and 
is critical in the regulation of B2 cell responses in germinal centres. Mice deficient in 
miR-155 show marked defects in both antibody secretion and class switching and 
these changes are a result of miR-155 mediated repression of >60 target genes (Thai 
et al., 2007, Vigorito et al., 2007). In addition to B2 cells, mice deficient in miR-150 
show abnormal expansion of B1 cells accompanied by dramatic increases in steady 
state immunoglobulin levels. Constitutive expression of miR-150 also arrests cells at 
the pro-B cell stage. These defects were explained by dysregulation of c-Myb 
expression (Xiao et al., 2007, Zhou et al., 2007). In contrast, constitutive expression 
of miR-34a perturbs B cell development through increased cell numbers during pro-
B to pre-B cell transition by targetting the transcription factor Foxp1, which regulates 
expression of the recombination-activating genes Rag1/2 (He et al., 2007).  
Granulocytes arise from granulocyte-monocyte progenitors and this process is 
controlled by the transcription factor GFI1 (Velu et al., 2009). Overexpression of 
miR-21 and miR-196b blocks granulopoiesis and, in agreement with this, it was 
found that GFI1 binds to the promoter regions of pri-miR-21 and pri-miR-196b, 
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thereby repressing their expression (Hock et al., 2003). Sustained expression of miR-
155 can also increase granulocyte numbers in vivo by targeting SHIP1 (O'Connell et 
al., 2008, O'Connell et al., 2009). Besides regulating granulocyte development, 
microRNAs also have the ability to regulate granulocyte function. The myeloid 
transcription factors PU.1 and C/EBPβ are known to induce expression of miR-223 
(Fukao et al., 2007). MiR-223 negatively regulates both the activation and 
proliferation of neutrophils, and neutrophils lacking miR-223 have been shown to 
undergo an increased oxidative burst and efficiently kill Candida albicans in 
comparison to wild type cells (Johnnidis et al., 2008). This was the first report that 
genetic ablation of microRNAs can influence myeloid cell development and function 
in vivo. In the same study, it was shown that miR-223 also directly targets MEF2C, a 
transcription factor which promotes myeloid progenitor differentiation, is also 
important for the increased neutrophil expansion observed in miR-223 deficient 
mice. MiR-223 null mice also develop inflammatory lung pathology and exacerbated 
tissue destruction following endotoxin challenge suggesting that miR-223, like miR-
146a and miR-155, is also an integral component of the homeostatic maintenance 
machinery (Johnnidis et al., 2008).  
 
1.9.1 MicroRNAs in the regulation of monocytes, macrophages and dendritic 
cells 
A number of studies have also implicated roles for specific microRNAs in the 
regulation of transcription factors involved in monocytopoiesis. During 
differentiation of human haematopoietic progenitors into monocytes, the expression 
levels of members of the miR-17~92 and the related miR-106a~92 families are 
significantly reduced, resulting in the de-repression of the transcription factor 
RUNX1. This increase in RUNX1 leads to the promotion of monocyte differentiation 
through an increase in CSF1R expression. Moreover, RUNX1 also binds to the 
promoter region of these microRNA families, thus creating a mutual negative 
feedback loop (Fontana et al., 2007). PU.1 is a transcription factor essential for 
monocyte and macrophage differentiation. PU.1 has been shown to up-regulate miR-
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424 expression, which promotes TPA (12-O-tetra-decanoylphorbol-13-acetate) 
mediated monocyte differentiation of NB4 cells (Rosa et al., 2007), a human acute 
promyelocytic leukemia derived cell line, thereby increasing the numbers of CD11b+ 
and CD14+ expressing cells. This is achieved through the suppression of the nuclear 
factor I/A (NFIA), a transcription factor important for myeloid cell differentiation 
(Fazi et al., 2005). Furthermore, expression levels of miR-146a, miR-155, miR-342 
and miR-338 are also increased under the influence of PU.1 and ectopic expression 
of miR-146a is sufficient to direct HSC differentiation and commitment to the 
myeloid cell lineage in mouse transplantation assays (Ghani et al., 2011).  
Monocytes comprise two functionally distinct subsets: inflammatory Ly-6Chi (human 
CD14hi) and patrolling Ly-6Clo (human CD14lo/CD16+) cells. Whilst miR-146a is 
constitutively expressed by Ly-6Clo monocytes, following inflammatory challenge, 
Ly-6Chi monocytes selectively induce miR-146a expression. MiR-146a limits the 
expansion of these cells in the bone marrow, thereby limiting the magnitude of the 
inflammatory response mediated by these cells (Etzrodt et al., 2012). Because of this, 
miR-146a-/- mice exhibit chronic myeloproliferation and develop malignancies (Zhao 
et al., 2011). Additionally, miR-146a impairs CCR2 (Chemokine CC Ligand CCL2 
Receptor) expression, which is essential for the recruitment of Ly-6Chi monocytes to 
sites of insult and injury, where they differentiate into macrophages. This miR-146a 
mediated regulation in monocytes is cell autonomous and dependent on RELB, a 
direct target of this microRNA (Etzrodt et al., 2012).  
There are a number of microRNAs known to modulate macrophage activation and 
function. MiR-9, miR-21, miR-146, miR-147 and miR-155 have all been shown to 
be upregulated in macrophages in response to infection (O'Connell et al., 2008, 
Taganov et al., 2006, Sheedy et al., 2010, Liu et al., 2009a, Bazzoni et al., 2009). 
Specifically, miR-155 expression is induced in mouse bone marrow derived 
macrophages through TLR ligation and also by the proinflammatory cytokine TNFα 
and interferons (O'Connell et al., 2008). The primary transcript that encodes miR-155 
has also been shown to be activated by NF-κB (O'Connell et al., 2008, Thai et al., 
2007, Gatto et al., 2008, Yin et al., 2008). MiR-146 expression is induced in 
macrophages by cognate ligands for TLRs and the cytoplasmic sensor RIG-1 in an 
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NF-κB dependent manner (Taganov et al., 2006, Hou et al., 2009). In humans, miR-9 
is upregulated by pro-inflammatory signals that are dependent on LPS activation of 
MYD88 and NF-κB (Bazzoni et al., 2009). Induction of miR-9 is also mediated by 
the proinflammatory cytokines IL-1β and TNF-α, but not by IFN-γ. These 
microRNAs all appear to be transcriptionally regulated in a manner similar to other 
inflammatory genes but can negatively influence the activation of inflammatory 
pathways in myeloid cells. For example, miR-146 is induced by NF-κB and directly 
targets several signalling molecules downstream of TLRs that promote inflammation, 
such as the adaptor molecules IRAK1, IRAK2 and TRAF6 in the TLR/ NF-κB 
pathway, in a negative feedback loop (Taganov et al., 2006, Hou et al., 2009). In 
contrast to miR-146a limiting proinflammatory responses, a model for miR-9 
preventing the negative regulation of NF-κB signalling in monocytes has been 
proposed. miR-9 represses NFKB1 to help maintain NF-κB protein levels and 
proinflammatory action during TLR4 mediated activation of monocytes (and 
neutrophils) (Ma et al., 2011). 
MiR-155 provides an example of a microRNA with complex effects on myeloid 
activation. Overexpression of miR-155 in the bone marrow of adult mice results in a 
myeloproliferative phenotype mirroring that observed following LPS injection 
(O'Connell et al., 2008). SHIP1 is a negative regulator of TLR signalling and the 
PI3K/AKT pathway (Sly et al., 2004, Costinean et al., 2009, O'Connell et al., 2009). 
MiR-155 has been shown to negatively regulate SHIP1, thereby countering the 
negative influence of SHIP1 and increasing downstream AKT1 signalling. In 
macrophages, AKT signalling has interestingly been shown to repress miR-155 
expression, indicating the existence of a negative feedback loop (Androulidaki et al., 
2009). Moreover, macrophages deficient in AKT that are stimulated with LPS 
express higher levels of miR-155 and also miR-125b in comparison to wild type 
controls and these Akt-/- macrophages are more sensitive to LPS. In this study, miR-
155 was shown to directly target SOCS1, another native regulator of the TLR 
pathway. This sensitisation to LPS was achieved in combination with a reduction in 
levels of let-7e, which downregulates the expression of the LPS receptor TLR4. In 
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agreement with these findings, Akt-/- mice display a lower tolerance when challenged 
with LPS (Androulidaki et al., 2009). 
In addition to macrophages, miR-155 is also known to fine tune the functioning of 
dendritic cells (DCs). In human DCs, knockdown of miR-155 expression results in a 
significant increase in the expression of the pro-inflammatory cytokine IL-1β. 
Consistent with its role in regulating pro-inflammatory responses, miR-155 was 
also reported to repress the expression of an NF-κB reporter and TAB2, an important 
signal transduction molecule, in the same study (Ceppi et al., 2009). Furthermore, 
DCs from Bic-/- mice that are deficient in miR-155 are defective in their ability to 
present antigens, despite normal MHC Class II expression and other co-stimulatory 
molecules (Rodriguez et al., 2007). MiR-155 also downregulated the expression of 
the DC specific molecule DC-SIGN (CD209), which is a C-type lectin that binds to 
pathogens, thus implicating a role for microRNAs in pathogen uptake (Martinez-
Nunez et al., 2009). Taken together, these results suggest that microRNAs are 
important regulators of inflammation and key players in the maintenance of a 
balanced response to pathogens and stimuli.  
Owing to the diversity of microRNA targets, the roles of microRNAs can be 
extremely complex and context dependent with microRNA targets and functions at 
times specific to a particular cell type and activation status. For example, miR-125 is 
a microRNA that is rapidly induced in macrophages by TLR ligands. The miR-125 
family is composed of the miR-125a/b-1 and miR-125b-2 members, which are 
mammalian homologues of the first discovered microRNA, lin-4, in C. elegans. 
Bone marrow derived macrophages express high levels of both miR-125a and miR-
125b. Whilst miR-125a is upregulated, miR-125b is downregulated in response to 
LPS (Tili et al., 2007, Androulidaki et al., 2009, Graff et al., 2012b). Nevertheless, 
evidence suggests that both microRNAs enhance NF-κB signalling through the 
repression of the NF-κB regulator TNFAIP3 (Kim et al., 2012). In agreement with 
these findings, macrophages overexpressing miR-125b are highly responsive to IFNγ 
(Chaudhuri et al., 2011). In addition, miR-125b also directly targets and destabilises 
the TNFα mRNA transcript and downregulation of miR-125b in response to LPS 
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results in enhanced TNFα production (Androulidaki et al., 2009). Moreover, 
miR-125b is involved in the sustenance of classical activation by targeting the 
transcription factor IRF4, which is a mediator of alternative macrophage activation 
(Chaudhuri et al., 2011).  
As mentioned earlier, miR-223 is a microRNA preferentially expressed in the 
myeloid lineage. Recent studies have suggested that miR-223 is induced in response 
to LPS and acts to limit inflammatory activation of macrophages. Consistent with 
this finding, bone marrow macrophages lacking miR-223 express significantly higher 
levels of IL-1β, IL-6 and TNFα (Zhuang et al., 2012).  
 
1.9.2 MicroRNAs in alternative activation 
As opposed to the well-studied roles of microRNAs in the regulation of classically 
activated macrophages and proinflammatory responses, existing literature 
implicating functional roles of microRNAs in alternative activation is relatively 
sparse [reviewed in (Squadrito et al., 2013)]. The expression of several microRNAs 
has been reported to be altered in response to IL-4 in bone marrow derived 
macrophages, however, the functional significance of these microRNAs is still 
unknown (Squadrito et al., 2014). To date, three studies delineating the functional 
roles of microRNAs in alternative activation have been reported.  
The first of these came from our lab and was reported by Ruckerl et al (2012). Using 
an in vivo model of B. malayi implant in the peritoneal cavity of mice, the authors 
identified the differential expression of four different microRNAs in helminth 
induced alternatively activated macrophages, namely miR-125b-5p, miR-146a-5p, 
miR-199b-5p and miR-378-3p. Of these, miR-378-3p was specifically identified as 
being induced by IL-4 and shown to target the IL-4 induced PI3K/AKT proliferative 
pathway. MiR-378-3p is encoded within the first intron of the Ppargc1b gene, which 
has previously been shown to be associated with the alternative activation phenotype. 
The expression of miR-378-3p was confirmed as being IL-4Rα dependent and 
strongly associated with alternative activation. MiR-378 was hypothesised to operate 
in a negative feedback loop to limit IL-4 induced macrophage proliferation. To this 
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end, AKT1 was established as a direct target of this microRNA in vitro, although 
analysis of inhibition of AKT1 by miR-378-3p could not be achieved in vivo due to 
technical hurdles (Ruckerl et al., 2012).  
Work by other labs has also linked other microRNAs to alternative macrophage 
activation, although not strictly with the M(IL-4) phenotype. The use of microRNA 
sensor lentiviral vectors has shown that miR-511-3p is upregulated in AAMϕ. 
However, functionally miR-511-3p has only been shown to downregulate genes with 
a pro-tumoural effector function in Tumor Associated Macrophages (TAMs). Of 
note, miR-511-3p has been indirectly linked to AAMϕ through the suppression of 
ROCK2, a kinase that phosphorylates IRF4, which is a transcription factor involved 
in the promotion of alternative activation (Squadrito et al., 2012).  
Lastly, miR-223 has been studied as a mediator of PPARγ regulated alternative 
macrophage activation. In this study, the expression of miR-223 was enhanced 
directly by PPARγ upon exposure to TH2 stimuli through binding of regulatory 
elements upstream of the pre-miR-223 coding region. Moreover, deletion of miR-
223 impaired alternative activation ex vivo and also in mice fed a high fat diet. These 
effects were mediated by direct targeting of Rasa1 and Nfat5, genes essential for 
PPARγ dependent alternative activation (Ying et al., 2015). 
  
1.10 Hypotheses and aims of this thesis 
As described earlier, AAMϕ are involved in a range of effector functions that range 
from helminth infections to TH2 weighted disorders such as asthma and fibrosis. 
Although our knowledge of macrophage function in a TH2 environment is rapidly 
increasing, a number of questions still remain to be addressed about the regulation of 
the AAMϕ phenotype, particularly by microRNAs.  
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We, therefore, hypothesised that:  
 MicroRNAs are altered in response to IL-4 and IL-13 in macrophages. 
 With their ability for vast gene regulation, microRNAs could target genes and 
pathways critical for the induction, maintenance and proliferation of the 
AAM phenotype. 
 
To test these hypotheses, the following aims were addressed in this project: 
1. Identification of microRNAs associated with alternative activation. 
2. Investigation of the functional role of lead microRNA candidates in vitro and 
in vivo. 
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Chapter 2: Identification and selection of 
microRNAs for further study 
 
SUMMARY:  
In this chapter, in light of the increasing evidence that microRNAs are involved in 
the regulation of different macrophage phenotypes, we determined the expression 
profiles of microRNAs that are highly regulated during IL-4Rα dependent alternative 
activation. To this end, we utilised microarray data previously generated in the lab to 
identify microRNAs differentially expressed in AAMΦ. This included a two-way 
comparison of AAMΦ elicited in response to a nematode B. malayi with 
macrophages from IL-4Rα deficient animals (IL-4Rα-/-) and inflammatory 
thioglycollate-elicited macrophages (Thio MΦ) from wild type animals. 
Additionally, a second microarray dataset identified microRNAs that were altered in 
response to IL-4 stimulation of bone marrow derived macrophages. The ten most 
significantly regulated microRNAs identified as being differentially expressed in 
AAMΦ and/or common to both datasets were selected for further study. The 
expression profiles of these ten microRNAs were then validated under a range of 
conditions of alternative activation ranging from a complex in vivo TH2 infection to 
in vitro stimulation of macrophage cell lines with IL-4 and IL-13. Based on 
consistency in expression profiles across the range of these conditions of alternative 
activation, microRNA candidates were selected for further study in the subsequent 
chapters to determine their contribution to the induction, maintenance and 
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2.1 Introduction 
Depending on the external stimuli and environmental cues encountered, 
macrophages can develop into various highly distinct functional phenotypes 
(Mantovani et al., 2004, Mantovani et al., 2005, Mosser and Edwards, 2008, Sica and 
Mantovani, 2012, Gordon and Martinez, 2010). CAMΦ and AAMΦ represent two 
highly polarised activation states that, when uncontrolled, can lead to either 
excessive inflammation and tissue destruction or TH2 weighted inflammatory 
disorders such as asthma and fibrosis respectively (Gordon, 2003, Wynn, 2004, 
Gordon and Martinez, 2010). Hence, macrophage responses must be tightly regulated 
for the maintenance of homeostasis both during and after infection and tissue injury. 
As previously mentioned in the introductory chapter, several mechanisms are 
involved in the regulation of the functional polarisation and activation of 
macrophages. Besides signalling cascades essential for triggering an activation state, 
it has been shown that transcriptional and chromatin-mediated control are the key 
players that determine macrophage identity (Sica and Mantovani, 2012, Martinez and 
Gordon, 2014). These include regulation via transcription factor families such as 
STAT proteins (Hu et al., 2008, Blanc et al., 2013), IRFs (Dror et al., 2007, Gunthner 
and Anders, 2013), PPARs (Odegaard et al., 2007, Chawla, 2010, Szanto et al., 
2010) and others such as GATA6 (Okabe and Medzhitov, 2014, Rosas et al., 2014). 
Additionally, chromatin remodelling and histone demethylation (Bowdridge and 
Gause, 2010), the tyrosine kinase receptor STK/RON (Iwama et al., 1996, Liu et al., 
1999), retinoic acid (Manicassamy and Pulendran, 2009), adenosine (Csoka et al., 
2012, Hasko and Cronstein, 2013) and cell death by apoptosis (Munn et al., 1995) 
have all been implicated in the functional regulation of macrophage responses.  
MicroRNAs are a class of naturally occurring, short (~22nt), non coding RNA that 
have the potential for vast gene regulation by binding target messenger RNAs 
(mRNAs) resulting in the inhibition of translation and/or mRNA destabilization 
(Bartel, 2009, Fabian and Sonenberg, 2012). Most microRNAs bind to the 3’ UTR of 
the target mRNA via a conserved “seed” site, which is defined as nucleotides (nt) 2-
8nt at the 5’ end of a microRNA (Bartel, 2004, Doench and Sharp, 2004, Brennecke 
et al., 2005). Although outside of this seed region perfect complementarity between 
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the microRNA and its target is not required, additional supplementary and 
compensatory pairing mechanisms can enhance target inhibition (Grimson et al., 
2007, Bartel, 2009). Additionally, interactions between microRNAs and the 5’UTR 
or coding sequences of target mRNAs have also been reported (Zhou et al., 2009). 
Directly or indirectly, a single mature microRNA has the capacity to regulate 
multiple components within complex regulatory networks. In recent years, 
microRNAs have gained importance as immunomodulatory regulators. Genetic 
ablation of the microRNA processing or functional machinery, or deregulation of 
certain individual microRNAs can severely compromise immune development and 
responses leading to several immune disorders (Xiao and Rajewsky, 2009). 
The role of microRNAs in the functional regulation of macrophage responses has 
been widely studied. MicroRNAs have been shown to be key players right from the 
early stages of macrophage development and production to the later stages involving 
macrophage polarisation and maintenance of activation (Graff et al., 2012b, Liu and 
Abraham, 2013b, Squadrito et al., 2013). TLR signalling is a key feature of CAMΦ 
involved in microbial killing (Mosser, 2003, Mosser and Edwards, 2008, Mosser and 
Zhang, 2008, Martinez and Gordon, 2014). MicroRNAs are known to be fine tuners 
of TLR signalling and hence can act as regulators of CAMΦ to limit excessive 
inflammation during infection [reviewed in (O'Neill et al., 2011)]. In this regard, 
miR-146 and miR-155 are the best examples of microRNAs that are well-established 
regulators of classical activation. MiR-146a is rapidly induced in macrophages in an 
NF-κB dependent manner in response to LPS stimulation and has been shown to 
modulate classical activation through a negative feedback regulatory loop (Taganov 
et al., 2006, Rusca and Monticelli, 2011). A more specific role for miR-146a has also 
been suggested in the regulation of IL-6 production in response to LPS (He et al., 
2014c). MiR-155 is a microRNA whose expression is induced in macrophages in 
response to a broad range of inflammatory mediators (O'Connell et al., 2007). 
Deficiency of miR-155 in macrophages also has a direct influence on the expression 
levels of other microRNAs (Dueck et al., 2014).  
Besides miR-146 and miR-155, roles for other microRNAs have also been 
implicated in regulating macrophage activation. For example, macrophages, 
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compared to other immune cells, are enriched in the expression of miR-125b, which 
is known to potentiate classical activation through suppression of IRF4 leading to 
enhancement of costimulatory factors and increased responsiveness to IFN-γ 
(Chaudhuri et al., 2011). Like miR-146a, miR-125b is also transcriptionally induced 
by NF-κB and promotes a positive self-regulatory loop that prolongs NF-κB activity, 
thereby prolonging macrophage activation (Kim et al., 2012). Macrophages are also 
involved in the progression of tumours and metastasis (Pollard, 2004, Solinas et al., 
2009, Noy and Pollard, 2014) and defined microRNA signatures have been shown to 
be associated with this progression (Squadrito et al., 2013). MiR-125b is also a 
known oncomir that promotes tumorigenesis, also through the repression of IRF4, in 
line with the finding that microRNAs involved in cancers can function via dual 
mechanisms (Fabbri et al., 2007, So et al., 2014). 
In contrast to the fairly extensive literature on microRNAs in the regulation of 
CAMΦ, there is still a gap in the existing literature and current understanding of how 
microRNAs regulate IL-4Rα dependent AAMΦ and their responses. Although the 
expression profiles of several microRNAs have been implicated with the M2 
phenotype, currently only a few microRNAs are associated with the functional 
regulation of AAMΦ. Of these, miR-223 and miR-124a serve as regulators of M2 
polarisation (Zhuang et al., 2012, Veremeyko et al., 2013) while miR-7a-1 is 
involved in IL-4 directed giant cell formation (Sissons et al., 2012). Additionally, a 
study from our lab has shown the functional relevance of miR-378 as a negative 
modulator of IL-4 induced macrophage proliferation (Ruckerl et al., 2012).  
AAMΦ have been implicated in a wide range of processes including homeostasis, 
thermoregulation, malignancy, wound healing and tissue repair. This is in addition to 
the established role of AAMΦ during infection with multicellular parasitic 
(helminths), allergy, metabolic functions and inflammatory disorders such as fibrosis 
(Fairweather and Cihakova, 2009, Gordon and Martinez, 2010). Given their 
association with such a diverse range of functions, it is likely that the current 
knowledge and understanding in terms of microRNA regulation of AAMΦ is only 
the tip of the iceberg. Thus, investigating the role of microRNAs in the regulation of 
AAMΦ could have important implications for therapeutic targeting of macrophages 
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in not only the context of disease and disorders, but also for a greater understanding 
of how microRNAs in general contribute towards maintenance of the balance and 
efficiency of the immune response.   
The purpose of the work described in this chapter was to identify microRNAs 
associated with AAMΦ under a range of conditions and to select the most 
appropriate microRNA candidates for further study in the subsequent chapters.  
 
2.2 Results 
2.2.1 Identification of microRNAs associated with alternative activation 
In order to identify microRNAs associated with AAMΦ, microarray datasets 
previously generated by Dominik Ruckerl in our lab were utilised. These datasets 
provide information on the differential regulation of microRNAs under two distinct 
conditions of alternative activation: 
1. Macrophages generated via in vitro stimulation of bone marrow derived 
macrophages.  
Cells were harvested from the bone marrow of WT C57BL/6 mice and 
cultured in vitro in M-CSF/CSF-1 containing medium for 7 days to obtain 
bone marrow derived macrophages (BMDMs) (Weischenfeldt and Porse, 
2008). These differentiated BMDMs were either left untreated as an 
unstimulated control or stimulated with either IL-4 or LPS for 24 hours. 
Stimulation with LPS generated classically activated BMDMs whereas IL-4 
treatment resulted in alternative activation of these macrophages (Figure 2.1). 
Total RNA was extracted from these distinct treatment groups and a 
microRNA array screen (Dharmacon/Thermofisher Agilent array) was carried 
out to identify microRNAs that are differentially expressed between the 
samples. Microarray analysis of these BMDMs stimulated with either LPS or 
IL-4 compared with the unstimulated control identified 118 microRNAs that 
were differentially expressed upon treatment (unpublished data, D.Ruckerl). 
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Changes in the expression profiles of these 118 microRNAs were further 
categorised into three groups: 
 
a. LPS or IL-4: microRNAs differentially expressed in BMDMs in 
response to LPS only were deemed to be associated with classical 
activation while microRNAs whose expression was altered upon 
stimulation with IL-4 only were considered to be associated with 
alternative activation. 
 
b. LPS = IL-4: microRNAs that exhibited similar changes in expression, i.e. 
either upregulated or downregulated, in response to both LPS and IL-4. 
These microRNAs were excluded from further consideration based on the 
assumption that they were more likely to be associated with general 
macrophage function and activation rather than being associated with a 
particular phenotype.  
 
c.  LPS ≠ IL-4: microRNAs whose expression was altered in response to 
both LPS and IL-4, but differentially, were designated as being associated 
with either the classical or alternative activation phenotype and included 
for further study (Figure 2.1).  
  
Taking into consideration microRNAs that were altered in BMDMs in response to 
IL-4 treatment only or in response to both LPS and IL-4, but differentially, 15 
microRNAs were identified to be potentially associated with alternative activation 
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2. AAMϕ elicited in response to Brugia malayi implant in the peritoneal 
cavity 
B. malayi is a parasitic nematode that results in a strong TH2 response when 
adult worms are implanted in the peritoneal cavity of mice. This leads to the 
accumulation of AAMΦ at the site of implantation. In a study carried out by 
Ruckerl et al. (2012) from our lab, AAMΦ elicited upon exposure to B. 
malayi were harvested from the peritoneal cavity of wild type (WT) mice 3 
weeks post implant. Additionally, IL-4Rα deficient animals (IL-4Rα-/-), 
which fail to produce AAMΦ, were also implanted with B. malayi adults. As 
a secondary comparison, WT mice were subject to sham surgery and injected 
with thioglycollate 3 days prior to necropsy. These thioglycollate-elicited 
macrophages (Thio MΦ) are monocyte-derived macrophages that are not 
alternatively activated and not associated with helminth infection. Total RNA 
was extracted from these three distinct cell populations and subject to a 
microRNA array screen (Exiqon miRCury 8.1 platform) to identify 
microRNAs that are differentially expressed between the samples. 
Comparison of the WT B. malayi elicited AAMΦ with macrophages from IL-
4Rα-/- mice identified IL-4Rα dependent microRNAs. An additional 
comparison between the WT AAMΦ elicited in response to B. malayi implant 
and Thio MΦ identified microRNAs that were altered only in response to B. 
malayi and not in Thio MΦ (Figure 2.2). Together, these two comparisons 
revealed differential expression of 19 microRNAs (cut off > 2 fold) in the B. 
malayi elicited AAMΦ compared with macrophages either from IL-4Rα-/- 
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2.2.2 Identification of microRNAs consistently associated with alternative 
activation 
Tables 2.1 and 2.2 list microRNAs that were identified as being associated with 
AAMΦ through analyses of two different microarray datasets from macrophages 
generated following IL-4 stimulation of BMDMs and B. malayi implants in mice 
respectively. Based on rationales explained below and considering microRNA 
isoforms as single microRNAs, these tables were then assessed to generate a final list 
of ten microRNAs either common to both datasets or other interesting candidates that 
may potentially be associated with AAMΦ. 
Analysis of Tables 2.1 and 2.2 revealed four microRNAs that were common to both 
datasets – namely miR-125a-5p, miR-146a, miR-199b-5p and miR-378. Three of 
these microRNAs were also identified as being IL-4Rα dependent (Table 2.2) and 
therefore, selected for further study. Moreover, these four microRNAs were the most 
likely to be associated with AAMΦ being differentially expressed under two separate 
conditions of alternative activation. Although miR-378 was not significantly altered 
in BMDMs in response to IL-4 according to our cut-off values (Table 2.1), given its 
known association with AAMΦ (Ruckerl et al., 2012), it was selected as a positive 
control for future experiments regardless.  
MiR-125b-5p, miR-146b and miR-199a-5p are isoforms of miR-125a-5p, miR-146a 
and miR-199b-5p respectively. Isoforms share identical seed sequences and hence 
are predicted to bind the same target mRNA 3’ UTRs. These isoforms were 
identified as being differentially expressed in Table 2.1 and were therefore, also 
selected for further analysis. Moreover, as discussed earlier in the introduction for 
this chapter, miR-125b and miR-146a/b already play established roles in regulating 
CAMΦ. Thus, it would be interesting to try and dissect their functional roles and 
association with AAMΦ. MiR-199-3p, which arises from the same microRNA 
precursor and is transcribed at the same time as miR-199a/b-5p (reviewed later in 
Chapter 3) was identified as being differentially expressed in response to IL-4 in 
BMDMs (Table 2.1). For this reason, miR-199-3p was also selected as a potential 
candidate.  
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As shown in Table 2.1 both miR-99b and miR-99b* are regulated by IL-4. 
Interestingly, miR-99 and miR-99b* are derived from the same precursor microRNA 
that also forms a microRNA cluster with miR-125a-5p, which was identified as being 
common to both datasets. Majority of the times clustered microRNAs tend to be 
regulated and transcribed together (Bartel, 2004, Altuvia et al., 2005). Hence, both 
miR-99b and miR-99b* appeared to be interesting candidates given their association 
with miR-125a-5p and were also selected for further analysis.  
MiR-223 has recently been shown to play a role in macrophage polarisation (Zhuang 
et al., 2012). It was also identified as being IL-4 receptor dependent (Table 2.2). 
Moreover, miR-223 was also regulated by IL-4 according to the BMDM microarray 
results, however, below our threshold (cut off > 2 fold) and hence does not feature in 
Table 2.1. Based on the above reasoning, miR-223 was also included for further 
study.  
Finally, miR-221 and miR-222 are paralogues that were also identified as being 
differentially expressed in AAMΦ (Table 2.2). Both miR-221 and miR-222 have 
been classified as oncogenic microRNAs with great involvement in the progression 
of several kinds of tumours (Garofalo et al., 2012).  Since a role for M2 polarised 
macrophages has been implicated in tumour progression (Solinas et al., 2009, 
Gocheva et al., 2010, Wang and Joyce, 2010), these microRNAs were also 
considered as interesting candidates for further analysis.  
All of these microRNA candidates selected for further study are listed in Table 2.3. 
We then set out to identify which of these ten microRNAs (classifying isoforms as 
single microRNAs) were consistently associated with the alternative activation 
phenotype. To do this, their expression profiles were studied in different conditions 
of alternative activation ranging from a reductionist in vitro IL-4/13 stimulation of 
macrophage cell lines to a complex in vivo TH2 infection to (Figure 2.3) as outlined 
below.  
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2.2.2.1 In vitro stimulation of macrophage cell lines RAW 264.7 and J774A.1 
Having identified ten microRNAs that were differentially expressed and potentially 
associated with two different models of alternative activation, we set out to validate 
the association of these microRNAs with alternative activation. As a starting point, 
we used two different macrophage cell lines, RAW 264.7 and J774A.1. We decided 
to study the expression profiles of these microRNAs in cell lines initially as they 
provide a homogenous/pure cell population that is cost effective and easy to 
manipulate. Both RAW 264.7 and J774A.1 are functional monocytic macrophage 
cell lines derived from BALB/c mice, with RAW 264.7 being transformed by 
Abelson leukaemia virus (Raschke et al., 1978) while J774A.1 cells were isolated 
from a reticulum cell sarcoma (Ralph et al., 1976).  
Prior to utilisation of these cell lines as in vitro models representative of alternative 
activation, it was essential to establish the individual ability of both RAW 264.7 and 
J774A.1 cells to alternatively activate. Both RAW 264.7 and J774A.1 cells were 
stimulated with IL-4 and/or IL-13 to compare the capacity of these two macrophage 
cell lines to alternatively activate. Additionally, a secondary aim of these 
experiments was to compare and select one of the two cell lines as an in vitro system 
for the identification of microRNA targets. This aligned with the aim of Chapter 5, 
which involves the use of immunoprecipitation of the RISC complex to identify 
microRNA targets in a macrophage cell line.  
Both RAW 264.7 and J774A.1 cells were either left untreated or stimulated with 
10ng/mL of IL-4 and IL-13. Supernatants were harvested for ELISAs and cells lysed 
for extraction of RNA. The parameters measured were primarily the production of 
the characteristic markers of alternative activation - YM-1 (Chi3l3), RELM-a 
(Retnla) and Arginase-1 (Arginase-1) (Gordon, 2003, Martinez and Gordon, 2014). 
Changes in RNA expression and expression of mRNA transcripts were quantified by 
qRT-PCR (Figure 2.4A). At 4hr post stimulation with IL-4 and IL-13, no alternative 
activation was observed as measured by transcript levels of Arginase-1, Chi3l3 and 
Retnla for RAW 264.7 cells. Although no changes were observed in the expression 
levels of Arginase-1 and Chi3l3 in J774A.1 cells, Retnla levels were elevated by 5 
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fold at 4hr. At 24hr post stimulation, a 2 fold, 6 fold and 5 fold increase (relative to 
Gapdh) was observed in the expression of  Arginase-1, Chi3l3 and Retnla in RAW 
264.7 cells. No significant changes in expression of these markers of activation were 
observed in J774A.1 cells, except for Retnla, which showed ~10 fold increase in 
expression relative to Gapdh. At 48hr post stimulation, this increase in Retnla 
expression was not noticeable in J774A.1 cells and the increase in Chi3l3 expression 
had also subsided. Only Arginase-1 levels were still increased by 2 fold at 48hr in 
this cell line. In contrast, activation was at its peak in RAW 264.7 cells at 48hr post 
IL-4/IL-13 stimulation, with ~6 fold increase in expression of both Arginase-1 and 
Chi3l3 (Figure 2.4A). Secreted protein concentrations of YM-1 and RELM-α were 
also measured by ELISA. Only YM-1 was detected in the supernatant (Figure 2.4B). 
No RELM-α was detected in the supernatant for both RAW 264.7 and J774A.1. We 
also assessed the capacity of these cell lines to express other markers of alternative 
activation and to exhibit classical activation markers (described in Appendix 1).  
Having confirmed the ability of both RAW 264.7 and J774A.1 cells to alternatively 
activate, we next sought to validate the expression of the selected microRNAs (Table 
2.3) in these alternatively activated cell lines. To validate the association of these ten 
shortlisted microRNAs from the microarray datasets with alternative activation, both 
RAW 264.7 and J774A.1 cells were either left untreated or stimulated with a 
combination of both IL-4 and IL-13. Cells were harvested and RNA was extracted 48 
hours post stimulation. As previously mentioned, both IL-4 and IL-13 signal through 
a shared IL-4Rα chain (Gordon, 2003) and we have shown above that alternative 
activation in these cell lines is mainly IL-4 driven (Appendix 2). However, the 
addition of IL-13 to the culture medium enhances the state of alternative activation 
and was therefore used in combination with IL-4 in this experiment (Appendix 2). Of 
the ten microRNAs selected, three that were identified as being common to both 
microarray datasets and/or IL-4Rα dependent were selected for initial quantification 
by qRT-PCR. These included miR-125b, miR-146a and miR-378. Additionally, miR-
146b, an isoform of miR-146a that shares the same seed sequence and hence 
functional overlap through shared targets, was included for the quantification as it 
was also differentially regulated in response to IL-4 in BMDM.  
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Consistent with the array results, there was an increase in the levels of miR-125b and 
miR-146b and a reduction in the expression of miR-146a in response to IL-4 and IL-
13 in both RAW 264.7 and J774A.1 cell lines (Figure 2.4C). However, miR-378, 
whose expression was previously shown to be IL-4Rα dependent and upregulated in 
response to IL-4 (Ruckerl et al., 2012), was not altered in either of the cell lines upon 
treatment with IL-4 and IL-13 (Figure 2.4C). This can potentially be explained by the 
fact that both RAW 264.7 and J774A.1 are immortalised tumour cell lines that are 
constantly proliferating and it is probable that microRNAs such as miR-378, which 
are involved in the regulation of macrophage proliferation, are dysregulated in such 
modified cell lines. The lack of miR-378 regulation exposed a serious limitation in 
the use of these cell lines for subsequent analysis of microRNAs involved in the 
regulation of AAMΦ. 
 
2.2.2.2 Analysis of microRNA expression levels in BMDM stimulated with IL-4 
and IL-13 in vitro 
Due to the limitations involved in the use of macrophage cell lines, exemplified by 
the lack of differential expression of miR-378, we next sought out to study the 
expression profiles of the ten shortlisted microRNAs (Table 2.3) in primary 
macrophages. Additionally, although microarrays are a powerful tool for studying 
simultaneous expression profiles on a scale that is impossible using conventional 
analysis, occasionally reliability and reproducibility issues are still encountered. 
Hence, validation of these ten microRNAs in alternatively activated BMDM in vitro 
also provided a secondary confirmation of the differential expression observed in the 
aforementioned microarray dataset. To do this, we generated BMDM as previously 
described (Weischenfeldt and Porse, 2008) and stimulated these BMDM with IL-4 
and IL-13 in vitro or left them untreated for 24 and 48 hours. In the microarray 
described in section 2.3.1, BMDM were stimulated with IL-4 only. It is possible that 
IL-4 and IL-13 exert different effects downstream and regulate the transcription of 
different microRNAs. To account for this, a combination of both IL-4 and IL-13 was 
used as a stimulus for the activation of BMDM. In order to examine their association 
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with alternative activation, the expression levels of the ten shortlisted microRNAs 
(Table 2.3) were validated by qRT-PCR at both 24 and 48 hours post stimulation 
with IL-4 and IL-13. The data were normalised to RNU6B, which displayed stable 
expression in BMDM (data not shown). Of the ten microRNAs examined, all except 
miR-99b* and miR-199-3p were differentially expressed between untreated and 
BMDM treated with IL-4 and IL-13 (Figure 2.5A). Of note, the expression of miR-
199-5p was not detectable in BMDM (Ct value > 38). MiR-125b, miR-146b, miR-
221, miR-222 and miR-378 were all upregulated. Of these, miR-378 was found to be 
the most differentially regulated with an average of a 3-fold change in expression at 
48 hours post stimulation. Conversely, miR-99b, miR-125a, mir-146a and miR-223 
showed a reduction in expression levels by 48 hours. The changes in the expression 
of these microRNAs correlated with an increase in alternative activation over time, 
with greatest changes observed at peak of activation at 48 hours (Figure 2.5B). 
Additionally, thioglycollate elicited macrophages stimulated with IL-4 and IL-13 in 
vitro also displayed similar expression profiles of the ten selected microRNAs 
(Appendix 3). These results demonstrate that the altered expression of the majority of 
these microRNAs appears to be associated with alternative activation of 
macrophages.  
 
2.2.2.3 Expression profiles of microRNAs upon IL-4 complex injection in the 
peritoneal cavity of mice 
Although primary macrophages were a reliable source for validation of the micro-
array analysis, often in vitro systems fail to represent in vivo biological systems in 
terms of complexity. Hence, following validation of the ten shortlisted microRNAs 
with in vitro alternative activation of primary BMDM, we next sought to examine the 
consistency of their association with AAMΦ in in vivo conditions. IL-4 complex (IL-
4c) injection into the peritoneal cavity of mice involves the delivery of recombinant 
IL-4 complexed to an anti IL-4 monoclonal antibody. Slow dissociation of the 
complex allows release of IL-4 from the anti-IL-4 antibody over time (Jenkins et al., 
2013). This results in the proliferation and accumulation of tissue resident 
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macrophages that are also alternatively activated in the peritoneal cavity. Total 
macrophages were isolated from the peritoneal cavity and sorted by flow cytometry 
24 hours post either PBS or IL-4c injection based on the hallmark signatures of 
macrophages, namely F4/80 and CD11b. RNA was then extracted from the sorted 
macrophages and the expression profiles of the ten shortlisted microRNAs examined 
by qRT-PCR. Consistent with the array results, miR-99b*, miR-146b, miR-199b-5p, 
miR-199-3p, miR-221, miR-222 and miR-378 were all found to be upregulated in 
response to IL-4c. MiR-378, which is known to be associated with AAMΦ and has 
been shown to target AKT-1 and thought to negatively regulate IL-4 induced 
proliferation, displayed the largest fold change amongst all the microRNAs whose 
expression was enhanced (Ruckerl et al., 2012). On the other hand there was a 
reduction in the expression of miR-125a, miR-125b, miR-146a and miR-223. MiR-
99b was the only microRNA that did not display differential expression upon 
treatment (Figure 2.6). This data demonstrated consistency in the alteration of 
expression of the majority of the selected microRNAs in AAMΦ both in vitro and in 
vivo.  
 
2.2.2.4 Differential expression of microRNAs during Litomosoides sigmodontis 
infection time course 
We had now validated differential expression of the selected microRNAs under three 
different conditions of alternative activation with increasing complexity. However, 
these conditions were restricted to in vitro IL-4/IL-13 stimulation or IL-4c injection 
in the peritoneal cavity. None of these represented a natural physiological system. 
Although delivery of IL-4c to the peritoneal cavity provides information about the 
expression of these microRNAs in a biological system, it is still a reductionist 
approach that utilises levels of IL-4 that may not be physiological, especially in the 
absence of tissue-specific signals that may normally operate. Additionally, even 
though the expression of these microRNAs was altered in response to B. malayi 
implant, it is possible that the change in their expression following implant was 
infection specific. Hence, to investigate whether in a more complex scenario and in a 
Chapter 2: Selection of microRNAs  
  61 
completely distinct TH2 infection setting these microRNAs would still be 
differentially expressed and associated with alternative activation, we used 
Litomosoides sigmodontis, a murine model of filarial nematode infection.  
Mice were injected subcutaneously with either infective L. sigmodontis L3 larvae or 
injected with control RPMI medium. As the larvae migrate to the pleural cavity 
between day 4 and 6, a TH2 biased immune response is mounted. This was 
characterised by the presence of alternative activation markers, YM-1 and RELMα, 
from day 8 onwards (Figure 2.7), as previously shown (Nair et al., 2005, Jenkins et 
al., 2011). As the infection progressed over time, this state of alternative activation 
continued to rise peaking at day 14 and was maintained until day 28 thereafter. 
During this 28 day period, the lifecycle of the nematode progresses from the L3 
larval stage through to the development into adult worms at day 28 with moulting to 
the L4 stage in between (reviewed in Chapter 1).  We utilised C57BL/6 mice for this 
experiment and the time course was allowed to progress until day 28 and no further 
as C57BL/6 mice have been shown to be resistant to L. sigmodontis infection; the 
fecundity of adult worms is largely affected and no microfilariae are produced 
(Marechal et al., 1997, Babayan et al., 2003b). With the core aim of this study being 
the identification of microRNAs associated with AAMΦ and with alternative 
activation being well established by day 14 post infection (Figure 2.7), the need for a 
long-term patent infection was eliminated. 
It has previously been shown that besides alternative activation, the resident pleural 
macrophages also undergo proliferation (Jenkins et al., 2011). Although the initial 
burst of proliferation is CSF-1 dependent, it is mainly IL-4 dependent mechanisms 
that drive the expansion of the tissue resident population with the progression of 
infection (Jenkins et al., 2011, Jenkins et al., 2013). Consistent with the published 
data, we observed a peak in this IL-4 driven proliferation at day 11 as shown in 
Figure 2.7. Contrary to the maintenance of alternative activation during the time 
course, proliferation steadily declined to baseline levels by day 18. A second burst of 
proliferation was observed at day 28, presumably to return to homeostatic levels of 
steady state proliferation.  
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Having determined that the infection progressed as expected through analysis of 
characteristic markers of alternative activation and proliferation through FACS 
(Figure 2.7), we next sought to examine the expression profiles of the ten selected 
microRNAs over the course of L. sigmodontis infection. At each selected time point, 
macrophages were isolated from the pleural lavage through adherence purification 
and RNA extracted. Changes in microRNA expression levels were measured through 
qRT-PCR and normalised to RNU6B expression. Fold changes were calculated as a 
ratio of values from infected versus naïve mice. As shown in Figure 2.8, consistent 
with our previous findings and in line with the microarray data, expression profiles 
of all the selected microRNAs were altered. Expression levels of miR-99b*, miR-
146b, miR-199b-5p, miR-221, miR-222, miR-223 and miR-378 were significantly 
enhanced. Once again, miR-378 showed the greatest fold change amongst all the 
microRNAs with increased expression levels. Downregulation in the expression of 
miR-99b, miR-125a, miR-125b and miR-146a was observed. Besides examining the 
consistency of expression of the selected microRNAs in this infection model, a 
secondary aim of this infection time course was to gain insight into the expression 
kinetics of these microRNAs over the course of infection and to compare them to the 
expression of characteristic markers of alternative activation and proliferation. This 
data provides some insight regarding the expression levels of several microRNAs in 
relation to the activation and proliferative state of macrophages at specific time 
points over the course of infection.  
 
2.3 Discussion 
MicroRNAs play a critical role in the regulation of cellular processes. Numerous 
studies have shown that microRNAs participate in immune responses and 
specifically in the regulation of CAMΦ. However, it is less clear how microRNAs 
regulate AAMΦ and their responses. The primary objective of this chapter was to 
identify microRNAs differentially expressed in AAMΦ under a range of conditions 
and to select the most appropriate microRNA candidates for further study. Utilising 
microarray datasets previously generated in the lab by Dominik Ruckerl, we 
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identified microRNAs that are highly regulated by IL-4 in either BMDMs in vitro or 
in a B. malayi implant model in mice. In the first microarray dataset obtained through 
stimulation of BMDMs with either IL-4 or LPS, a total of a 118 microRNAs were 
differentially expressed. Based on the selection criteria detailed in section 2.3.1, 15 
microRNAs were deemed to be differentially expressed in response to IL-4 and 
considered for further study (Table 2.1). A recent study conducted by (Squadrito et 
al., 2014), although primarily focused on exosomes, also studied changes in 
microRNA expression levels following IL-4 stimulation of BMDMs. They identified 
29 microRNAs that were significantly regulated by IL-4. Of note, 18 of these 
microRNAs also featured in our BMDM microarray data (data not shown). However, 
only 4 of these microRNAs were shortlisted based on our selection criteria – namely 
miR-125a-5p, miR-146a-5p, miR-149 and miR-378 (summarised in Table 2.1). The 
other 14 had not been considered to be as interesting because their expression levels 
were below our selected threshold (> 2 fold) or because similar changes in their 
expression was observed in response to both IL-4 and LPS. Our focus was to identify 
microRNAs strictly associated with alternative activation; changes in expression 
levels in response to both IL-4 and LPS would suggest a greater likelihood for the 
microRNA function to be associated with macrophage activation in general.  
The information for the second microarray dataset available to us was taken from the 
study performed by Ruckerl et al. in 2012 (Supplementary table 1). This involved the 
use of 19 microRNAs that were identified as being differentially expressed in 
AAMΦ isolated from mice implanted with the nematode B. malayi. Some of these 
microRNAs were also identified as being IL-4Rα dependent (reviewed in Table 2.2). 
Having identified microRNAs differentially expressed in response to IL-4 under two 
distinct conditions of alternative activation, based on our reasoning in section 2.3.2, 
we shortlisted ten microRNA candidates potentially associated with AAMΦ for 
further study. These shortlisted microRNA candidates are listed in Table 2.3. 
To validate the microarray data and to examine the consistency in their expression 
and association with AAMΦ, the expression profiles of these selected microRNA 
candidates were studied under different conditions of alternative activation ranging 
from a complex TH2 infection setting to a reductionist IL-4/IL-13 stimulation of 
Chapter 2: Selection of microRNAs  
  64 
macrophage cell lines. Due to the limitations involved with the use of macrophage 
cell lines, demonstrated by the lack of differential expression of microRNAs with 
known function, data generated using these cell lines was excluded from the final 
analysis for selection of candidates for further study in the subsequent chapters 
(Figure 2.9).  
Among these microRNAs, miR-378, which has previously been shown to directly 
target AKT-1, crucial for the modulation of IL-4 induced proliferation in AAMΦ by 
our lab (Ruckerl et al., 2012), consistently displayed the highest fold change increase 
in its expression. MiR-378 has previously been linked to adipogenesis (Gerin et al., 
2010, Pan et al., 2014, Kulyte et al., 2014, Huang et al., 2015). In relation to this, a 
role for AAMΦ has also been implicated in thermogenesis (Odegaard et al., 2007, 
Kang et al., 2008, Chawla, 2010, Nguyen et al., 2011). Hence, it is possible that 
besides proliferation, miR-378 might regulate other functions of AAMΦ. Given the 
strong association of miR-378 with the alternatively activated phenotype as 
demonstrated in this chapter along with it’s previously published role in their 
regulation, miR-378 was selected for further study in Chapter 4 to delineate its role 
in regulating AAMΦ responses other than proliferation.  
Besides miR-378, two other microRNAs miR-125a-5p and miR-146a also showed a 
consistent downregulation in their expression under all the different conditions of 
alternative activation that were analysed. MiR-125a-5p has previously been shown to 
suppress TLR4 mediated proinflammatory responses and promote macrophage 
polarisation towards the M2 phenotype (Banerjee et al., 2013a). In their study, 
Banerjee et al. show that the induction of miR-125a-5p expression is NF-κB and 
MYD88 dependent. Inhibition of miR-125a-5p enhances levels of TNF-α, IL-12 and 
iNOS. Induction of miR-125a-5p expression upon LPS stimulation is in agreement 
with our results (Table 2.1). However, contrary to our results in terms of alternative 
activation, Banerjee et al. suggest that expression of miR-125a-5p is higher in M2 
macrophages and enhances Arginase-1 levels. Arginine metabolism is a shared 
characteristic of both AAMΦ and CAMΦ. There are circumstances in which 
Arginase-1 expression can be induced by pro-inflammatory signals (El Kasmi et al., 
2008, Mylonas et al., 2009). Hence, solely using Arginase-1 as a marker for 
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enhanced M2 polarisation may not be reliable. Ruckerl et al. (2012) previously found 
the expression of miR-125a-5p to be IL-4Rα dependent. IL-4 has been shown to 
inhibit alternative NF-κB signalling and with miR-125a-5p expression being NF-κB 
dependent (Lawrence, 2009, Sun et al., 2013), the downregulation of miR-125a-5p 
seen in our different models of alternative activation could possibly be explained.  
Besides miR-378 and miR-125a-5p, miR-146a was the third microRNA that was 
consistently downregulated in all conditions of alternative activation that were 
studied. MiR-146a is one of the most widely studied microRNAs and a well-known 
mediator of inflammation, especially in T-cell responses (Curtale et al., 2010, Rusca 
and Monticelli, 2011, Labbaye and Testa, 2012, Yang et al., 2012, Baumjohann and 
Ansel, 2013). As for macrophages, miR-146a is a key player in controlling 
inflammation, myeloproliferation and oncogenic transformation (Taganov et al., 
2006, Boldin et al., 2011, O'Neill et al., 2011). It is known to regulate IL-6 
production and is a known inhibitor of TRAF6 and IRAK1 involved in the regulation 
of TLR signalling in a negative feedback loop (Taganov et al., 2006, He et al., 
2014c). However, a role for miR-146a in the regulation of AAMΦ is yet to be 
determined. We observed a consistent reduction in the expression of miR-146a in 
response to IL-4 both in vitro and in vivo. Conversely, expression of miR-146a was 
significantly enhanced upon LPS stimulation. Like miR-125a-5p, expression of miR-
146a is also NF-κB dependent (Taganov et al., 2006). Both AAMΦ and CAMΦ 
activation states promote changes in patterns of macrophage gene expression that are 
transcriptionally distinct. Keeping this in mind and with the knowledge that IL-4 can 
also inhibit alternative NF-κB signalling, the observed reduction in miR-146a in our 
different models of alternative activation can potentially be explained through the 
NF-κB dependent downregulation of miR-146a by IL-4.  
While expression of miR-146a was reduced in AAMΦ, there was a significant 
increase in the levels of miR-146b, an isoform of miR-146a, under the same 
conditions of alternative activation except in response to B. malayi implant, wherein 
no significant alteration in miR-146b expression was observed. In addition to a Th2 
immune response, exposure to helminths results in complex changes in the 
surrounding environment (MacDonald et al., 2002, Anthony et al., 2007, McSorley 
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and Maizels, 2012). Furthermore, the immune response following an implant is much 
more inflammatory than other infections such as L. sigmodontis because of the initial 
surgery. Hence, there is the possibility that the expression of miR-146b is masked by 
other factors with a stronger influence in this particular scenario. As mentioned 
previously, microRNA isoforms share identical seed sequences (2-8nt) and are 
predicted to bind the same targets and hence, functionally overlap. Like miR-146a, 
miR-146b also regulates TRAF6 and IRAK1 function and is involved in a negative 
feedback loop downstream of TLR signalling (Taganov et al., 2006). Genes encoding 
these microRNAs are found on separate chromosomes. While miR-146a is known to 
be NF-κB dependent, miR-146b is STAT3 induced (Xiang et al., 2014). Whilst IL-4 
can inhibit alternative NF-κB signalling, there have been reports that the shared IL-
4Rα/ IL-13Rα can lead to STAT3 activation (Wery-Zennaro et al., 1999, Umeshita-
Suyama et al., 2000, Bhattacharjee et al., 2013). Hence, the probability exists that 
these isoforms have evolved with redundancy in function, but are expressed in 
response to different environmental cues. This would explain our finding that whilst 
miR-146a expression is reduced in AAMΦ, expression of miR-146b is enhanced.  
Ruckerl et al. (2012) identified miR-199b-5p as being the second most highly 
regulated by IL-4 after miR-378. Moreover, miR-199a-5p and miR-199-3p, which 
belong to the same family as miR-199b-5p, were also differentially expressed in 
AAMΦ according to our lab’s microarray dataset. However, since miR-199b-5p and 
miR-199a-5p are isoforms with identical seed sequences, we decided to focus on 
miR-199b-5p because its expression was IL-4Rα-dependent (Table 2.1). Although a 
role for the miR-199 family has been suggested in several different cancers, the 
specific function of miR-199b-5p is still largely unknown (Sakurai et al., 2011, 
Alexander et al., 2013, Yi et al., 2013, He et al., 2014c, Hashemi Gheinani et al., 
2015). Our investigation of the expression profile of this microRNA under various 
conditions of alternative activation revealed an increase in its expression in vivo.  
MiR-199b-5p was upregulated both in response to IL-4 complex delivery i.p and 
during L. sigmodontis infection. Interestingly, the microarray data from BMDMs 
stimulated with IL-4 suggested a downregulation in the expression of miR-199b-5p 
in response to IL-4. However, upon validation of this data with in vitro stimulation of 
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BMDMs with IL-4 and IL-13, it was found that miR-199b-5p is not expressed very 
highly in these cells indicated by a Ct value >38. These results are in agreement with 
the finding of Ruckerl et al. (2012) that in vitro stimulation of Thio MΦ with IL-4 
does not result in an increase in miR-199b-5p expression. Even though miR-199b-5p 
expression was enhanced in response to two different nematodes and IL-4 injection 
in vivo, the same was not true for stimulation with IL-4 in vitro. Additionally, these 
results might suggest that IL-4Rα signalling on its own is not sufficient to induce the 
expression of miR-199b-5p and that a secondary extrinsic factor that is only found in 
an in vivo environment may be needed. It may also suggest that IL-4Rα expression 
on the macrophage may not be required, but that some other IL-4Rα expressing cell 
type may be involved in the induction of this microRNA. These findings together 
rendered miR-199b-5p a very interesting candidate to pursue for further study as 
described in Chapter 3.  
Next, we examined the expression levels of miR-125b-5p, an isoform of miR-125a-
5p, which has been discussed earlier on in this section. Like miR-125a-5p, miR-
125b-5p is a well-known oncomir known to potentiate macrophage activation 
(Chaudhuri et al., 2011, Kim et al., 2012, Sun et al., 2013, So et al., 2014). Contrary 
to the consistent downregulation of miR-125a-5p under all the different conditions of 
alternative activation, the expression of miR-125b-5p varied greatly. It was 
upregulated in the microarray data obtained from AAMΦ isolated following B. 
malayi implant in mice as well as in BMDMs stimulated with IL-4. The increased 
expression of this microRNA in BMDMs was further validated by qRT-PCR 
following in vitro stimulation with IL-4 and IL-13. However, expression of miR-
125b-5p was reduced during the course of L. sigmodontis infection and also in 
response to IL-4c injection in the peritoneal cavity. A notable contrast to the 
expression profile miR-125b-5p were miR-221 and miR-222, whose pattern of 
expression was opposite to that of miR-125b-5p.  MiR-221 and miR-222 showed 
elevated levels during L. sigmodontis infection and following IL-4 delivery to the 
peritoneal cavity. Their expression, on the other hand, was reduced in the arrays 
involving AAMΦ isolated from B. malayi implant in mice and IL-4 stimulation of 
BMDMs (also confirmed by in vitro stimulation by IL-4 and IL-13). As mentioned 
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previously, miR-221 and miR-222 are paralogs that have been strongly linked with 
angiogenesis and progression of tumours (Suarez and Sessa, 2009, Zhang et al., 
2010b, Zhang et al., 2010a, Zhang et al., 2010d, Shah and Calin, 2011, Garofalo et 
al., 2012, Falkenberg et al., 2013, Gan et al., 2014). A role for AAMΦ has been 
implicated in tumour progression since tumour associated macrophages share many 
properties of AAMΦ (Gordon, 2003, Solinas et al., 2009, Gordon and Martinez, 
2010, Wang and Joyce, 2010). Given that miR-125b-5p has been classified as an 
oncomir (Klusmann et al., 2010, Chaudhuri et al., 2012, Amir et al., 2013), it is 
plausible that these microRNAs are associated with the regulation of some of those 
tumour-promoting properties. What is potentially more interesting is the origin of the 
macrophages under the different conditions of alternative activation. AAMΦ elicited 
following B. malayi implant and BMDMs are both of blood monocyte derived 
macrophage origin whereas AAMΦ isolated during L. sigmodontis infection and in 
response to IL-4c injection in the peritoneal cavity are tissue resident macrophages 
(Ruckerl and Allen, 2014). It has recently been shown that AAMΦ derived from 
monocytes and tissue macrophages are phenotypically and functionally distinct 
(Gundra et al., 2014). Thus, it is intriguing that miR-125b-5p, miR-221 and miR-222 
exhibit differential expression in macrophages based on their origin. Although these 
microRNAs were not selected for further study due to the main focus of this study 
being the association of microRNAs with alternative activation in general, dissecting 
the functional roles of these microRNAs in context of macrophage origin may be 
worth pursuing.  
MiR-223, another IL-4Rα-dependent microRNA, plays a role in macrophage 
polarisation through suppression of proinflammatory activation (Zhuang et al., 
2012). It is also known to play a critical role in haematopoiesis through the 
regulation of progenitor cell proliferation and granulocyte function (Johnnidis et al., 
2008). We have shown that levels of miR-223 were increased in AAMΦ elicited in 
response to both B. malayi and L. sigmodontis. Conversely, a reduction in the 
expression of miR-223 was observed in response to IL-4 in peritoneal macrophages 
and BMDMs. Helminth infections create complex environments wherein several 
factors such as heterogeneous cell populations and varied environmental cues can 
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influence gene expression. In contrast, in vitro stimulation of cells and IL-4 delivery 
to the peritoneal cavity are relatively reductionist approaches restricted to cells 
expressing the IL-4Rα. Hence, it is likely that the enhanced levels of miR-223 in 
response to helminths may be infection specific and a result of interactions between 
the IL-4Rα and other parasite-induced signals.  
In conclusion, we have identified several microRNAs that are differentially 
expressed in AAMΦ. A growing body of evidence discussed in this chapter suggests 
that some of these microRNAs are consistently associated with varying conditions of 
alternative activation. The aim of this study was to shortlist microRNA candidates 
for further study in the subsequent chapters. Of all the selected microRNAs, due to 
the consistency of their expression in AAMΦ under all the different conditions 
studied, miR-125a-5p, miR-146a and miR-378 were considered the most likely to 
play crucial roles in the regulation of this phenotype. Of these, given the importance 
of miR-146a as a mediator of inflammatory responses and the differential expression 
of its isoform miR-146b under the same conditions of alternative activation, we 
decided to evaluate the role of these isoforms in the regulation of AAMΦ in Chapter 
5. With their recognised roles as suppressors of inflammatory responses, we 
hypothesised that under conditions of alternative activation, miR-146b suppresses 
genes otherwise targeted by miR-146a, so as to allow efficient alternative activation 
to occur. Additionally, miR-378 is a known regulator of IL-4 induced proliferation 
(Ruckerl et al., 2012). Given its strong association with the alternatively activated 
phenotype as shown in this chapter, miR-378 was also selected for further analysis of 
its role in fine tuning AAMΦ responses in contexts other than proliferation 
(discussed in Chapter 4). Lastly, the finding that miR-199b-5p is an IL-4 receptor 
dependent microRNA that appears to be expressed highly in AAMΦ only in vivo and 
not in vitro compelled us to investigate the contribution of this microRNA in the 
regulation of AAMΦ further in Chapter 3. 
 
Chapter 2: Selection of microRNAs  
  70 
 
Figure 2.1 Generation of BMDM and identification of microRNAs differentially 
expressed in alternatively activated BMDM.  
BMDM were obtained through in vitro differentiation of bone marrow precursors in M-CSF 
containing medium for 7 days. These BMDM were stimulated with either LPS or IL-4 only 
for 24 hours or preincubated with either LPS or IL-4 for 4 hours followed by treatment with 
either IL-4 or LPS overnight. A microarray screen was then performed with samples (n=3) 
from each treatment group to identify microRNAs differentially regulated in classical and 
alternative activation (Experiment designed, conducted and analysed by D. Ruckerl).  
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TABLE 2.1 Fold changes (Log2) of microRNAs altered in BMDMs in response to either 
IL-4 or LPS treatment 24 hours post stimulation.  
Results adapted from unpublished microarray analysis carried out by D. Ruckerl. Data are 
representative of results obtained from analysis of a single microarray (n=3).  
MicroRNA selection was based on a minimum 2-fold (cut off value) change in expression 
post treatment. MiR-378 (highlighted in red) was included as an exception based on its 
previous association with alternative activation (Ruckerl et al., 2012).  
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Figure 2.2 Identification of IL-4Rα dependent microRNAs during B. malayi infection.  
Thioglycollate elicited macrophages or macrophages elicited in response to B. malayi 
infection from WT and IL-4Rα-/- mice (BALB/c) were harvested from the peritoneal cavity 
of mice and subject to a microRNA array screen. WT B. malayi elicited AAMΦ were 
compared to macrophages from IL-4Rα-/-  animals also implanted with B. malayi to identify 
IL-4Rα dependent microRNAs. Additionally, WT B. malayi elicited AAMΦ were also 
compared to thio elicited MΦ to identify microRNAs expressed only in response to B. 
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TABLE 2.2 Log 2 ratios of microRNAs found to be significantly altered in WT mice 
implanted with B. malayi in comparison to either IL-4Rα-/-  mice or Thio MΦ isolated 
from WT animals.  
Data are representative of results obtained from a single microarray analysis (n=3). 
 **(data table adapted from Ruckerl et al., 2012) 
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TABLE 2.3 Log 2 ratios of microRNA candidates shortlisted for further validation in 
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Figure 2.3 Identification of microRNAs consistently associated with alternative 
activation.  
Previously generated microarray datasets from B. malayi implant and alternatively activated 
BMDMs were utilised to shortlist ten highly regulated microRNAs. The expression profiles 
of these ten microRNAs were then validated by qRT-PCR in four different conditions of 
alternative activation that included macrophage cell lines, BMDM stimulated in vitro with 
IL-4 and IL-13, peritoneal macrophages sorted from mice injected with IL-4 complex and 
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Figure 2.4 Comparison of the ability of macrophage cell lines to alternatively activate 
in response to IL-4 and IL-13 in vitro.  
Macrophage cell lines RAW 264.7 and J774A.1 cells were stimulated with 10ng/mL of IL-4 
and IL-13 for 24 and 48 hours. A) Their ability to alternatively activate was measured 
through quantification of characteristic markers of alternative activation, namely Arginase-1 
(Arg-1), Chi3l3 (YM-1) and Retnla (Relm-a) by qRT-PCR. B) Secreted YM-1 protein was 
quantified by ELISA. RELMa was not detectable in the supernatants for either cell line. Data 
are presented as the mean fold change ± SEM and representative of two separate 
experiments (n=3). Statistical significance for differences between treated and untreated 
samples were determined using one-way ANOVA (Kruskal Wallis test) (* P< 0.05, ** P< 
0.01, *** P< 0.001).  
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Figure 2.4C Analysis of microRNA expression levels in macrophage cell lines upon 
alternative activation in vitro. J774A.1 (coral) and RAW 264.7 (navy) cells were either left 
untreated or stimulated with 20ng/ml IL-4 and IL-13 for 48 hours. Samples were harvested 
for RNA extraction and microRNAs were quantified by qRT-PCR. RNU6b was used as a 
reference gene for normalisation and fold changes were calculated against untreated samples. 
Data are presented as the mean fold change ± SEM and representative of two separate 
experiments (n=3). Statistical significance for differences between treated and untreated 
samples were determined using a two-tailed unpaired student’s T-test (* P< 0.05, ** P< 0.01, 
*** P< 0.001).  
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Figure 2.5 Differential expression of shortlisted microRNAs in BMDM 24 and 48hr 
post IL-4 and IL-13 stimulation.  
Bone marrow precursors isolated from C57BL/6 mice were used to generate BMDM in vitro 
in culture media containing M-CSF for 7 days. A) BMDM were left untreated or stimulated 
with a combination of IL-4 and IL-13 at 20ng/ml for 24 and 48 hours. MicroRNAs were 
quantified by qRT-PCR and normalised using RNU6b as a reference gene. B) Chi3l3 (YM-1) 
expression was quantified as a measure of alternative activation and normalised to Gapdh 
expression. Fold changes are calculated as the ratio of values from untreated samples versus 
samples stimulated with IL-4 and IL-13. Data are presented as the mean fold change ± SEM 
and representative of two separate experiments (n=3). Statistical significance for differences 
between treated and untreated samples were determined using one-way ANOVA (Kruskal 
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Figure 2.6 Expression profiles of the ten shortlisted microRNAs following injection of 
IL-4 complex in the peritoneal cavity of mice.  
WT C57BL/6 mice were injected with either PBS or 5μg of IL-4 complexed with an anti IL-
4 antibody intraperitoneally. Total macrophages were sorted from the peritoneal lavage 
based on F4/80 and CD11b expression. A) MicroRNAs were quantified by qRT-PCR and 
normalised to RNU6b expression. Fold changes are calculated as the ratio of values obtained 
from naïve mice vs. mice injected with IL-4c B) Chi3l3 (YM-1) expression was quantified as 
a measure of alternative activation and normalised to Gapdh expression. Fold changes are 
calculated as the ratio of values from PBS treated mice versus mice injected with IL-4c. Data 
are presented as the mean fold change ± SEM and representative of three separate 
experiments (n=5). Statistical significance for differences between treated and untreated 
samples were determined using a two-tailed unpaired student’s T-test [Mann Whitney] (* P< 
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Figure 2.7 Expression kinetics of markers of alternative activation and proliferation 
during L. sigmodontis infection.  
WT C57BL/6 mice were infected with infective L3 larvae subcutaneously. With the 
migration of larvae into the pleural cavity and progression of infection, the resident 
macrophage population alternatively activates as characterised by the expression of YM-1 
(blue) and RELMα (green). At the same time, macrophages undergo proliferation 
(characterised by Ki67 expression in red), which switches from CSF-1 dependent to CSF-1 
independent IL-4 driven mechanisms after day 6. While a state of alternative activation 
continues to be maintained throughout the infection, the rate of proliferation steadily declines 
to homeostatic levels at day 18. Data are presented as percentage of Cd11b+ F4/80+ 
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Figure 2.8 Validation of expression profiles of selected microRNAs during L. 
sigmodontis infection.  
Pleural macrophages were isolated from pleural exudate cells through adherence purification 
(4 hours) on days 4, 6, 8, 11, 14, 18 and 28 post infection. RNA was extracted and 
microRNAs quantified by qRT-PCR,. Expression was normalised to RNU6B and fold 
changes calculated in comparison to a pool of naïve animals from various time points (days 
4, 11 and 18. Data are presented as the mean fold change ± SEM and representative of a 
single experiment (n=5). Statistical significance for differences between treated and 
untreated samples were determined using two-way ANOVA (* P< 0.05, ** P< 0.01, *** P< 
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Figure 2.9 Venn diagram summary of microRNAs identified as being consistently 
associated with alternative activation across a range of in vitro and in vivo conditions  
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Chapter 3: Functional role of miR-199b-5p in the 
regulation of alternatively activated macrophages 
 
SUMMARY:  
Having identified the association of miR-199b-5p with alternative activation in 
macrophages in Chapter 2, this chapter focuses on elucidating the functional role of 
miR-199b-5p in the regulation of the AAMΦ phenotype. Our lab has previously 
shown that the expression of miR-199b-5p is IL-4Rα dependent. Interestingly, we 
also identified miR-199b-5p as being highly expressed in AAMΦ in vivo but not in 
vitro. Pathway analysis identified insulin signalling and other proliferative pathways 
such as PI3K/AKT as being highly targeted by miR-199b-5p. Overexpression of 
miR-199b-5p in RAW 264.7 cells resulted in a reduction in the rate of proliferation 
and a change in the levels of Insulin Receptor Substrate -1 (IRS-1), suggesting that 
miR-199b-5p might regulate macrophage proliferation via insulin signalling. In 
addition, miR-199b-5p overexpression also resulted in a decrease in secreted YM-1 
and RELM-α proteins, although the effect was less profound than that on the rate of 
proliferation. To address whether these effects also translated in vivo, miR-199b-5p 
was injected in the peritoneal cavity of mice. Consequently, this resulted in an 
inflammatory influx and the disappearance of tissue resident macrophages. 
Subsequently, miR-199b-5p was successfully delivered to the lung and 
overexpressed in alternatively activated alveolar macrophages. No effect was 
observed on IL-4 induced proliferation, potentially due to the lack of insulin receptor 
and IRS-1 expression in alveolar macrophages. However, secreted levels of YM-1, 
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3.1 Introduction 
3.1.1 The miR-199 family 
Genes encoding microRNAs can be intronic or exonic to annotated genes or reside in 
the intergenic regions in both sense and antisense orientations. The miR-199 family 
comprises three paralogs, namely miR-199a-1, miR-199a-2 and miR-199b. All miR-
199 genes are located on separate chromosomes on strands opposite (antisense) to 
intronic regions of Dynamin genes, a family of microtubule binding GTPases, and 
are conserved across vertebrates. MiR-199a-1 and miR-199a-2 are located opposite 
to the intronic regions of Dynamin2 (Dnm2) and Dynamin3 (Dnm3) respectively 
whereas miR-199b is encoded antisense to the intronic region of Dynamin 1 (Dnm1) 
(Figure 1A). Of the miR-199 family, miR-199a-2 is the only member known to 
cluster with another microRNA (miR-214). 
Following transcription and further processing of the primary transcript, the 
precursor microRNAs (pre-miRNAs) derived from each miR-199 gene give rise to 
two mature microRNAs – miR-199-5p and miR-199-3p. The 3’ arm of all three miR-
199 precursors (miR-199a-1, miR-199a-2 and miR-199b) gives rise to a mature 
microRNA product (miR-199-3p) that is identical in sequence and hence its origin 
can only be distinguished at the precursor microRNA or primary microRNA 
transcript levels. However, there are slight differences in the mature microRNA 
comprising the 5’ arm. MiR-199a-1-5p and miR-199a-2-5p, which originate from 
miR-199a-1 and miR-199a-2 precursors respectively, are identical in sequence but 
differ from miR-199b-5p (derived from miR-199b) by one nucleotide. Nevertheless, 
the seed sequences (nucleotides 2-8 from the 5’ end of the miRNA) of miR-199a-5p 
and miR-199b-5p are identical. Since the seed sequences are thought to be the key 
specificity determinants in target recognition (Bartel, 2009, Wang, 2014), these 
miRNAs are therefore predicted to bind to the same targets and presumably share 
significant overlap in function (Figure 1B).  
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A.      
                       
 
 
B.          
    
 
 
Figure 1. MiR-199b-5p is a member of the miR-199 family A) MiR-199b is encoded 
antisense to the intronic region of Dynamin 1. B) All miR-199 genes are antisense to intronic 
regions of Dynamin genes on different chromosomes and give rise to highly related mature 
microRNA sequences. Alignment of 5’ and 3’ mature microRNA sequences derived from 
the three different miR-199 precursors suggests 100% homology in sequence of the 3’ arm 
whereas the 5’ arm differs by a single nucleotide (Identical seed regions are highlighted in 
blue and any differences in nucleotide sequences represented in yellow).  
 
The chromosomal location of the miR-199 family members is distinct and thus, also 
their transcriptional regulation. Previous studies have suggested that STAT3 is 
involved in the regulation of miR-199a-1 (Haghikia et al., 2011), whilst miR-199a-2 
along with its clustered partner miR-214, are regulated by the transcription factor 
Twist-1 during development (Lee et al., 2009). On the other hand, the expression of 
miR-199b-5p has previously been associated with the transcription factors GATA-1 
and NF-E2 (Rosas et al., 2014). Hence, despite their sequence similarity and overlap 
in function, the induction of each of the miR-199 family members appears to be 
                    
miR-199b 
Dnm1 
5’    3’ 
5’ 3’ 
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distinct. Both of the mature microRNAs originating from miR-199a-1 and miR-199a-
2 (miR-199a-5p and miR-199a-3p) are fairly well characterised with implicated roles 
in several different pathways. MiR-199b on the other hand is less described in the 
literature. Expression of the miR-199 family members has been strongly linked with 
several different cancers (Chen et al., 2008, Song et al., 2010, Hou et al., 2011, He et 
al., 2014b, Chen et al., 2014a). MiR-199a has also been associated with the 
progression of liver fibrosis (Murakami et al., 2011, Hoy et al., 2014). MiR-199b 
specifically has been implicated as a therapeutic target in cardiac failure (da Costa 
Martins et al., 2010), as a regulator of the phenotypic switch during vascular cell 
differentiation (Chen et al., 2015) and is known to be involved in the control of 
receptor-mediated endocytosis (Aranda et al., 2015). In the context of macrophages, 
miR-199a-5p and miR-199a-3p were found to be dysregulated in RAW 264.7 
macrophages upon silencing of CD14 that is involved in LPS induced 
proinflammatory cytokine release (Du et al., 2014). Furthermore, miR-199a-5p is 
involved in the inhibition of monocyte/macrophage differentiation (Lin et al., 2014). 
However, a role for miR-199b-5p in the regulation of macrophage responses is yet to 
be determined.  
 
3.1.2 IL-4Rα dependent expression of miR-199b-5p 
Ruckerl et al. (2012) previously showed the differential expression of miR-199b-5p 
in alternatively activated macrophages during B. malayi implant in the peritoneal 
cavity of mice. B. malayi implant results in a strong TH2 response leading to the 
accumulation of alternatively activated macrophages. These B. malayi elicited 
AAMΦ were compared with macrophages isolated from animals also implanted with 
B. malayi, but lacking the IL-4 receptor (IL-4Rα) in order to distinguish IL-4Rα 
dependent microRNA expression.  Mice lacking the IL-4Rα fail to produce 
AAMΦ. Microarray analysis to compare microRNA expression in these 
macrophage populations identified miR-199b-5p as significantly upregulated in 
the AAMΦ elicited in response to B. malayi implant. Additionally this study also 
examined the expression of miR-199b-5p in thioglycollate-elicited macrophages 
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(Thio MΦ) isolated from WT and IL-4Rα-/- animals to validate the findings from 
the microarray results. qRT-PCR analysis of alternatively activated Thio MΦ 
confirmed that the expression of mir-199b-5p is abrogated in mice deficient in the 
IL-4Rα indicating that macrophage expression of miR-199b-5p is IL-4Rα 
dependent. However, no significant change was observed in the expression of miR-
199b-5p upon stimulation of Thio MΦ with IL-4 for 16 hours in vitro suggesting that 
the increase in expression of miR-199b-5p in vivo is not a direct effect of IL-4Rα 
signalling and possibly the induction of this miRNA involves a secondary factor 
(Ruckerl et al., 2012).  
 
3.1.3 Aims of chapter 
As described in Chapter 2, miR-199b-5p was validated as being differentially 
expressed in macrophages under a range of alternative activation conditions. 
However, the role of miR-199b-5p in regulating AAMΦ and their responses is still 
unknown. Thus, the focus of this chapter is aimed at determining the 
contribution of miR-199b-5p in the regulation of the AAMΦ phenotype. To this 
end, previously generated mRNA array data from the lab and algorithmic 
prediction software were utilised to identify potential targets of miR-199b-5p.  
The biological functions and signalling pathways associated with these potential 
targets were deduced using pathway analysis software. MiR-199b-5p was then 
synthetically overexpressed both in vitro and in vivo followed by target validation to 
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3.2 Results 
 
3.2.1 MiR-199b-5p is expressed highly in AAMΦ in vivo but not in 
vitro 
In the study by D. Ruckerl et al. (2012), expression of miR-199b-5p was initially 
identified as being IL-4Rα dependent and associated with alternative activation, as 
described above. However, the levels of miR-199b-5p were found to be highly 
regulated only in AAMΦ isolated from the B. malayi implant in vivo but not in 
thioglycollate-elicited macrophages stimulated with IL-4 for 16 hours in vitro. We 
have already shown in Chapter 2 that the differential expression of miR-199b-5p is 
not restricted to B. malayi implant but was also seen during infection of mice with 
the nematode L. sigmodontis (Figure 2.8, Chapter 2). Moreover, miR-199b-5p was 
also upregulated in response to IL-4 complex injection in the peritoneal cavity 
(Figure 2.6, Chapter 2). All of these results suggested that miR-199b-5p is highly 
regulated in vivo under diverse conditions of alternative activation. In contrast, the 
expression of miR-199b-5p was not altered in bone marrow derived macrophages 
(BMDM) stimulated with IL-4 and IL-13 in vitro for up to 48 hours (Figure 3.1). 
This is consistent with the finding of Ruckerl et al. (2012) that miR-199b-5p is not 
regulated in thioglycollate-elicited macrophages stimulated with IL-4 in vitro. In 
fact, based on a Ct value >35 as measured by qRT-PCR, miR-199b-5p was expected 
to be present only at very low levels in BMDM (reviewed in Chapter 2). 
Additionally, no changes were observed in the expression of miR-199b-5p in RAW 
264.7 cells in response to stimulation with IL-4 and IL-13 for 48 hours (Figure 3.1). 
Analysis of copy number determined by qRT-PCR using a synthetic standard 
revealed that miR-199b-5p was expressed at significantly lower levels in vitro than 
in vivo as shown in Figure 3.1. MiR-199b-5p was only expressed at 5-10 x 103 copies 
per ng of RNA in BMDM and RAW 264.7 cells and these numbers remained 
unchanged upon stimulation with IL-4/IL-13. On the other hand, levels of miR-199b-
5p reached 100-200 x 103 copies/ng RNA in response to IL-4c delivery or during L. 
sigmodontis infection. In summary, though miR-199b-5p expression was highly 
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regulated in vivo in a TH2 environment, this miRNA does not appear to be regulated 
in alternatively activated BMDMs and RAW 264.7 cells stimulated with IL-4/13 in 
vitro. These results are consistent with the hypothesis that the regulation of miR-
199b-5p is not a direct effect of IL-4Rα signalling and that the involvement of a 
secondary extrinsic factor is necessary for the induction of miR-199b-5p expression. 
 
3.2.2 Prediction of a putative functional role of miR-199b-5p in 
AAMΦ 
A key objective of this study was to understand the contribution of miR-199b-5p in 
the regulation, maintenance and proliferation of AAMΦ. To this end, we utilised 
target prediction to elucidate the putative functional significance of miR-199b-5p in 
AAMΦ. As microRNAs have gained importance as regulators of gene expression, 
several approaches have been developed for identifying their targets. One of the most 
extensively used techniques involves prediction of targets using algorithm-based 
software such as TargetScan (www.targetscan.org). TargetScan relies on the 
identification of potential microRNA targets based on a minimum 7 nucleotide 
consecutive match/base pairing between the seed site (2-7nt) found at the 5’ end of a 
microRNA and the 3’UTR of the target mRNA. In addition to the seed region, 
TargetScan extends the analysis to 21-23 nucleotide long fragments representing true 
interactions. Based on this length of base pairing between the microRNA and target 
mRNA, the occurrence of an evolutionarily conserved adenine at the first position of 
the mRNA target site that is thought to act as an anchor for RISC, is also considered. 
In some cases, the AU content 30nt upstream or downstream of the predicted site 
may also be taken into account (Witkos et al., 2011). Since miR-199b-5p is an 
isoform of miR-199a-5p with an identical seed sequence, TargetScan does not 
differentiate between the two mature microRNAs and they are thus predicted to have 
the same set of targets. Based on these predicted canonical interactions by 
TargetScan, a list of 3,267 predicted targets of miR-199a/b-5p irrespective of site 
conservation amongst species was generated. Of note, a brief pathway analysis of 
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these predicted targets (data not shown) revealed that the majority of these predicted 
targets are associated with known proliferative pathways.  
As described in Chapter 2, macrophages in the pleural cavity proliferated and 
alternatively activated during infection with L. sigmodontis (Chapter 2, Figure 2.8). 
Since a significant proportion of the predicted miR-199b-5p targets appeared to be 
associated with proliferative pathways, the expression of miR-199b-5p during the 
course of this infection was correlated with the expression of Ki67, a marker of 
proliferation (Figure 3.2). Interestingly while proliferation started to steadily decline 
with the progression of infection from day 8 onward, expression of miR-199b-5p 
also increased. In the introductory chapter, we discussed the dynamics of IL-4 
dependent and independent (CSF-1 driven) macrophage proliferation during L. 
sigmodontis infection as shown by Jenkins et al (2011). Interestingly, as shown in 
Figure 3.2, the upregulation of miR-199b-5p expression appeared just as 
proliferation switches from a CFS-1 dependent phase to IL-4 driven proliferation 
between day 8 and day 11 with the progression of infection (Jenkins et al., 2011, 
Jenkins et al., 2013). Furthermore, this was also consistent with the earlier finding 
that the expression of miR-199b-5p is IL-4Rα dependent (Ruckerl et al., 2012).   
The inverse relationship between IL-4 dependent proliferation and miR-199b-5p 
expression in the L. sigmodontis time course led to the hypothesis that IL-4Rα 
dependent expression of miR-199b-5p acts as a regulator of IL-4 induced 
proliferation in a negative feedback loop. This was supported by the dependency of 
miR-199b-5p expression on IL-4Rα signalling and the association of the predicted 
targets of miR-199b-5p with proliferative pathways. Since we have shown here that 
miR-199b-5p expression is enhanced in response to IL4/IL-13 only in vivo and not in 
vitro, the presence of a secondary extrinsic factor or cell type may also be needed for 
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3.2.3 MiR-199b-5p regulates proliferation in RAW 264.7 cells 
To address the question of whether or not miR-199b-5p regulates proliferation in 
macrophages, the effect of overexpression of miR-199b-5p on proliferation was 
studied in RAW264.7 cells. Significant macrophage proliferation cannot be achieved 
with primary macrophages in response to IL-4 or IL-13 in vitro. Thus, RAW 264.7 
cells were chosen based on their capacity to constantly proliferate making them a 
useful tool to assess the role of miR-199b-5p in regulating macrophage proliferation.  
Cells were prestained with CFDA-SE (carboxy fluorescein diacetate - succinimidyl 
ester); a dye that passively diffuses into cells and forms fluorescent conjugates with 
intracellular amines upon cleavage by non-specific esterases (Figure 3.3). The dye-
protein adducts are retained by the cell throughout division and the fluorescence 
intensity is reduced by half with each cell division.  Following staining with CFDA-
SE, cells were transfected with synthetic oligos that are double-stranded RNAs 
which mimic mature endogenous microRNAs in the cell. Cells were transfected with 
either miR-199b-5p or the relevant controls. The negative controls were a C.elegans 
microRNA and an siRNA that fails to incorporate into the RISC complex (termed 
RISC free here on). The positive control was miR-378, which has already been 
shown to negatively regulate proliferation in RAW 264.7 cells through suppression 
of AKT-1(Ruckerl et al., 2012).  
As mentioned previously, miR-199b-5p is a member of the miR-199 family that is 
differentially expressed in AAMΦ. Since miR-199a-5p and miR-199b-5p share the 
same seed sequence and are predicted to bind the same targets, cells were also 
transfected with miR-199a-5p to study the functional overlap between these 
microRNAs. As discussed earlier in this chapter, miR-199-3p arises from the same 
precursor microRNAs as miR-199a/b-5p but with a distinct seed region and hence, a 
separate repertoire of predicted targets. However, it is known that about 1/3 of 
mature microRNAs originating from the same precursor are involved in regulation of 
the same biological pathways (Bartel, 2004). Moreover, miR-199-3p is known to 
regulate proliferation of other cell types (Shatseva et al., 2011). Thus, cells were also 
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transfected with miR-199-3p to investigate whether it also regulates proliferation of 
macrophages.  
Cells from each treatment group were harvested at 24 hours and 48 hours post 
transfection and analysed for fluorescence as a measure of cell division by flow 
cytometry. 4 hours prior to each harvest, Alamar blue was added to each well and the 
supernatant harvested just before cells were prepared for FACS analysis. Alamar 
blue is a cell viability indicator that utilises the metabolic activity of living cells to 
convert resazurin to a fluorescent molecule, resorufin. Viable cells continuously 
convert resazurin to resorufin, thereby generating a quantitative measure of cell 
viability and cytotoxicity (and by inference, replication capacity). In this experiment, 
cell viability was used as an indirect secondary measure of cell expansion. RNA was 
also isolated at each time point to measure transfection efficiency.  
Analysis of CFSE intensity through flow cytometry revealed that cells transfected 
with miR-199a-5p, miR-199b-5p and miR-378 showed a significant reduction in the 
loss of CFSE intensity over time in comparison to cells transfected with miR-199a-
3p, RISC free siRNA and the C. elegans microRNA (Figure 3.4A). While only 30% 
of cells transfected with miR-199a-3p, RISC free siRNA and the C. elegans 
microRNAs stained positive for CFSE, ~60-70% of cells transfected with miR-199a-
5p, miR-199b-5p and miR-378 still contained CFSE. Similarly, cells transfected with 
miR-199a/b-5p were significantly brighter (~1.5 fold) in terms of the median 
fluorescence intensity (Figure 3.4 C). In agreement with this, the rate of conversion 
of alamar blue was also significantly reduced in cells transfected with miR-199a/b-5p 
and miR-378, with no change in the conversion rate over a 24 hour period (Figure 
3.4 B). In contrast, miR-199a-3p had no significant effect on the rate of alamar blue 
conversion as indicated by constant breakdown of the reagent and thus, increased 
fluorescence over time suggesting that the negative regulation of cell expansion is 
specific to miR-199a/b-5p. These results indicate that miR-199b-5p negatively 
regulates proliferation in RAW 264.7 cells and also confirms the overlap of function 
between miR-199a-5p and miR-199b-5p. 
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3.2.4 MiR-199b-5p also negatively impacts alternative activation in 
RAW 264.7 cells 
Individual microRNAs have the capacity to directly or indirectly regulate the 
expression levels of hundreds of genes (Krek et al., 2005, Lim et al., 2005, Jackson 
and Standart, 2007, Fabian et al., 2010).  
Although a brief literature search and pathway analysis revealed that predicted 
targets of miR-199b-5p identified through TargetScan were mostly associated with 
proliferation, regulation of other pathways is possible and even likely. The main goal 
of our study is to identify the functional role of microRNAs in the regulation, 
maintenance and proliferation of AAMΦ. Hence, the impact of miR-199b-5p 
overexpression on alternative activation was also examined in RAW 264.7 cells. 
The ability of RAW 264.7 cells to alternatively activate has previously been 
discussed in Chapter 2. RAW 264.7 cells were transfected under identical conditions 
to those described in the previous experiment above, however cells in this case were 
harvested following stimulation with 20ng/ml of IL-4 and IL-13 (Figure 3.5A). Cells 
were also transfected with miR-199a-5p and miR-199-3p for reasons described 
previously.  MiR-378 was also included in this experiment because it has been 
shown to target AKT-1, which negatively affects levels of RELM-α, a marker of 
alternative activation (Ruckerl et al., 2012).  
Supernatants were harvested 24 hours post stimulation with IL-4 and IL-13 and 
subject to ELISAs for YM-1 and RELM-α, markers characteristic of alternative 
activation. Analysis of YM-1 levels revealed a reduction in secreted protein 
concentration in cells transfected with members of the miR-199 family and miR-378 
compared to cells transfected with either lipid only or cells that received the negative 
controls, RISC-free siRNA and C.elegans microRNA (Figure 3.5B). Among the 
miR-199 family, cells transfected with miR-199-3p produced essentially no YM-1 
compared to miR-199a-5p and miR-199b-5p, which displayed a comparable 50% 
reduction in protein levels.  A similar trend was observed for levels of RELM-α, 
although it is worth mentioning that RAW 264.7 cells do not secrete significant 
amounts of RELM-α as reflected in Figure 3.5B. Levels of RELM-α were 
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significantly reduced in cells transfected with miR-199a-5p, miR-199b-5p and miR-
199-3p when compared to RISC free, lipid only and C. elegans controls. As 
predicted, considerable suppression of RELM-α was also observed in cells 
transfected with the positive control miR-378. These results indicate that miR-199b-
5p not only affects proliferation, but also alternative activation in RAW 264.7 cells. 
Additionally, although miR-199-3p did not affect proliferation of RAW 264.7 cells, 
it appears to have a substantial effect on alternative activation.  
 
3.2.5 Identification and functional analysis of predicted targets of 
miR-199b-5p  
We have shown that miR-199b-5p has the ability to reduce both proliferation and 
alternative activation in RAW 264.7 cells.  However, RAW 264.7 cells do not secrete 
copious amounts of YM-1 and RELM-α as shown in Figure 3.5B. Given that miR-
199b-5p had a considerable effect on RAW 264.7 cell expansion, we decided to 
focus on its role in regulating macrophage proliferation. To gain insight into the 
biology of genes regulated by miR-199b-5p leading to this effect, we sought to 
identify pathways targeted by this microRNA. As mentioned previously, we initially 
identified 3,267 predicted targets of miR-199b-5p using the target prediction 
program TargetScan. These putative targets were identified on the basis of predicted 
direct binding sites for miR-199b-5p in the 3’UTR of target mRNAs. To help narrow 
down this number and to select the most promising targets of miR-199b-5p in the 
context of proliferation, we also utilised additional mRNA array data previously 
generated in our lab by Graham Thomas. This mRNA array data was generated using 
MΦ from an L. sigmodontis infection time course. Graham Thomas used a 
generalised linear modelling approach to identify and rank genes that change either 
positively or negatively in relation to Ki67 expression over the course of infection. In 
this study, this list of genes was then overlapped with the list of predicted targets of 
miR-199b-5p to generate a list of 2,440 genes (Figure 3.6). The primary aim of 
generating this list was to try and tease apart genes and pathways targeted by miR-
199b-5p that ultimately result in an effect on macrophage proliferation. To achieve 
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this, the Ingenuity Pathway Analysis (IPA) program, a web based software, was 
utilised (http://www.ingenuity.com).  
IPA classifies genes based on existing literature and known functions; related sets of 
genes are then grouped into cellular pathways or biological functions. However, 
these classifications can be based on both direct and indirect interactions. Given the 
large number of genes presented in our list of putative targets, the indirect 
relationships identified by this software posed a possible hindrance in terms of low 
stringency in selection of pathways targeted by miR-199b-5p. Hence, out of the 
2,440 genes identified, we selected for pathway analysis only the top 300 significant 
genes that change positively in relation to Ki67 and based on P-values obtained from 
the mRNA array data (P value < 0.005). The significance of the association between 
these predicted miR-199b-5p targets and pathways identified by IPA were assessed 
based on two separate conditions:  
1. A P-value (right-tailed Fisher’s exact test) demonstrating the likelihood 
that the assembly of genes in a particular dataset within a pathway could 
be interpreted by random chance alone. 
2. A ratio of the number of genes (from our 300 selected genes) that are 
involved in a given pathway to that of the total number of genes known to 
be associated with that particular pathway.  
 
Based on the above measures and analysis, the IPA library of canonical pathways 
identified 11 significantly enriched pathways associated with the 300 genes predicted 
to be miR-199b-5p targets (P value < 0.001). These included Insulin – like growth 
factor 1 (IGF-1) signalling, PPARα/RXRα activation, insulin receptor signalling, 
Type II diabetes mellitus signalling, PI3K/AKT signalling, phosphoinositide 
biosynthesis and NF- κB signalling among others suggesting that miR-199b-5p may 
be involved in the modulation of several different pathways (Table 3.1). Various 
cancer related pathways such as molecular mechanisms of cancer and role of tissue 
factors in cancer were also presented in the results of this analysis.  
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To elucidate the role of miR-199b-5p in regulating macrophage proliferation, an 
examination of existing literature was conducted to determine whether any of the 
pathways predicted by IPA as being regulated by miR-199b-5p are known to be 
important in proliferation. Of the 11 pathways identified using IPA, IGF-1 signalling 
was predicted to be the most significantly regulated by miR-199b-5p (Table 3.1). 
IGF-1 signalling is crucial for normal embryonic growth and development in mice 
and this is reflected in the fact that null mutants for the IGF-1 receptor gene (Igf1r) 
die invariably at birth with a severe growth defect, reaching only 45% of the normal 
size (Liu et al., 1993). Similarly, mice with disrupted Igf1 gene exhibit a growth 
deficiency (60% of normal birth weight) and depending on the genetic background 
these Igf-1-/- dwarfs die shortly after birth (Liu et al., 1993).  
IGF-1 signalling has a well-established role in the regulation of proliferation of 
various cell types including neural progenitor-like and other progenitor cells (Choi et 
al., 2008, Huat et al., 2014), myoblasts and myocytes (Engert et al., 1996, Yu et al., 
2015), skeletal muscle (Schiaffino and Mammucari, 2011) and sertoli cells (Pitetti et 
al., 2013). Additionally IGF-1 signalling and specifically IGF1R has been implicated 
in cancer biology, with a reduction in levels of this receptor leading to apoptosis of 
cancer cells making it an attractive therapeutic target (Yu and Rohan, 2000, Baserga 
et al., 2003, Werner and Bruchim, 2009, Davison et al., 2011). IGF-1 signalling has 
also been shown to be essential for proliferation of human fibroblasts and hepatic 
stellate cells (Sell et al., 1993, Svegliati-Baroni et al., 1999). More importantly, IGF-
1 signalling is known to be involved in the proliferation and differentiation of murine 
BMDM precursors (Long et al., 1998) and has been shown to affect the proliferation 
rate and morphology of RAW 264.7 cells (Smith et al., 2000).   
With the known association of IGF-1 signalling with cancer biology (Baserga et al., 
2003, Denduluri et al., 2015), it was interesting to observe that the second most 
highly regulated pathway predicted to be targeted by miR-199b-5p was “molecular 
mechanisms of cancer” along with “role of tissue factors in cancer” also featuring in 
the list of the 11 significant pathways identified (Table 3.1). Of additional interest 
was insulin receptor signalling, which was also present in this list and predicted to be 
regulated by miR-199b-5p. The reason being that insulin receptor (IR) and IGF1R 
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are highly related receptor tyrosine kinases that are capable of forming heterodimers 
(Treadway et al., 1989, De Meyts and Whittaker, 2002, Cabail et al., 2015). 
Depending on the IR isoform involved, these hybrid receptors can bind both IGF-1 
and insulin (Pandini et al., 2002).  
Like IGF1 signalling, IR signalling also plays a role in the proliferation of various 
cell types (Shawl et al., 2009, Amaya et al., 2014, Escribano et al., 2015). Similar to 
the IGF1R, IR is also involved in cancer progression and downregulation of IR also 
results in inhibition of cancer cell proliferation and metastasis (Zhang et al., 2010c, 
Belfiore and Malaguarnera, 2011). This partial overlap in function may be explained 
by the well-established roles of the downstream kinases AKT and MEK, through 
which both the IR and IGF1R function to regulate gene expression as shown in 
Figure 3.7 (Adams et al., 2004, Cohen, 2006, Taniguchi et al., 2006, Laviola et al., 
2007, Siddle, 2011). Activation of these kinases is dependent on phosphorylation of 
insulin receptor substrates 1 and 2 (IRS-1 and IRS-2), leading to the activation of 
PI3K and the G-protein Ras respectively (Siddle, 2011).  In line with this, IPA 
analysis also revealed PI3K/AKT signalling as being highly regulated by miR-199b-
5p (Table 3.1). 
The primary aim of this study is to elucidate the functional role of miR-199b-5p in 
the proliferation of AAMΦ and the cytokines IL-4 and IL-13 signal through a shared 
IL-4Rα chain resulting in proliferation and alternative activation of macrophages 
(Gordon, 2003, Jenkins et al., 2011, Jenkins et al., 2013). IL-4 has previously been 
shown to directly phosphorylate insulin receptor substrates (IRS-1 and 2) that are 
downstream of both IR and IGF1R signalling (Wang et al., 1993a, Wang et al., 
1993b, Wang et al., 1995, Zamorano et al., 1996, Nelms et al., 1999). A schematic 
representation of the association of IR, IGFR1 and IL-4 signalling is depicted in 
Figure 3.7. Given the strong association of the insulin/IGF-1 signalling axis with 
proliferation and the association of IL-4 with elements common to these pathways, 
we decided to focus on the regulation of these shared pathways by miR-199b-5p. 
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3.2.5.1 Validation of predicted targets of miR-199b-5p in the insulin/IGF-1 
signalling axis 
Having identified insulin/IGF-1 signalling as a pathway potentially regulated by 
miR-199b-5p that could link to IL-4 induced proliferation, we next sought to identify 
genes within this pathway that were putative miR-199b-5p targets that could result in 
the miR-199b-5p directed inhibition of macrophage proliferation. All the predicted 
targets of miR-199b-5p that form part of this signalling cascade have been depicted 
in Figure 3.7. The pathway is predicted to be targeted by miR-199b-5p at multiple 
levels, from the receptors found on the extracellular membrane through to nuclear 
cell cycle genes. Both the IR (Insr) and IGF-1R (Igf1r) are putative targets along 
with IRS-1 (Irs1), which forms the core of this signalling cascade. Whilst there are 3 
predicted binding sites for miR-199b-5p in the 3’UTR of the Insr, both Igf1r and Irs1 
have only one predicted site each (based on prediction by TargetScan). Downstream 
of these molecules, Pik3r1 and Pik3cd, which are the regulatory and catalytic 
subunits of PI3K respectively, and the kinase AKT (Akt3) are also predicted targets 
of miR-199b-5p with a single binding site in their 3’UTRs. Several other genes that 
are downstream substrates and involved in the cell cycle were also identified as 
potential targets. However, since we were interested specifically in macrophage 
proliferation, we decided to focus on validating the receptors (Insr and Igf1r), which 
are known to be expressed on macrophages and their substrate Irs1 as miR-199b-5p 
targets. Additionally, downstream molecules in the PI3K/AKT signalling cascade are 
well established as key components of other canonical pathways and may not be 
specific to macrophages and were, therefore, not considered for initial validation.  
In order to determine whether miR-199b-5p regulates macrophage proliferation by 
targeting the insulin/IGF-1 signalling cascades, the effect of mir-199b-5p 
overexpression on the expression levels of its predicted targets (shown in Figure 3.7) 
was studied. Similar to the experiment described above, RAW 264.7 cells were either 
left untransfected or transfected with members of the miR-199 family and the 
appropriate controls, namely miR-378 (positive control), RISC free and a C. elegans 
microRNA (negative controls). Cells were harvested 48 hours post transfection and 
RNA extracted. The mRNA transcripts of interest were quantified by qRT-PCR. Cell 
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lysates were also harvested for protein quantification. As can be seen in Figure 3.8A, 
no effect was observed on the mRNA levels of Insr and Igf1r following transfection 
with miR-199b-5p. Unexpectedly, the mRNA levels of Irs1 were significantly 
enhanced. This was also observed in cells transfected with miR-199a-5p, which 
shares the same seed sequence as miR-199b-5p, but not in any of the other 
conditions. To confirm that this increase in Irs1 expression was not an artefact of the 
experiment, levels of Akt1, a known target of miR-378 (Ruckerl et al., 2012) were 
also quantified. As expected, a considerable reduction in Akt1 expression was 
observed in cells transfected with miR-378 while expression remained unchanged in 
cells transfected with all the other mimics (Figure 3.8B).  
To investigate whether this increase in expression of the Irs1 mRNA was also 
reflected at the protein level, lysates were subjected to Western blot analysis. As is 
evident in Figure 3.9, IRS1 was not highly expressed in RAW 264.7 cells. However, 
upon transfection with miR-199a/b-5p, these levels were enhanced, confirming our 
earlier finding that miR-199b-5p increased Irs1 expression. As mentioned 
previously, IL-4 can positively affect levels of IRS1. Moreover, our main goal is to 
identify the function of miR-199b-5p in the regulation of AAMΦ. During alternative 
activation, several different factors and signalling cascades downstream of the IL-
4Rα can be activated simultaneously. Since IL-4 is not the sole regulator of IRS 
expression, its levels may be altered by factors other than IL-4. Thus, we also 
stimulated RAW 264.7 cells with IL-4 following transfection with microRNA 
mimics to study whether these changes in IRS-1 levels by miR-199b-5p also hold 
true under conditions of alternative activation. As expected, levels of IRS1 were 
elevated following stimulation with IL-4 as shown in Figure 3.9. Furthermore, 
expression of IRS1 was regulated by miR-199a/b-5p in AAMΦ with an increase in 
protein following transfection (Figure 3.9).  This increase was not observed in cells 
transfected with the other microRNA mimics suggesting that regulation of IRS1 was 
restricted to miR-199a/b-5p.  
The increase in levels of IRS1 was contrary to the known function of microRNAs, 
which is to regulate gene expression through destabilisation and/or degradation of 
target mRNA (Bartel, 2009, Guo et al., 2010, Eichhorn et al., 2014). Hence, it was 
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possible that the reduction in macrophage proliferation may not be IRS-1 mediated. 
Thus, we also chose to validate other predicted targets of miR-199b-5p downstream 
of IRS1 that may be downregulated resulting in decreased proliferation. Levels of 
Pi3kr1, Pi3kcd, Akt3 and other genes involved in cell cycle regulation including 
E2f2, Cdc6, Rbl1, Tk1, Ncapg2, Ccne1 and Tab1 were quantified (Figure 3.10). 
Although no significant changes were observed in the expression levels of any of 
these genes following transfection with miR-199b-5p, it is important to note that 
microRNAs impose subtle effects and as such it may be difficult to discern these 
subtle differences that may combinatorially influence proliferation.    
 
3.2.6 In vivo delivery of miR-199b-5p 
3.2.6.1 Delivery of miR-199b-5p to the peritoneal cavity of mice 
We have already shown that miR-199b-5p reduces the rate of proliferation in RAW 
264.7 cells. While studies to validate the targets of miR-199b-5p in vitro were 
underway, we attempted to deliver a synthetic mimic of miR-199b-5p in vivo to 
further validate its role in regulating macrophage proliferation. This experiment had 
4 separate aims: 1) To establish the conditions for microRNA delivery in vivo, 2) To 
validate that the delivered microRNAs are functional, 3) To investigate whether 
macrophages were the primary cell type to be transfected and 4) To determine 
whether miR-199b-5p affected steady state CSF-1 derived proliferation in 
macrophages. To do this, we utilised microRNA mimics complexed to jetPEI. JetPEI 
is a lipid-based polymer that forms stable cationic complexes with the mature mimic 
microRNA, thus facilitating delivery. 20μg of microRNA was complexed to jetPEI 
(N:P ratio = 6) in 5% glucose and injected intraperitoneally. For efficient transfection 
of these cationic complexes, the ionic balance within lipid /nucleic acid complexes is 
crucial. For effective cell entry, these complexes should be cationic. The N:P ratio is 
a measure of the ionic balance within the complexes and is defined as the number of 
nitrogen residues of the jetPEI lipid per nucleic acid phosphate. The conditions used 
in this experiment were based on unpublished transfection data from our lab along 
with manufacturer suggestions of N:P ratios. Control animals received 5% glucose 
Chapter 4: miR-378/378* mice  
  105 
only whereas other groups of mice received either miR-199b-5p or a C. elegans 
microRNA as negative control (3.11A). To examine whether the delivered 
microRNA complexes were functional, an additional group of mice received a 
microRNA that binds to the 3’UTR of GAPDH resulting in reduction of GAPDH 
expression (termed siRNA GAPDH here on). Since one of the aims of this 
experiment was to determine the effect of miR-199b-5p on steady state CSF-1 driven 
proliferation, animals were injected with bromodeoxyuridine (BrdU) 3 hours prior to 
culling. BrdU is a thymidine analogue that gets incorporated into newly synthesised 
DNA and is thus a measure of active proliferation. Animals were culled 48 hours 
post microRNA delivery and peritoneal exudate cells (PEC) were collected via 
washing of the peritoneal cavity. Supernatants were collected for ELISAs. PEC cells 
were divided for FACS analysis and RNA extraction for qRT-PCR. One of the 
experimental aims was to investigate whether macrophages were the primary cell 
type to be transfected. To do this, PEC cells were adherence purified to isolate 
macrophages and the washes collected to harvest other cell types. qRT-PCR analysis 
revealed that miR-199b-5p and other microRNAs can successfully be delivered in 
vivo (Figure 3.11B). Levels of miR-199b-5p were significantly increased (nearly 
3000 fold) in peritoneal macrophages 48 hours post delivery. However, it appears 
that macrophages may not be the primary cell type that is transfected as other cells in 
the PEC washes also showed similar increased levels of miR-199b-5p (Figure 
3.11B). These other cell types may include other phagocytic cells such as dendritic 
cells and neutrophils. However, the adherence purification is relatively crude and the 
washes may still contain macrophages. Similarly, quantification of the C. elegans 
microRNA revealed a significant increase in its expression in the relevant group of 
mice (Figure 3.11B). Analysis of qRT-PCR results also demonstrated that the 
microRNAs delivered are indeed functional as represented by the significant 
reduction in GAPDH expression in the group of mice that received siRNA GAPDH 
(Figure 3.11B). These results demonstrate that functional microRNAs can be 
delivered in vivo.  
The primary aim of this chapter is to elucidate the role of miR-199b-5p in regulating 
AAMΦ and their responses. Hence, it was important to investigate whether the effect 
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of miR-199b-5p was specific to IL-4Rα dependent processes. Therefore, having 
confirmed successful delivery of miR-199b-5p in macrophages, we next investigated 
whether miR-199b-5p influenced IL-4Rα independent steady state CSF-1 driven 
proliferation to rule out effects of miR-199b-5p or transfection itself on IL-4Rα 
independent pathways.  To this end, we used flow cytometry to identify peritoneal 
macrophages based on the expression of CD11b and F4/80. Live cells were identified 
using Aqua live/dead stain. Lineage negative cells were excluded based on a 
combined stain that included SiglecF, CD19, TCR-β and Ly6G, which are 
characteristic markers of eosinophils, B cells, T cells and neutrophils respectively. 
Next, cells that do not express MHC-II and F4/80 were excluded. Dendritic cells 
were then identified based on high MHC-II and CD11c expression and also 
excluded. Macrophages were then identified based on CD11b and F4/80 expression. 
Response to injection in the peritoneal cavity can result in some blood monocyte 
derived inflammatory macrophages being recruited to the peritoneal cavity. These 
were segregated from the tissue resident macrophages based on F4/80 and Tim4 
expression. Tissue resident macrophages are F4/80hi and 90% of the tissue resident 
macrophages also express Tim4 whereas monocyte derived macrophages are F4/80lo 
and do not express Tim4 (Davies et al., 2013a). Proliferation was quantified using 
Ki67 and BrdU. In an additional stain panel, Ly6C and Ly6G were used to identify 
monocytes and neutrophils respectively as markers of inflammatory influx 
(Soehnlein & Lindbom, 2010).  
FACS analysis of the PEC populations revealed that transfection causes an 
inflammatory influx resulting in tissue resident macrophage disappearance (Barth et 
al., 1995, Davies et al., 2013b) as shown in Figure 3.12. In a naïve mouse, the 
majority of the peritoneal macrophage population is tissue resident derived and this 
was also reflected in the group of mice that received 5% glucose only. The 10% of 
macrophages that are F4/80lo and monocyte derived were presumably a result of the 
inflammatory response to the injection itself (Figure 3.12). In contrast, the majority 
of the macrophage population detected in the mice that received the mimic 
microRNAs was monocyte derived with low F4/80 expression (~70-80%). This was 
consistent with the influx of monocytes and to a lesser extent, also neutrophils, which 
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were not present in the control glucose group. Even though 20-30% of the 
macrophages in the transfected groups were still tissue resident derived as 
represented by F4/80hi expression, these numbers were not considered to be enough 
for further analysis. With a significant disruption to the natural balance of the 
immune cell populations as represented by the inflammatory influx and resident 
macrophage disappearance, these results indicated that the peritoneal cavity was an 
unsuitable site for delivery of miR-199b-5p using this method.   
 
3.2.6.2 Overcoming inflammation – delivery of miR-199b-5p to the lung 
Having established previously that inflammatory influx in response to microRNA 
delivery rendered the peritoneal cavity unsuitable for further use, we next aimed to 
deliver miR-199b-5p to the lung. We chose to deliver miR-199b-5p to the lung as 
previous work has shown that it has a higher threshold for mounting an immune 
response in response to external stimuli compared to the peritoneal cavity (Wissinger 
et al., 2009, Findlay and Hussell, 2012).  As described earlier, 20μg of microRNA 
was complexed to jetPEI (N:P ratio = 6) in 5% glucose. The microRNAs were 
delivered to the mice intranasally in this experiment (Figure 3.13A). The 
experimental aims were similar in terms of confirming microRNA delivery to 
macrophages in the lung and determining the effect of miR-199b-5p on steady state 
proliferation. It is important to note that two distinct macrophage populations exist in 
the lung, namely alveolar and interstitial macrophages (Crowell et al., 1992). 
Additionally, while peritoneal macrophages are dependent on CSF-1 for their steady 
state renewal, this is not entirely the case with macrophages in the lung. Self-renewal 
of alveolar macrophages has been shown to be both CSF-1 and CSF-2 dependent 
(Guilliams et al., 2013, Hashimoto et al., 2013). 48 hours post transfection the 
bronchoalveolar lavage (BAL) and whole lung tissue were harvested for FACS 
analysis and qRT-PCR. Quantification of miR-199b-5p by qRT-PCR revealed a high 
level of overexpression in both the BAL cells and whole lung tissue, however, to a 
lesser extent in the lung tissue (Figure 3.13B). This was reflected in the copy 
numbers with miR-199b-5p transfected mice expressing 109 copies/ng RNA 
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compared to 107-108 copies/ng in whole lung tissue. Of note, from other research 
conducted in our lab, it is known that alveolar macrophages comprise approximately 
60-70% of the BAL cells. In contrast, macrophages comprise a mere 10% of total 
lung tissue. This would potentially explain the difference in overexpression of miR-
199b-5p between the BAL and lung tissue. BAL cells are limited in number and 
hence, were prioritised for the quantification of miR-199b-5p by qRT-PCR and could 
not be FACS analysed. Results from the analysis of different cell populations in the 
whole lung tissue by FACS were promising with both the alveolar and interstitial 
macrophage populations intact despite influx of some monocytes and neutrophils in 
the transfected groups (Figure 3.13C). Alveolar macrophages were classed as being 
CD11b- CD11c+ SiglecF+ and F4/80+ whereas interstitial macrophages were 
considered to be CD11b+ CD11c- SiglecF- and F4/80+. These results demonstrate 
that microRNAs can be delivered to the lung without the consequences of a 
disruptive inflammatory influx.  
A secondary aim of this experiment was to determine the effect of miR-199b-5p on 
steady state proliferation of macrophages in the lung. This was measured by Ki67 
expression. FACS analysis of alveolar macrophages in whole lung tissue showed no 
difference in Ki67hi levels between mice transfected with miR-199b-5p or the C. 
elegans microRNA C. el miR-231. Levels of active proliferation in mice that 
received glucose only were also comparable (Figure 3.14). Thus, delivery of miR-
199b-5p as described above did not alter basal levels of steady state macrophage 
proliferation in the lung.  
 
3.2.6.2.1 MiR-199b-5p and the regulation of IL-4 induced proliferation in the 
lung 
We have demonstrated that miR-199b-5p can be successfully delivered to the lung 
without disrupting the macrophage populations. Additionally, the data suggested that 
miR-199b-5p does not affect steady state proliferation of these macrophage 
populations. In line with our hypothesis, our next experimental aim was to 
investigate whether miR-199b-5p regulates IL-4 induced macrophage proliferation in 
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the lung. Unpublished data previously generated in our lab has shown that two doses 
of IL-4c are necessary to induce macrophage proliferation in the lung as opposed to a 
single dose that is sufficient for the peritoneal macrophages. To this end, we 
delivered either PBS or two doses of IL-4c at 5μg each intraperitoneally on day 0 and 
day 2 respectively. 20μg of the microRNA complexed to jetPEI was delivered 
intranasally as already described. However, having established that an N:P ratio of 6 
has no adverse effects, the N:P ratio was increased to 8 in this experiment in an effort 
to improve transfection efficiency in the lung. This was based on existing literature 
that supports the fact that N/P ratio can significantly influence transfection efficiency 
(Morimoto et al., 2003, Zhao et al., 2009). Groups of mice injected with either PBS 
or IL-4c received either miR-199b-5p or the C. elegans microRNA while control 
mice received 5% glucose only (Figure 3.15A). MicroRNAs were delivered on day 1 
between the two doses of IL-4c.  This rationale is based on the assumption that by 
the time the second dose of IL-4c provided the necessary boost for macrophage 
proliferation to occur, the microRNAs would have already suppressed their targets, 
which may be important for IL-4 induced proliferation. In the peritoneal cavity, 
macrophage proliferation in response to IL-4c peaks at 42 hours (Jenkins et al., 2011, 
Jenkins et al., 2013).  
However, it is still unknown at which time point the peak of proliferation is observed 
in the lung. Hence, for this experiment, mice were culled 42 hours post the second 
dose of IL-4c. 3 hours prior to being culled, mice were injected with BrdU 
subcutaneously. Having previously identified that miR-199b-5p is the most highly 
expressed in BAL cells following delivery compared to total lung, BAL cells were 
harvested for FACS analysis. Lung tissue was also harvested for RNA and protein 
quantification. We have shown in the previous section that increase in miR-199b-5p 
levels in BAL cells following intranasal delivery is 10 fold higher than lung tissue. 
Therefore, lung tissue was used as an indirect measure of transfection efficiency in 
BAL cells. Quantification of miR-199b-5p and C.elegans miR-75 in whole lung 
tissue revealed significant overexpression of both microRNAs in the relevant groups 
(Figure 3.15B). Whilst a 6 fold overexpression of miR-199b-5p was observed in total 
lung, overexpression of C.elegans microRNA was significantly higher at ~1000 fold. 
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This is because the C.elegans microRNA is not endogenously expressed resulting in 
a much greater difference in overexpression. To confirm that IL-4c treatment was 
successful, RELM-α expression was analysed by flow cytometry as a marker of 
alternative activation. It is worth mentioning that BAL only contains alveolar 
macrophages; no interstitial macrophages are found. As shown in Figure 3.15C, 
expression levels of RELM-α were increased in response to IL-4c treatment in the 
control mice that received glucose only. However, transfection appeared to have an 
effect on RELM-α expression with levels significantly enhanced in mice that 
received both miR-199b-5p and C. elegans microRNA, even without IL-4c. In mice 
that received both a microRNA and two doses of IL-4c, RELM-α levels were the 
greatest suggesting an additive or possible synergistic effect of transfection with IL-4 
(Figure 3.15C). Nevertheless, these results still confirm that IL-4 delivery to the lung 
was successful resulting in alternative activation of alveolar macrophages.  
The main purpose of this experiment was to determine whether miR-199b-5p affects 
IL-4 induced proliferation in alveolar macrophages. Active proliferation was 
analysed by measuring both BrdU levels and Ki67hi expression through FACS. As 
predicted, a significant rise in proliferation was observed based on an increase in the 
percentage of macrophages staining positive for BrdU (10%) in control mice injected 
with IL-4c compared to 2% macrophages staining positive for BrdU in glucose only 
injected mice. (Figure 3.16A & B). Similarly, Ki67hi expression was higher in 
macrophages isolated from mice injected with IL-4c only (~15%) compared to mice 
that received glucose only (5%). However, a lower rate of proliferation was observed 
in mice that received both microRNA complexes (miR-199b-5p or C. elegans miR-
75) and IL-4c injections, with only 2-5% of macrophages staining positive for BrdU. 
There was no difference in BrdU levels between these mice and mice that received 
microRNA complexes only as shown in Figure 3.16A. An increase in the percentage 
of macrophages expressing Ki67hi was detected in mice that received microRNA 
complexes and IL-4c (~10-12%) compared to mice that received microRNA 
complexes without IL-4c (8-10%). However, the median fluorescence intensity 
(MFI), which is a measure of total protein expression in a cell population, reflected a 
difference in Ki67hi expression when compared to the percentage of macrophages 
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expressing the protein. Whilst an increase in Ki67hi was detected in control mice that 
received IL-4c compared to mice that received glucose only (from 60,000 to 
~65000), the same was not true for mice that received microRNA complexes and IL-
4c when compared to mice that received microRNAs only. The MFI for these groups 
remained unchanged at 62000 regardless of IL-4c treatment (Figure 3.16A). The MFI 
results for BrdU, however, were in agreement with the results obtained when 
comparing percentage of macrophages positive for BrdU. The control mice treated 
with IL-4c express higher levels than mice that received glucose only (from 3,500 to 
~6000). Although there was no significant difference between the IL-4c treated 
control group and groups that received the microRNA and IL-4c both (from ~4000 to 
5000), the average fold change compared to their relevant control groups was lower 
(1.7 fold in control mice vs 1.2 fold) (Figure 3.16A). Together, these results would 
suggest that either miR-199b-5p does not affect IL-4 induced proliferation or that 
transfection of alveolar macrophages with microRNA complexes hampers IL-4 
induced proliferation in general since the control C.elegans group also behaves in a 
similar manner.  
 
3.2.6.2.2 MiR-199b-5p and alternative activation of alveolar macrophages 
Although the primary focus of this study was to delineate the role of miR-199b-5p in 
regulating alveolar macrophage proliferation, we also measured YM-1 and RELM-α 
levels in the BAL supernatant as we previously saw a minor effect of miR-199b-5p 
on alternative activation in vitro. Protein levels were quantified by ELISA. In 
agreement with the FACS data (Figure 3.16A), ELISA results showed that 
transfection alone enhanced RELM-α expression to levels similar to those observed 
with IL-4c treatment in control mice that receive glucose only (Figure 3.16B). 
Transfection in combination with IL-4c treatment appeared to have an additive or 
possibly even a synergistic effect pushing RELM-α levels close to saturation (Figure 
3.16B).  In contrast, basal YM-1 levels were not affected by transfection. As 
expected, YM-1 levels were significantly enhanced in response to IL-4c treatment. 
Interestingly, in line with our in vitro data, the levels of secreted YM-1 were 
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considerably reduced in mice transfected with miR-199b-5p that also received two 
doses of IL-4c. No such changes were observed in mice that received both C. elegans 
miR-75 and IL-4c.  These results show that miR-199b-5p has the capacity to 
significantly reduce YM-1 expression in alternatively activated alveolar 




The primary aim of this chapter was to understand the contribution of miR-199b-5p 
in regulating AAMΦ and their responses. A role for miR-199a-5p, an isoform of 
miR-199b-5p, has previously been implicated in inhibiting monocyte/macrophage 
differentiation (Lin et al., 2014). However, to date the functional significance of this 
microRNA in regulating macrophage responses has not been reported. Our lab has 
previously shown that the expression of this microRNA is IL-4Rα dependent 
(Ruckerl et al., 2012). In this study, we have demonstrated that miR-199b-5p was 
expressed at high copy numbers in vivo but not in vitro. Specifically, we found that 
miR-199b-5p is expressed at 103 copies/ng RNA in RAW 264.7 cells and BMDM 
compared to ~105 copies in response to IL-4c delivery to the peritoneal cavity and 
during L. sigmodontis infection. Additionally, the IL-4Rα dependent increase in 
miR-199b-5p expression appeared to be restricted to in vivo models of alternative 
activation and did not occur in vitro. These results suggest that the increase in 
expression of miR-199b-5p was not a direct effect of IL-4Rα signalling and the 
involvement of a secondary factor or another cell type expressing IL-4Rα may be 
necessary for its induction. Indeed, IL-4Rα expression can be found on cells of 
varying origins including haematopoietic, endothelial, epithelial, muscle, fibroblast 
and more (Nelms et al., 1999). While in vivo conditions of alternative activation 
would involve the presence of such cell extrinsic factors, the same is not true for in 
vitro situations that involve a homogeneous cell population. This might be the reason 
why the enhanced expression of miR-199b-5p is limited to AAMΦ isolated from in 
vivo conditions.  
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With the purpose of identifying the functional significance of miR-199b-5p, we 
utilised the target prediction software TargetScan to identify predicted targets of this 
microRNA. The majority of these putative targets were associated with known 
proliferative pathways. Furthermore, during L. sigmodontis infection miR-199b-5p 
expression negatively correlated with the expression of Ki67, a marker of 
proliferation. On the basis of these findings, we hypothesised that IL-4Rα dependent 
expression of miR-199b-5p acts as a regulator of IL-4 induced proliferation in a 
negative feedback loop. It was also hypothesised that this negative modulation 
requires the presence of a secondary extrinsic factor or cell type.  
In agreement with our hypothesis, overexpression of miR-199b-5p in RAW 264.7 
cells resulted in a reduction in proliferation. Additionally, a reduction in the levels of 
YM-1 and RELM-α was also observed when miR-199b-5p was overexpressed in 
cells stimulated with IL-4 and IL-13. However, RAW 264.7 cells did not secrete 
significant amounts of these proteins, especially RELM-α (<1ng/mL), making it 
difficult to arrive at a concrete conclusion regarding the effect of miR-199b-5p on 
alternative activation in RAW 264.7 cells. MiR-199a-5p, which shares an identical 
seed sequence with miR-199b-5p and is predicted to bind the same targets, has been 
shown to be important in regulating proliferation in various different cell types 
(Alexander et al., 2013, Song et al., 2014, Hashemi Gheinani et al., 2015).  
Hence we further investigated the role of miR-199b-5p in regulating macrophage 
proliferation. The most promising targets of miR-199b-5p were selected utilising the 
prediction software TargetScan and previously generated mRNA array data. One 
caveat to this approach is that TargetScan is known to have a 50-70% rate of false 
positive predictions besides being unable to predict non-canonical microRNA-target 
interactions such as bulge and centred sites (Yue et al., 2009, Shin et al., 2010, 
Witkos et al., 2011, Chi et al., 2012, Martin et al., 2014). This approach would, 
therefore, result in the exclusion of several “real” targets of miR-199b-5p (greater 
false negative rate) and inclusion of many genes that are not real targets. Moreover, 
genes from the mRNA array were selected on the basis of their change in relation to 
Ki67 during the infection. It is important to note that these changes may have been 
the result of regulation by several other factors besides microRNAs or a cumulative 
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effect of different microRNAs operating together. In other words, these changes in 
gene expression during L. sigmodontis infection are not all expected to be specific to 
miR-199b-5p. Nevertheless, in the absence of additional data from other approaches 
this was the most reasonable way forward.   
Pathway analysis of these shortlisted predicted targets identified 11 significantly 
enriched pathways including Insulin – like growth factor 1 (IGF-1) signalling, 
PPARα/RXRα activation, insulin receptor signalling and PI3K/AKT signalling, 
amongst others suggesting that miR-199b-5p may be involved in the modulation of 
several different proliferative and other pathways. Various cancer related pathways 
such as molecular mechanisms of cancer and role of tissue factors in cancer were 
also present in the results of this analysis. The enrichment of these cancer related 
pathways in results obtained from IPA analysis is consistent with previous reports 
that have shown the involvement of miR-199a-5p in the progression of several 
carcinomas (Sakurai et al., 2011, Xu et al., 2012, Yi et al., 2013, He et al., 2014b, 
Kim et al., 2015, Kobayashi et al., 2015, Mussnich et al., 2015, Shin et al., 2015). 
However, the expression of miR-199a-5p has been found to be variable in different 
cancers; it is enhanced in some whereas reduced in others. This variation in function 
could be explained by the fact that the genetic expression profiles between different 
cell types are not identical and hence, the same target gene may have opposing 
functions in different cell types resulting in a change in the role of this microRNA 
accordingly. 
As a result of this pathway analysis, the finding that miR-199b-5p could potentially 
regulate the insulin/IGF-1 signalling axis was novel and thus, interesting to pursue 
further. As discussed previously, there is a high degree of crosstalk between the 
insulin and IGF-1 signalling cascades as evident from the formation of receptor 
heterodimers that can bind and signal via both insulin and IGF-1 (Treadway et al., 
1989, De Meyts and Whittaker, 2002, Pandini et al., 2002, Cabail et al., 2015). 
Macrophages are a well-known source of IGF-1, which is necessary for coordinating 
muscle regeneration and inflammation following injury (Lu et al., 2011, Tidball and 
Welc, 2015, Tonkin et al., 2015). In fact, AAMΦ are known to produce IGF-1 in 
response to the TH2 cytokines IL-4 and IL-13 in a STAT6 dependent manner (Wynes 
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and Riches, 2003, Forbes and Rosenthal, 2014). In addition, macrophages themselves 
express large amounts of IGF1R on their surface and the secreted IGF-1 can also 
modulate macrophage polarisation to a pro-repair phenotype through an autocrine 
loop (Higashi et al., 2011, Tonkin et al., 2015). Moreover, the role of macrophages in 
conferring insulin resistance and the effect of insulin on macrophage metabolism and 
function are already well defined (Costa Rosa et al., 1996, Charo, 2007, Odegaard et 
al., 2007, Chawla, 2010, Olefsky and Glass, 2010, Wynn et al., 2013).  
The existing literature also suggests that there is a strong link between IL-4 
signalling and the insulin/IGF-1 axis. Besides being critical for the production of 
IGF-1, IL-4 plays a crucial role in the regulation of insulin sensitivity in a STAT6 
dependent manner (Ricardo-Gonzalez et al., 2010, Chang et al., 2012). Moreover, a 
common link between IL-4, insulin and IGF-1 pathways has been suggested in 
haematopoietic cells through the phosphorylation of the central molecule IRS-1 
(Wang et al., 1993a). IL-4 can also cooperate with STAT6 and IRS-2 to induce 
proliferation and differentiation in T cells (Wurster et al., 2002). In macrophages, 
phosphorylation of IRS-2 by IL-4 is regulated by SOCS1, another molecule 
important during alternative activation (Losman et al., 1999). IL-4 is also known to 
protect cells from apoptosis through an IRS-1 mediated mechanism (Zamorano et al., 
1996).  Furthermore, IRS-1 is also essential for insulin and IL-4 stimulated 
mitogenesis in haematopoietic cells (Wang et al., 1993b). Additionally, IRS 
molecules central to the insulin/IGF-1 signalling cascades have also been implicated 
as being essential for IL-4 induced proliferation through their ability to recruit PI3K 
(Jiang et al., 2000). Together, the previous literature cited above renders the 
insulin/IGF-1 signalling as an extremely interesting target for miR-199b-5p and it 
was hypothesised that miR-199b-5p could exert its effects on IL-4 induced 
macrophage proliferation by targeting the insulin/IGF-1 signalling axis. 
To this end, miR-199b-5p was overexpressed in RAW 264.7 cells and the expression 
levels of Insr, Igf1r and Irs1 quantified. RAW cells were used in this analysis 
because we had already shown an effect on proliferation of these cells by miR-199b-
5p. As detailed in the results section, no effect was observed on the levels of Insr and 
Igf1r, despite 3 predicted binding sites for miR-199b-5p in the 3’UTR of Insr. 
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Unexpectedly, the expression of Irs1 was enhanced several fold upon miR-199b-5p 
overexpression. It has previously been reported that target mRNAs can be localised 
to processing bodies (P-bodies), which serve as a site for degradation of untranslated 
mRNAs (Liu et al., 2005). It was thought that this might be a possibility for the 
enrichment/increase seen in Irs1 transcript following miR-199b-5p overexpression. 
In agreement with the qRT-PCR data, Western blot analysis also revealed a similar 
increase in the protein levels of IRS1.  
Besides localisation to P-bodies, several other factors might contribute to the 
increase observed in IRS1 expression. In the past, non-canonical binding of 
microRNAs to their targets has been reported. Conserved microRNA binding sites 
have been found in the 5’UTR and coding sequence (CDS) regions of a target 
mRNA (Zhou et al., 2009, Hausser et al., 2013). Moreover, there have been reports 
of simultaneous 5’UTR and 3’UTR interactions between a microRNA and its target 
(Lee et al., 2009). MiR-155 has also been shown to enhance TNF-α expression by 
stabilisation of the transcript by binding to the 3’UTR (Tili et al., 2007, Faraoni et 
al., 2009). Hence, it is possible that miR-199b-5p exerted its effect on IRS1 through 
one of these mechanisms. However, upon scanning the 5’UTR and CDS regions of 
Irs1, no such non-canonical binding sites were found. A study by Gokhale & Gadgil 
(2012) made use of mathematical modelling to formulate a comprehensive model 
that suggests an explanation for increase in target protein levels based on reversible 
mRNA-microRNA interactions and selective return of RNA. The authors suggest 
that in certain cases microRNAs can bind to the target mRNA near degradation 
signals such as ARE sites (AU rich elements), thereby masking the degradation 
signal leading to protection of the mRNA (Gokhale and Gadgil, 2012).  
From the literature it is expected that an increase in IRS-1 expression would result in 
an increase in proliferation. However, we observed an increase in IRS-1 expression 
but an overall reduction in the proliferation of RAW 264.7 cells.  It is well 
established that IRS-1 is the major substrate of IR and IGF1R and essential for 
normal growth and development. This is reflected in the fact that Irs1-/- mice are 
retarded in embryonic and postnatal growth, reaching only 50% of normal size 
(Araki et al., 1994, Tamemoto et al., 1994, Dong et al., 2006). Given that IRS1 is 
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crucial in growth and development and assuming that IRS1 is a target of miR-199b-
5p, one explanation for our results would be that a compensatory mechanism exists 
wherein the cell produces copious amounts of IRS1 to counterweigh the effects of 
IRS1 downregulation by miR-199b-5p. Having studied the expression of IRS1 48 
hours post transfection, it is probable that by this time point, the cell has already 
recovered from any loss of IRS1. A time course experiment with monitoring of IRS1 
levels at regular intervals following overexpression of miR-199b-5p could help 
answer whether this might be the case.  
It is important to note that besides the amount of protein available, the state of 
activation of IRS1 is important in determining downstream signals for proliferation. 
This is determined by its phosphorylation and depending on the residue 
phosphorylated, IRS1 can act as both a positive or negative regulator of proliferation 
(Gual et al., 2005). For example, phosphorylation of IRS1 at tyrosine residues 
provides a positive stimulus for proliferation whereas phosphorylation of serine 
residues may positively or negatively regulate proliferation depending on the kinase 
involved (Gual et al., 2005). Hence, besides quantification of total protein, it would 
be useful to examine the active phosphorylated IRS1 sites.  
Furthermore, it is highly plausible that the increase in IRS1 levels are in fact indirect 
rather than a direct effect of miR-199b-5p. In this scenario it would be expected that 
miR-199b-5p targets a repressor of IRS1. SOCS1 and SOCS3, which are both 
associated with macrophage activation, are known potent inhibitors of IRS proteins 
(Ueki et al., 2004). SOCS3 also has a predicted binding site for miR-199b-5p in its 
3’UTR. Further experiments are needed to test these hypotheses. Another possibility 
is that overexpression of miR-199b-5p can potentially saturate RISC complexes and 
displace other endogenous microRNAs leading to this effect (Khan et al., 2009, 
Thomson et al., 2011). Although a range of possibilities exist, to explain the up-
regulation of IRS1, it seem most likely that miR-199b-5p targets a complex network 
of genes that cumulatively result in the unexpected increase of IRS1.  
While these in vitro studies were underway, we next aimed to deliver miR-199b-5p 
in vivo to determine its effect on macrophage proliferation. MiR-199b-5p along with 
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control microRNA mimics were delivered to the peritoneal cavity of mice.  In the 
absence of an external stimulus, one would not expect IRS substrates to be active and 
hence most of the macrophage proliferation observed is presumed to be CSF-1 
dependent (Hume and MacDonald, 2012, Jenkins et al., 2013). Although functional 
microRNAs can be delivered to the peritoneal cavity as reflected by reduction in 
levels of GAPDH following delivery of a microRNA targeting its 3’UTR, this 
delivery results in an inflammatory influx of monocytes and neutrophils resulting in 
the disappearance of tissue resident macrophages. Originally characterised by Nelson 
and Boyden, Barth et al have reported that macrophages undergo a physiological 
response known as the macrophage disappearance reaction (MDR) in response to 
certain stimuli in the peritoneal compartment, including the recruitment of 
inflammatory populations such as neutrophils and monocytes (Barth et al., 1995).  It 
was concluded that the remaining tissue resident macrophage numbers are not 
enough for further analysis. Besides, with the disruption of the natural balance of the 
immune populations normally found in the peritoneal cavity, any effects observed 
may not have been significant.  
Next, miR-199b-5p was delivered to the lung as this organ is known to have a higher 
threshold of activation before mounting a strong immune response when compared to 
the peritoneal cavity (Wissinger et al., 2009, Findlay and Hussell, 2012). Delivery of 
miR-199b-5p to the lung was successful with no disruption to the two macrophage 
populations found in the lung, namely alveolar and interstitial. Transfection 
efficiency in BAL was 10 fold higher than whole lung tissue. It is presumed that 
most of the microRNAs are delivered to macrophages and this result would fit with 
the fact that 70% or BAL cells are alveolar macrophages compared to whole lung 
tissue wherein macrophages make up only 10% of the total cell population. As 
discussed earlier, homeostatic levels of proliferation are maintained by CSF-1 (Hume 
and MacDonald, 2012, Jenkins et al., 2013). However, a role for GM-CSF has also 
been implicated in the self-renewal of alveolar macrophages in the lung (Guilliams et 
al., 2013, Hashimoto et al., 2013). Nonetheless, in both these situations, insulin/IGF-
1 signalling is not expected to be active and hence, it was hypothesised that no effect 
of miR-199b-5p will be observed on proliferation under steady-state conditions. In 
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agreement with our hypothesis, it was found that miR-199b-5p does not affect steady 
state alveolar macrophage proliferation. On the other hand, it was hypothesised that 
miR-199b-5p would effect IL-4 induced proliferation. This was based on our earlier 
hypothesis that miR-199b-5p negatively regulates IL-4 induced signalling by 
targeting the insulin/IGF-1 signalling cascades. This was tested by the delivery of 
miR-199b-5p or a control C.elegans microRNA to the lung either on their own or in 
combination with IL-4c. Although a reduction was observed in the percentage of 
alveolar macrophages expressing BrdU (as a measure of active proliferation) when 
compared to control mice, a similar effect was also observed in mice that received 
the C. elegans microRNA. Similar effects were observed with total Ki67hi protein 
levels, a secondary measure of proliferation. Hence, it is difficult to confidently 
conclude any effect of miR-199b-5p on IL-4 induced proliferation. Although the C. 
elegans microRNA utilised in this experiment is species restricted, off target effects 
of small synthetic RNAs have previously been reported (Jackson and Linsley, 2010). 
It is possible that the effect observed with this control microRNA was in fact an off 
target effect, as this microRNA is not present in mice endogenously. A solution to 
this would be to use several different non-specific controls as a comparison and to 
determine their effects on IL-4 induced proliferation. A scrambled sequence of miR-
199b-5p could also be used as an additional control. 
Another aspect to consider with this particular experiment would be the signalling 
cascade under consideration. Unpublished data from our lab has shown that IR is not 
very highly expressed in alveolar macrophages. Only ~2-4% of alveolar 
macrophages stain positive for IR and upon IL-4c injection, this percentage does not 
change. The same is also true for IRS1 expression in the lung (determined by Ct 
value >35). In contrast, about 15-20% of peritoneal macrophages express IR in 
steady state. Following IL-4c delivery, the expression of IR is upregulated with 
nearly 80% of the macrophages staining positive (unpublished, data not shown). 
Increasing evidence from data generated in our lab suggests that alveolar and 
peritoneal macrophages are very distinct populations that behave differently to the 
same stimuli. Hence, it is possible that the reason we see no difference between miR-
199b-5p and the C. elegans microRNA in the lung is because miR-199b-5p is not 
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able to mediate an effect on IL-4 induced proliferation in the absence of significant 
IR and IRS1 expression. The differences between the glucose and transfected groups 
in this case may just be a result of transfection in general. In the future, to overcome 
these inherent differences between macrophage populations and the inflammatory 
influx in response to transfection in the peritoneal cavity, experiments may be 
conducted wherein peritoneal or Thio MΦ could be transfected with miR-199b-5p ex 
vivo and injected back into the mouse intraperitoneally. This could be followed by 
IL-4c injection to determine the effect of miR-199b-5p on IL-4 driven proliferation 
in the presence of high IR and IRS1 expression.  
In the same experiment, we also measured secreted levels of YM-1 and RELM-α in 
the BAL supernatant. We had previously observed a reduction in the expression of 
the proteins in RAW 264.7 cells transfected with miR-199b-5p and stimulated with 
IL-4 and IL-13. However, the RAW 264.7 cells did not secrete significant amounts 
of protein to have confidence in the conclusions. In the BAL, no significant 
differences were observed in RELM-α levels between the different groups. Even 
though no differences were observed in RELM-α protein, it is possible that the 
additive effect of transfection and IL-4 saturated the system, thereby masking any 
subtle effects of miR-199b-5p.  However, YM-1 was considerably altered in mice 
that received miR-199b-5p mimic and showed a nearly 50% reduction in secreted 
protein. With no FACS data for intracellular protein quantification and no RNA for 
measuring transcript levels, whether this observed reduction is an effect on total 
protein or a secretion defect still remains unknown. No predicted direct binding sites 
for miR-199b-5p were found in the 3’UTR of Chi3l3 (YM-1). The reduction in 
protein levels observed is therefore likely to be an indirect effect. Mechanisms of 
YM-1 secretion are still unknown and hence, if this reduction relates to a secretion 
defect it is not clear how miR-199b-5p might mediate this (for example, which 
targets of miR-199b-5p would impact YM-1 secretion). Our lab has recently shown 
that YM-1 is involved in the recruitment of neutrophils during Nippostrongylus 
brasiliensis infection in the lung as a trade-off between nematode killing and host 
damage (Sutherland et al., 2014). Thus, it would be interesting to deliver miR-199b-
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5p to the lung in mice infected with N. brasiliensis to examine the effects of miR-
199b-5p mediated reduction in YM-1 levels in the context of infection. 
Overall, the results in this chapter demonstrate that miR-199b-5p has the ability to 
regulate proliferation in RAW 264.7 cells. The data in this chapter are the first to 
represent that miR-199b-5p regulates IRS1, which forms part of the insulin/IGF-1 
signalling pathway. Whether this effect translates in vivo with an effect on IL-4 
induced proliferation is still unclear. We have shown that delivery of microRNAs to 
the peritoneal cavity results in an inflammatory influx leading to macrophage 
disappearance. Additionally, we have established that miR-199b-5p can be delivered 
to the lung without disrupting the balance of the immune populations. It was further 
shown that miR-199b-5p does not affect steady state proliferation of alveolar 
macrophages. Besides proliferation, we are the first to show that miR-199b-5p has 
the ability to regulate alternative activation through downregulation of YM-1 
expression. Further experiments are still needed to delineate mechanisms to 
understand the contribution of miR-199b-5p in the regulation of AAMΦ and their 
responses. As a starting point, to overcome the lack of IR and IRS-1 expression in 
the lung and inflammation in response to microRNA delivery in the peritoneal 
cavity, peritoneal macrophages could be transfected ex vivo and injected into mice 
followed by IL-4c delivery to assess the role of miR-199b-5p in regulating insulin 
signalling in vivo. Additionally, the significance of the regulation of YM-1 by miR-
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Figure 3. Schematic summary of potential mechanisms resulting in increased IRS-1 
levels as a consequence of miR-199b-5p action 
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Figure 3.1 MiR-199b-5p is expressed at a higher copy number in AAMΦ in vivo 
compared to AAMΦ in vitro.  
For the in vivo conditions, AAMΦ were isolated from the pleural cavity of either WT 
C57BL/6 mice infected with L3 larvae of the nematode L. sigmodontis on various days post 
infection (n=6) or from the peritoneal cavity of WT C57BL/6 mice injected with 5μg of IL-
4c (n=5). For the in vitro conditions, BMDM were generated from bone marrow precursors 
derived from WT C57BL/6 mice cultured in CSF-1 containing medium. Both BMDM and 
RAW 264.7 cells were stimulated with 20ng/mL of IL-4/IL-13 for 48hr (n=3). In all 
conditions, cells were lysed and RNA extracted. Data were normalised to RNU6B 
expression. Data are presented as the mean fold change ± SEM and representative of one (L. 
sigmodontis infection) or two separate experiments (RAW 264.7, BMDM and IL-4c). 
Statistical significance for differences between naïve and treated animals during L. 
sigmodontis infection time course and following IL-4 complex injection was determined 
using two-way and one-way ANOVA (Kruskal Wallis test) respectively. For BMDM and 
RAW 264.7 cells, statistical significance was calculated using unpaired two-tailed student’s 
T-test (* P< 0.05, ** P< 0.01, *** P< 0.001). 
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Figure 3.2. Correlation between the expression of miR-199b-5p and Ki67 during L. 
sigmodontis infection in the pleural cavity.  
AAMΦ were isolated by adherence purification from the pleural cavity of WT C57BL/6 
mice infected with L3 larvae of the nematode L. sigmodontis on various days post infection. 
Cells were lysed and RNA extracted. Data were normalised to RNU6B for microRNA 
expression and Gapdh for mRNA expression. Data are presented as the mean fold change ± 
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Figure 3.3. Schematic of transfection and analysis of proliferation in RAW 264.7 cells 
upon transfection of synthetic oligos.  
RAW 264.7 cells were pre-stained with CFDA-SE and reverse transfected with synthetic 
mature microRNA mimics. 4 hours prior to harvest, alamarBlue was added to the 
supernatant as a measure of metabolic activity. Supernatants and cells were harvested for 
analyses at 24 and 48 hours post transfection respectively.  
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Figure 3.4 Transfection of miR-199a/b-5p suppresses proliferation in RAW 264.7 cells. 
 RAW 264.7 cells were transfected with 25nM of synthetic miR-199a/b-5p and miR-199-3p 
along with a positive control (miR-378) and negative controls (RISC Free and C.elegans 
microRNA).  A) Percentage loss of CFDA-SE intensity and B) alamar blue conversion over 
time compared to RISC Free control were used as indicative measures of proliferation. C) 
Mean fluorescence intensity indicative of CFDA-SE as measured by FACS. CFDA-SE 
intensity was measured by flow cytometry and alamar blue conversion was measured as a 
change in fluorescence over time. D) Fold change in levels of microRNAs following 
overexpression in RAW 264.7 cells. Fold changes were calculated as ratios of transfected 
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samples to RISC Free transfected control samples. Copy numbers of miR-199b-5p following 
transfection were also calculated using a synthetic standard of known concentration. 
Statistical significance was determined using one-way or two-way ANOVA where 
appropriate (* P< 0.05, ** P< 0.01, *** P< 0.001). Data are representative of measures from 






Figure 3.5 Overexpression of miR-199 family members and miR-378 negatively impacts 
alternative activation in RAW 264.7 cells.  
RAW 264.7 cells were transfected with synthetic miR-199a/b-5p, miR-199-3p and positive 
and negative controls. 24 hours post transfection cells were stimulated with 20ng/mL of IL-4 
and IL-13 resulting in their alternative activation. Supernatants were harvested 24 hours post 
stimulation with IL-4 and IL-13. YM-1 and RELM-α levels were measured by ELISA. Data 
are representative of a single experiment (n=3) and statistical significance was determined 


















































































































Chapter 4: miR-378/378* mice  
  128 
 
 
Figure 3.6 Schematic representing the selection of genes for pathway analysis to 
elucidate the functional role of miR-199b-5p.  
Putative targets of miR-199b-5p were identified on the basis of predicted direct binding sites 
for miR-199b-5p in the 3’UTR of target mRNAs using the prediction software TargetScan. 
Additional mRNA array data (Graham Thomas) using AAMΦ from an L. sigmodontis 
infection time course was also utilised. In this mRNA array, a generalised linear modelling 
approach was used to identify genes that change in relation to Ki67, a marker of 
proliferation, over the course of infection. This list of genes was then overlapped with the list 
of predicted targets of miR-199b-5p to generate a final list of 2,440 genes. Out of these 2,440 
genes, the top 300 significant genes that positively correlate with Ki67 expression based on 
P-values obtained from the mRNA array data were selected for pathway analysis (P value < 
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TABLE 3.1 Top 11 pathways identified predicted to be miR-199b-5p targets using 
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Figure 3.7 Relationship between the IGF-1, Insulin and IL-4Rα signalling pathways 
and molecules identified as being predicted targets of miR-199b-5p using TargetScan 
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Figure 3.8 Expression of Insr, Igf1r and Irs1 in RAW 264.7 cells following transfection 
with miR-199b-5p.  
RAW 264.7 cells were either left untreated or transfected with synthetic microRNAs (25nM) 
for 48 hours. Total RNA was extracted for quantification by qRT-PCR. Expression of A) 
Insr, Igf1r, Irs1 and B) Akt-1 transcripts was quantified. The expression of each gene was 
normalized to Gapdh. Data are presented as mean of fold change ± SEM of three technical 
replicates (n=3) compared to cells transfected with RISC Free siRNA and representative of 
three individual experiments. Statistical significance was determined using one-way 
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Figure 3.9 Protein expression of IRS-1 in response to miR-199b-5p overexpression in 
RAW 264.7 cells.  
RAW 264.7 cells were either left untreated or transfected with synthetic microRNAs (25nM) 
for 48 hours. Western blot analysis (ECL-based detection) of IRS-1 was carried out in cells 
transfected with miR-199b-5p, its isoform miR-199a-5p, miR-199a-3p, miR-378 and 
negative controls (RISC Free siRNA and C. elegans miR-231). Protein levels were 
quantified using Image Studio Lite software and normalized to β-actin. Results are 
represented as fold changes relative to cells transfected with C. elegans mimic.  50μg lysate 
was loaded in each lane (pooled n=3). Data are representative of two separate experiments.  
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Figure 3.10 Expression of predicted target genes downstream of the insulin/IGF-1 
signalling cascade following transfection with miR-199b-5p.  
RAW 264.7 cells were either left untreated or transfected with synthetic microRNAs (25nM) 
for 48 hours. Total RNA was extracted for quantification of expression of transcripts by 
qRT-PCR. The expression of each gene was normalised to Gapdh. Data are presented as 
mean of fold change ± SEM of three technical replicates compared to cells transfected with 
RISC Free siRNA and representative of two separate experiments (n=3). Statistical 
significance was determined using one-way ANOVA (Kruskal Wallis test) (* P< 0.05, ** P< 
0.01, *** P< 0.001).  
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Figure 3.11 Delivery of miR-199b-5p to the peritoneal cavity of mice.  
A) WT C57BL/6 mice were injected intraperitoneally with 20μg of microRNA complexed to 
jetPEI (N:P ratio = 6) in 5% glucose. Control animals received 5% glucose only whereas 
other groups of mice received either miR-199b-5p or C. elegans microRNA as negative 
control. A microRNA targeting the 3’UTR of GAPDH (siRNA GAPDH) was used as a 
positive control. Animals were injected with BrdU 3 hours prior to culling. Animals were 
culled 48 hours post microRNA delivery and peritoneal exudate cells (PEC) were collected 
via washing of the peritoneal cavity.   
B) Quantification of delivered microRNAs in PEC cells. PEC cells were adherence 
purified for 4 hours to obtain macrophages that were lysed to obtain RNA for qRT-PCR. 
Cells from the washes of adherence purification were also lysed to collect RNA. The 
expression of microRNAs was normalized to RNU6B. Copy number for miR-199b-5p was 
determined using a synthetic miR-199b-5p standard of known concentration. Expression of 
Gapdh was normalised to 18s RNA. Data are presented as mean of fold change ± SEM (n=3) 
and representative of a single experiment. Statistical significance was determined using one-
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Figure 3.12 Delivery of microRNAs to the peritoneal cavity causes an inflammatory 
influx resulting in macrophage disappearance.  
PEC cells isolated from mice in Figure 3.11A were FACS analysed for identification of 
immune cell populations. In a naïve mouse, majority of the peritoneal macrophage 
population is tissue resident derived and expresses high levels of F4/80. This was reflected in 
the group of mice that received 5% glucose. In contrast, majority of the macrophage 
population detected in the mice that received the mimic microRNAs was monocyte derived 
with low F4/80 expression (~70-80%). This was consistent with the influx of monocytes and 
to a lesser extent neutrophils, which were not present in the control glucose group. 
Inflammatory influx of these cells resulted in disappearance of the tissue resident 
macrophages in mice that received miR-199b-5p or siRNA GAPDH. Data are representative 
of a single experiment (n=3).  
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Figure 3.13 A) Delivery of miR-199b-5p to the lung.  
WT C57BL/6 mice were administered 20μg of microRNA complexed to jetPEI (N:P ratio = 
6) in 5% glucose intranasally. Control animals received 5% glucose only whereas other 
groups of mice received either miR-199b-5p or a C. elegans microRNA as negative control. 
Animals were culled 48 hours post microRNA delivery and bronchoalveolar lavage (BAL) 
fluid and whole lung tissue were harvested for FACS analysis and qRT-PCR. 
B) Quantification of miR-199b-5p following intranasal delivery in BAL cells and whole 
lung tissue. BAL cells were lysed to obtain RNA for qRT-PCR whereas whole lung tissue 
was digested prior to being lysed using a tissue lyser for extraction of RNA. Copy numbers 
for miR-199b-5p were determined using a synthetic miR-199b-5p standard of known 
concentration. Data are presented as mean of fold change ± SEM (n=3) and representative of 
a single experiment.  
C) Delivery of microRNAs to the lung does not significantly disrupt the macrophage 
populations. Whole lung tissue was digested into a single cell suspension. Subsequently, 
cells were stained with antibodies conjugated to the relevant fluorophores and FACS 
analysed. Data are representative of a single experiment (n=3). 
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Figure 3.14 miR-199b-5p does not affect basal levels of steady state macrophage 
proliferation in alveolar macrophages.  
Whole lung tissue was digested into a single cell suspension. Cells were stained with 
antibodies conjugated to the relevant fluorophores and FACS analysed. FACS analysis of 
alveolar macrophages in whole lung tissue showed no difference in Ki67hi* levels between 
mice transfected with miR-199b-5p or the C. elegans microRNA. Levels of active 
proliferation in mice that received glucose only were also comparable. *Ki67hi measures 
active proliferation and is only expressed in cells in the S-phase of the cell cycle. Data are 
presented are representative of a single experiment (n=3).   
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Figure 3.15 A) Experimental design to deliver miR-199b-5p and induce IL-4 driven 
proliferation in the lung.  
WT C57BL/6 mice received two doses of IL-4c at 5μg each on day 0 and day 2 respectively. 
Mice were administered with 20μg of microRNA complexed to jetPEI (N:P ratio = 8) in 5% 
glucose intranasally on day 1. Control animals received 5% glucose only whereas other 
groups of mice received either miR-199b-5p or the C. elegans microRNA as a negative 
control. Animals received 10μg of BrdU subcutaneously 3 hours before they were culled. 
Animals were culled 48 hours after the final dose of IL-4c. BAL fluid and whole lung tissue 
were harvested for FACS analysis and qRT-PCR. 
B) Quantification of miR-199b-5p following intranasal delivery in whole lung tissue. 
Whole lung tissue was digested and RNA extracted for qRT-PCR. MicroRNA expression 
was normalised to RNU6B. Fold change was calculated relative to the 5% glucose group.  
C) Confirmation of alternative activation in alveolar macrophages following IL-4c 
delivery. BAL cells were harvested from the mice described in Figure 3.15A and stained 
with antibodies conjugated to the relevant fluorophores and FACS analysed. RELM-α 
expression is depicted as median fluorescence intensity in CD11c+ SiglecF+ CD11blo/- cells 
classified as alveolar macrophages. Data presented in A, B & C are representative of a single 
experiment (n=5-12). 
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Figure 3.16 A) BrdU and Ki67hi levels in alveolar macrophages as measures of active 
cell proliferation by flow cytometry.  
BAL cells were harvested from mice injected with PBS or IL-4c along with administration 
of synthetic microRNAs as described in Figure 3.15A. BAL cells were stained for Ki67 and 
BrdU incorporation and FACS analysed. Data are presented as percentage positivity within 
alveolar macrophage populations and representative of a single experiment (n=5-12). 
Statistical significance was determined using one-way ANOVA (Kruskal Wallis test) (* P< 
0.05, ** P< 0.01, *** P< 0.001)  
B) Quantification of alternative activation proteins in BAL supernatant following 
microRNA and PBS or IL-4c delivery. BAL cells were harvested from the mice described 
in Figure 3.15A and centrifuged to obtain supernatants, which were subsequently subject to 
quantification by ELISA. Statistical significance was determined using one-way ANOVA 
(Kruskal Wallis test) (* P< 0.05, ** P< 0.01, *** P< 0.001). Data are presented as 
percentage positivity within alveolar macrophage populations and representative of a single 
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Chapter 4: Alternative activation and proliferation 
of macrophages in the absence of miR-378 
 
SUMMARY:  
The Allen lab has previously shown that miR-378-3p expression is associated with 
AAMΦ through targeting of AKT-1. Intact AKT-1 signalling is an essential 
component for IL-4 driven macrophage proliferation and despite the knowledge that 
AKT-1 is a direct target of miR-378-3p, the direct influence of this microRNA on the 
regulation of AAMΦ is still unknown. In this chapter, the consequences of the 
deficiency of the microRNAs miR-378-3p and miR-378-5p on AAMΦ in mice have 
been addressed. Various AAMΦ conditions, both in vitro and in vivo, were studied to 
elucidate the ability of macrophages isolated from WT, heterozygous and KO 
animals to alternatively activate. The influence of miR-378 deficiency on IL-4 
induced proliferation was also addressed in vivo. Although the lack of miR-378 had 
no significant effect on IL-4 driven macrophage proliferation, results from this 
chapter support a role for miR-378 in the regulation of alternative activation through 
an impact on YM-1 and RELM-α expression. Lastly, we also utilised Litomosoides 
sigmodontis, a murine model of filarial infection, to determine whether this 
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4.1 Introduction 
Tumour associated macrophages, which display an M2 phenotype and some 
characteristics of AAMΦ, are known to contribute to angiogenesis and play a dual 
role during development, tissue injury and regeneration (Sunderkotter et al., 1994, 
Lamagna et al., 2006, Ribatti et al., 2007, Nucera et al., 2011). The importance of 
microRNAs in angiogenesis and endothelial function has previously been shown 
through the disruption of Dicer and Drosha – two key enzymes for microRNA 
biogenesis (Kuehbacher et al., 2007). Endothelial specific deletion of Dicer in mice 
has provided evidence that microRNAs are required for postnatal angiogenesis in 
response to angiogenic stimuli (Suarez et al., 2008). MiR-378 is a well-known 
angiomiR with an established role in tumour angiogenesis (Urbich et al., 2008, Chen 
et al., 2012b, Chan et al., 2014). In mice, four isoforms of miR-378 (a-d) have been 
reported, with miR-378a being the only isoform that gives rise to both miR-378-5p 
(or miR-378*) and 3p. Whilst miR-378b gives rise to mature miR-378-3p only, both 
miR-378c/d give rise to miR-378-5p only. MiR-378 is enriched in CD34+ 
haematopoeitic progenitor cells and increases cell survival whilst reducing cell death 
(Wang and Olson, 2009).  Vascular endothelial growth factor (VEGF) plays a 
fundamental role as a key regulator of angiogenesis (Ferrara, 2001, Ferrara and 
Gerber, 2001). MiR-378-5p and miR-125a share the same seed region and miR-378 
promotes VEGF expression by competing with miR-125a for binding sites in the 
VEGF 3’UTR (Hua et al., 2006). MiR-378 also enhances angiogenesis in tumour 
progression by targeting Suppressor of fused (Sufu) and Fus-1, which are both 
tumour suppressors (Lee et al., 2007). Sufu is a negative regulator of Shh signalling. 
Vessels induced by Shh are characterised by expression of angiogenic cytokines, 
including VEGF and angiopoietin-1 and 2, and have large diameters (Wang and 
Olson, 2009).  
As reviewed already in the introductory chapter, AAMΦ are key orchestrators of 
metabolism (Odegaard and Chawla, 2011, Biswas and Mantovani, 2012). MiR-378 
has previously been reported to control glucose and lipid homeostasis (Fernandez-
Hernando et al., 2011, Liu et al., 2014). Peroxisome proliferator-activated receptors 
(PPARs) transcriptionally regulate alternative macrophage activation and hence, lipid 
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metabolism (Chawla et al., 2001, Odegaard et al., 2007, Chawla, 2010). 
Interestingly, miR-378 is embedded within the parent gene Ppargc1b, which encodes 
PGC-1β, a transcriptional regulator of oxidative energy metabolism. MiR-378 is 
known to counterbalance these metabolic actions of PGC-1β through the control of 
mitochondrial metabolism and systemic energy homeostasis (Eichner et al., 2010, 
Carrer et al., 2012).  
The major objective of this thesis is to identify microRNAs associated with 
alternative activation in macrophages and to understand their contribution in the 
regulation of this phenotype. As described in chapter 2, the expression profiles of ten 
microRNAs highly regulated by IL-4 were studied under various conditions of 
alternative activation. From these studies, the expression of miR-378 was identified 
as being strongly associated with AAMΦ (Figure 2.9, Chapter 2). Our lab has 
previously shown that miR-378-3p has the capacity to negatively modulate AKT-1 
expression, thereby potentially regulating IL-4 induced proliferation of AAMΦ 
(Ruckerl et al., 2012). However, a caveat in this study was the inability to 
demonstrate a direct effect of miR-378-3p on IL-4 driven proliferation of 
macrophages. Instead, following its validation as a direct target of miR-378-3p, 
AKT-1 expression was blocked with triciribine treatment in vivo. This resulted in a 
reduction in IL-4 induced proliferation as well as alternative activation (Ruckerl et 
al., 2012).  
Work in this chapter, therefore, aims to study the direct effects of miR-378 on IL-4 
driven activation and proliferation of macrophages that may in turn contribute to the 
various effector functions of AAMΦ. To this end, mice genetically lacking miR-378 
(miR-378-3p) and miR-378* (miR-378-5p) (obtained from the Olson lab) were 
utilised. The contribution of miR-378 to the activation, maintenance and proliferation 
of AAMΦ was investigated both in vitro and in vivo under varying conditions of 
alternative activation.  
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4.2 Results 
4.2.1 Validation of mice genetically lacking miR-378/378* 
MiR-378 knockout (miR-378 KO) mice were obtained from the Olson lab. The null 
allele of miR-378/miR-378* was generated using a targeting vector containing a 
neomycin resistance gene. This neomycin resistance gene was flanked by loxP sites 
and a diphtheria toxin gene cassette and its expression driven by the pGK promoter. 
The miR-378/378* targeting strategy was designed to replace the premiR sequence 
with the neomycin resistance cassette flanked by loxP sites. The targeting vectors 
were electroporated into 129SvEv-derived ES cells and analysed for homologous 
recombination. Selected clones were injected into C57BL/6 blastocysts. High-
percentage chimeric male mice were crossed to C57BL/6 females to achieve 
germline transmission of the targeted allele. Mice heterozygous for neomycin were 
crossed with CAG-Cre-transgenic mice to remove the cassette (Carrer et al., 2012).  
Prior to conducting any experiments on mice deficient in miR-378, an initial 
validation was carried out to confirm the expression levels of known miR-378 targets 
described in the literature. Carrer et al. from the Olson lab previously reported miR-
378 and miR-378* as integral components of a regulatory circuit that functions under 
conditions of metabolic stress to control systemic energy homeostasis. They have 
shown that carnitine O-acetyltransferase (CRAT), a mitochondrial enzyme involved 
in fatty acid metabolism, and MED13, a component of the Mediator complex that 
controls nuclear hormone receptor activity, are repressed by miR-378 and miR-378*, 
respectively (Carrer et al., 2012). CRAT and MED13 were, therefore, chosen as 
validated targets to confirm the functionality of miR-378/378* deficiency in these 
genetically altered mice in our husbandry conditions.  
Peritoneal exudate cells were harvested from the peritoneal cavity of naïve wild type 
(WT), heterozygous (Het) and knockout (KO) mice. Peritoneal tissue resident 
macrophages were then adherence purified for 4 hours before being subject to RNA 
extraction. As expected, qRT-PCR analysis of this macrophage population revealed 
significantly higher levels of miR-378 in WT mice in comparison to the 
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heterozygous animals (Figure 4.1A). Essentially no expression of miR-378 was 
found in macrophages harvested from the KO animals. Levels of CRAT and MED13 
were also measured in the same samples. Significantly elevated levels of both CRAT 
and MED13 were observed in both heterozygous and KO mice when compared to 
the WT animals (Figure 4.1B). Even though significant differences were observed 
between the WT and heterozygous animals with a 2 fold and ~5 fold change for 
CRAT and MED13 respectively, the disparity between the WT and KO mice was 
much greater with CRAT levels being 4 fold higher and MED13 levels being nearly 
15 fold higher in macrophages isolated from the KO mice.  
 
4.2.2 Alternative activation of bone marrow derived macrophages 
in the absence of miR-378 
Having validated the absence of miR-378 and modulation of known targets in these 
mice, the next aim of this study was to address the kinetics of alternative activation 
in the absence of this microRNA. Bone marrow derived macrophages (BMDM) were 
chosen for the initial study as they present a homogeneous primary macrophage 
population that is relatively simple to generate in vitro and possesses all the 
characteristics of AAMΦ, except proliferation, when stimulated with IL-4 and IL-13. 
Bone marrow precursors were isolated from WT, heterozygous and KO mice and 
cultured in L929 conditioned medium containing CSF-1 for 7 days to generate 
BMDMs. These BMDMs were seeded and stimulated with 20ng/mL of IL-4 and IL-
13 to obtain AAMΦ. Of note, no differences were observed in cell viability and total 
cell numbers between the different genotypes. Cells were harvested at 24 and 48 
hours post stimulation and subject to intracellular staining for FACS analysis and 
supernatants were collected for measuring secreted protein levels by ELISA (Figure 
4.2A).  
Due to lack of sufficient mouse numbers from each genotype at the time, 
experiments between heterozygous and KO mice and WT and KO mice were carried 
out separately as shown in Figure 4.2B and 4.2C. For FACS analysis, macrophages 
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were gated based on CD11b and F4/80 expression. Intracellular staining for both 
RELM-α and YM-1 revealed differences in expression between heterozygous and 
KO mice, with expression levels being higher in the KO mice as indicated by the 
percentage of macrophages expressing these proteins in Figure 4.2B. Approximately 
40-45% of macrophages isolated from heterozygous mice were positive for RELM-
α. In comparison, around 60% of the macrophages harvested from KO mice 
expressed RELM-α. These differences were also reflected in the levels of secreted 
protein, with the heterozygous BMDMs producing 1.5 fold lower levels of RELM-α 
(~150ng/mL) when compared to macrophages isolated from the KO animals 
(250ng/mL) as shown in Figure 4.2B. Similar to RELM-α, YM-1 was also expressed 
by ~40% macrophages isolated from heterozygous animals. In the KO animals, the 
expression of YM-1 was comparatively higher, with approximately 45% of the 
BMDMs positive for this protein. Reflecting the intracellular staining results, 
significant differences were also observed in levels of secreted YM-1 as measured by 
ELISA. BMDMs from the KO mice produced twice as much YM-1 as that produced 
by macrophages from heterozygous mice (Figure 4.2B). Similar results were 
obtained for samples harvested 48 hours post stimulation (data not shown).  
An identical comparison was also carried out between BMDMs generated from 
either WT or KO mice. However, as reflected in Figure 4.2C, expression levels of 
RELM-α and YM-1 observed were much lower, possibly due to staining and/or other 
experimental conditions. Nonetheless, results suggested a similar trend for increased 
RELM-α and YM-1 expression in BMDMs from KO mice when compared to WT 
(Figure 4.2C).  Macrophages derived from KO animals showed a 3 fold increase in 
the percentage of cells positive for RELM-α expression when compared to the WT 
controls. Similarly, a nearly 2 fold increase in secreted RELM-α levels was also 
observed.  Contrastingly but in agreement with previous findings from the last 
experiment, no significant differences were observed in the percentage of 
macrophages expressing intracellular YM-1, but secreted YM-1 levels were 2 fold 
greater in BMDMs from KO mice. (Figure 4.2C).  
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The experiment described above was then repeated with BMDMs derived from WT, 
heterozygous and KO mice in a single experiment. Intracellular staining of 
macrophages for RELM-α at 24 hours revealed a similar pattern of expression as 
observed previously. In particular ~20% of macrophages from WT mice were 
positive for RELM-α expression in comparison to approximately 40% and 55-60% 
of macrophages derived from heterozygous and KO animals, as depicted in Figure 
4.2D. Quantification of secreted RELM-α protein also displayed a similar trend with 
significantly higher RELM-α expression in BMDMs isolated from heterozygous and 
KO mice (~2 and 3 fold respectively). Additionally, a greater percentage of 
macrophages derived from mice lacking miR-378 were positive for YM-1 expression 
(Figure 4.2D) whereas no differences were observed in the number of macrophages 
expressing YM-1 from WT and heterozygous mice. In agreement with this, the 
amount of YM-1 detected in the supernatant harvested from KO BMDMs was twice 
as much as the amount detected in samples from the WT and heterozygous BMDMs 
(Figure 4.2D). As represented in Figure 4.2E, samples harvested 48 hours post 
stimulation with IL-4 and IL-13 also exhibited similar expression profiles for both 
RELM-α and YM-1 when stained intracellularly. Although the levels of secreted 
RELM-α were still significantly higher in the supernatants harvested from miR-378 
KO BMDMs at 48 hours, contrary to the differences observed at 24 hours, levels of 
YM-1 observed at 48 hours were indistinguishable between samples (Figure 4.2E). 
Taken together, these results suggest that in the absence of miR-378, the kinetics of 
alternative activation in BMDMs appear to be disrupted. This was reflected by the 
fact that levels of both YM-1 and RELM-α were significantly higher in mice lacking 
miR-378 at 24 hours post IL-4/13 stimulation. However, although these differences 
in RELM-α expression are still distinguishable after 48 hours, the effect of miR-378 
deficiency on YM-1 expression was much less evident. In addition, the lack of miR-
378 was also assessed in alternatively activated Thio MΦ. The results from these 
experiments involving Thio MΦ confirmed and supported the findings from BMDMs 
above (data not shown). A detailed discussion of the kinetics of alternative activation 
in Thio MΦ is covered later in this chapter.  
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4.2.3 IL-4 induced proliferation in the absence of miR-378 
From the above experiments it is clear that there are differences in the kinetics of 
alternative activation in BMDMs derived from mice deficient in miR-378 compared 
to WT or heterozygous controls. Until now, the conditions of alternative activation 
utilised were restricted to stimulation of primary macrophages in vitro that do not 
proliferate in response to IL-4. As mentioned earlier, miR-378 suppresses AKT-1; a 
factor important for enhancement of alternative activation and essential for IL-4 
induced macrophage proliferation (Ruckerl et al., 2012). Hence, the next goal of this 
study was to address the effect of miR-378 deficiency on IL-4 driven proliferation in 
vivo. To this end, WT or miR-378 KO mice were injected with a single dose of PBS 
or 5μg IL-4c intraperitoneally (Figure 4.3A). Heterozygous mice were not used in 
this experiment as a sufficient number of these mice were not available. However, 
experimental repeats including mice heterozygous for miR-378 are described in the 
next section. Tissue resident peritoneal macrophages alternatively activate and 
proliferate in response to IL-4c injection. Proliferation peaks at 42 hours post 
delivery and begins to decline around 72 hours. Thus, mice were sacrificed at 42 
hours and 72 hours post IL-4c delivery. Mice were also injected with BrdU 
subcutaneously as a measure for active proliferation 3 hours prior to being culled. 
Peritoneal exudate cells (PEC) were harvested through washing of the peritoneal 
cavity. The PEC was divided and cells were either stained directly for FACS analysis 
or adherence purified at 37°C for 4 hours and lysed for RNA extraction. Supernatants 
were also harvested for protein quantification by ELISA (Figure 4.3A).  
With the dependency of IL-4 driven proliferation on AKT-1 and the negative 
modulation of AKT-1 expression by miR-378, it was hypothesised that in the 
absence of miR-378, IL-4 induced proliferation would be enhanced. Active 
proliferation following IL-4c delivery was measured through the expression of BrdU 
and Ki67hi by peritoneal macrophages. Macrophages were identified based on 
CD11b and F4/80 expression by FACS. At 42 hours post injection, no changes were 
observed in the percentage of macrophages expressing BrdU or Ki67hi. 
Approximately 40% of peritoneal macrophages isolated from both WT and miR-378 
KO mice stained positive for BrdU whereas ~ 20% of the F4/80+ population was 
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positive for Ki67hi expression (Figure 4.3B). Contrary to our hypothesis, the 
percentage of miR-378 KO macrophages expressing BrdU at 72 hours post IL-4c 
delivery was in fact lower than the percentage of WT macrophages expressing BrdU 
(10% versus ~5%). Compared to the PBS injected controls, a sub population of WT 
macrophages was still actively proliferating at this time point, whereas no differences 
were observed between the PBS and IL-4c injected groups in miR-378 KO mice 
(Figure 4.3B).  A similar trend was observed with percentage positivity for Ki67hi, 
with ~ 20% of the macrophages still actively proliferating whilst the macrophages 
isolated from miR-378 KO mice had stopped proliferating at 72 hours as shown in 
Figure 4.3B.  
In the same experiment, the levels of RELM-α and YM-1 proteins were also 
measured. No significant differences were observed in the percentage of 
macrophages expressing RELM-α between the WT and KO groups at both 42 and 72 
hours post IL-4c delivery (Figure 4.3B). We observed very high levels of RELM-α 
expression in miR-378 KO mice in the absence of IL-4c at the 42 hour time point. 
However, the lack of RELM-α protein in the supernatants isolated from the 
peritoneal washes of these PBS injected control mice (as measured by ELISA) 
suggested this was an artefact of FACS staining. In agreement with the FACS results, 
no changes were observed in RELM-α protein between the WT and KO groups 
injected with IL-4c. Similarly, YM-1 expression was quantified in the supernatants 
and no noticeable differences were observed between samples obtained from mice 
regardless of a deficiency in miR-378.  
The experiment described above was repeated with mice that were either WT, 
heterozygous or deficient in miR-378 (Figure 4.4A).  Mice were injected with either 
PBS or 5μg IL-4c intraperitoneally and samples harvested at 42 and 72 hours post 
injection. In agreement with the previous experiment, a trend towards a lower rate of 
proliferation in macrophages isolated from mice lacking miR-378 was observed. 
However, no differences were observed in proliferation between macrophages 
obtained from WT or heterozygous mice (Figure 4.4B). Analysis of expression of 
YM-1 and RELM-α revealed no difference between the three groups at 42 hours post 
delivery, however, once again a slight trend towards increased number of 
Chapter 4: miR-378/378* mice  
  155 
macrophages expressing YM-1 and RELM-α was observed at 72 hours. With only 3 
mice at this time point in the KO group, these differences were not statistically 
significant (Figure 4.4B). Contrary to the results obtained for the intracellular 
staining of YM-1 and RELM-α wherein no differences were observed at 42 hours, 
secreted levels of YM-1 were significantly higher in miR-378 KO mice compared to 
the WT and heterozygous groups (Figure 4.4C). This difference in YM-1 expression 
at 42 hours was lost by 72 hours. Contrastingly no significant differences were found 
in the expression of RELM-α at 42 hours, but samples harvested from heterozygous 
and KO mice displayed significantly elevated levels at 72 hours when compared to 
the WT mice. It is important to note that the statistical analysis was underpowered 
due to limitations in animal numbers, thereby making it difficult to assess subtle 
effects that microRNAs are usually associated with.  
When IL-4c is injected into the peritoneal cavity, a small proportion of the 
recombinant IL-4 is also transported to the pleural cavity. The tissue resident 
populations in both the peritoneal and pleural cavity respond similarly to IL-4 
resulting in the alternative activation, proliferation and accumulation of the local 
macrophage population. Thus, in a separate experiment, pleural exudate cells (PLEC) 
were harvested, along with peritoneal macrophages to compare the activation and 
proliferation states of the resident macrophage populations in these cavities in the 
absence of miR-378 (Figure 4.5A). Because no significant differences were observed 
between the WT and heterozygous mice in the last two experiments involving 
peritoneal macrophages, only heterozygous and KO mice were used in this 
experiment. First, the peritoneal macrophage population was analysed. As shown in 
Figure 4.5B, consistent with the previous results in peritoneal macrophages, no 
significant differences were found in the intracellular levels of Ki67hi, RELM-α or 
YM-1 in peritoneal macrophages at both 42 and 72 hours following IL-4c delivery. 
However, once again, differences were observed in the amount of secreted RELM-α 
and YM-1 with the miR-378 KO mice producing greater quantities of both proteins, 
notably at 72 hours post IL-4c injection (Figure 4.5C).  
Next, the macrophage population isolated from the pleural cavity was analysed. 
Mirroring the results obtained from the tissue resident population in the peritoneal 
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cavity, no differences were observed in the percentage of macrophages positive for 
Ki67hi, RELM-α and YM-1 in the pleural cavity at both 42 and 72 hours following 
IL-4c treatment (Figure 4.5D). Consistent with the results from the peritoneal cavity, 
macrophages from the pleural cavity of mice lacking miR-378 also produced higher 
quantities of secreted RELM-α and YM-1 proteins compared to the heterozygous 
group of mice as represented in Figure 4.5E.  
Cumulatively, data from these three independent experiments suggest that the 
differences observed between mice deficient in miR-378 and those with miR-378 
partially or completely intact, particularly in case of characteristic markers of 
alternative activation, appear to be transient and time dependent. Whilst a time 
dependent increase in alternative activation was observed, the lack of miR-378 had 
no significant effect on IL-4 driven proliferation but a possible unexpected 
suppression in some experiments instead.  
 
4.2.4 Kinetics of alternative activation in thioglycollate elicited 
macrophages in miR-378 deficient mice 
Having verified that some differences exist in the alternative activation of 
macrophages in the absence of miR-378, we next sought to investigate whether these 
differences were the result of accumulation of small differences over time or an 
initial defect in activation. To this end, we utilised inflammatory Thio MΦ to 
perform a time course experiment. Besides their ability to alternatively activate in 
vitro, injection of thioglycollate into the peritoneal cavity results in the rapid 
recruitment of a large number of inflammatory macrophages sufficient to fill the 
need for a substantial number of cells in this experiment. WT, heterozygous or KO 
mice were injected with 4% thioglycollate intraperitoneally as depicted in the 
schematic in Figure 4.6A. Three days following injection, PEC was harvested and 
Thio MΦ adherence purified for 4 hours. These Thio MΦ were then stimulated with 
20ng/mL of IL-4/IL-13. Supernatants were harvested at 2hr, 4hr, 6hr, 8hr, 10hr, 12hr, 
16hr and 24hr post stimulation. Quantification of both YM-1 and RELM-α by 
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ELISA revealed that the differences observed previously between the KO and WT 
mice were due to an accumulation of minor differences in expression/secretion over 
time.  As detailed further in Chapter 5, we have shown that expression of RELM-α 
and YM-1 at the transcript level is initiated at 6-8 hours post stimulation with IL-4 
and IL-13. Thus, it is expected that protein will be produced at about 8-10 hours post 
stimulation. Consistent with this assumption, both RELM-α and YM-1 proteins were 
readily detectable by 12 hours post stimulation as shown in Figure 4.6B. Overall, the 
findings from this time course support both the in vitro and in vivo data discussed in 
the previous sections of this chapter.   
 
4.2.5 Functional significance of miR-378 in a murine model of 
filarial infection 
So far, this study has shown that the normal kinetics of alternative activation are 
altered in the absence of miR-378. To address the function of miR-378 as a regulator 
of alternative activation, a murine model of filarial infection was utilised. Mice either 
WT, heterozygous or KO for miR-378 were infected with 30 infective L3 larvae of 
Litomosoides sigmodontis (Figure 4.7A). As described previously in the introductory 
chapter and Chapter 2, L. sigmodontis is a nematode that migrates to the pleural 
cavity and induces a TH2 response. AAMΦ are a distinguishing feature of 
inflammation driven by helminth infections. As the larvae enter the pleural cavity, 
the tissue resident pleural macrophages undergo alternative activation and also 
proliferate in response to IL-4 (Chapter 2, Figure 2.7). Due to limitations in mouse 
numbers, a single time point of day 8 was chosen for harvest. The main aim of this 
study was to delineate the functional significance of miR-378 during an infection. At 
day 8-post infection, macrophages in the cavity are alternatively activated and 
beginning to switch from CSF-1 dependent steady state proliferation to IL-4 driven 
proliferation (Jenkins et al., 2011, Jenkins et al., 2013). We reasoned that at day 8, 
the subtle differences in activation and/or proliferation between the control mice and 
mice lacking miR-378 would be most evident. Since the effects observed both in 
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vitro and in vivo appeared to be transient and time dependent, the small differences 
may not be discernable at later time points.   
Mice were culled on day 8 and PLEC isolated from all three groups of mice, namely 
WT, heterozygous and KOs. Cells were stained and subject to FACS analysis whilst 
supernatants were used for quantification of secreted YM-1 and RELM-α. FACS 
analysis of pleural macrophages characterised by CD11b and F4/80 expression 
revealed no differences between the three groups of mice in terms of percentage 
positivity for Ki67, RELM-α or YM-1. Consistent with the intracellular expression 
of RELM-α and YM-1, no significant differences were observed between mice 
lacking miR-378 and control WT or heterozygous mice. In conclusion, these results 
suggest that miR-378 is not crucial for the activation and proliferation dynamics of 
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4.3 Discussion 
Our lab has previously indicated that miR-378 may potentially negatively regulate 
IL-4 driven proliferation and to an extent also alternative activation of macrophages 
through the modulation of its direct target AKT-1 (Ruckerl et al., 2012). To date, this 
is the only study linking miR-378 to the regulation of AAMΦ responses.  However, 
the effects of miR-378 shown through the use of an AKT-1 inhibitor were indirect 
evidence to support this hypothesis. Just like a single microRNA has the ability to 
regulate several hundred genes, an mRNA may also be targeted by many 
microRNAs, making fine-tuning of targets a complex relationship. Hence, the 
phenotype observed by Ruckerl et al. upon inhibition of AKT-1 could potentially 
have been the result of abrogation of regulation by additional microRNAs and 
mechanisms beyond miR-378. In this chapter, we have shown for the first time the 
direct effects of miR-378 deficiency on the regulation of AAMΦ and their responses.  
The effects of miR-378 deficiency on alternative activation were first examined in 
vitro. BMDMs derived from WT, heterozygous or miR-378 KO mice were 
stimulated with IL-4/IL-13 for up to 48 hours. Levels of both intracellular and 
secreted RELM-α and YM-1 were enhanced in the KO mice when compared to the 
WT and heterozygous controls. Although no significant changes were observed in 
YM-1 expression between the WT and heterozygous animals, changes in RELM-α 
levels were evident between these two groups. This in line with the findings of 
Ruckerl et al. wherein in vitro inhibition of AKT-1 with triciribine in alternatively 
activated Thio MΦ results in abrogation of Retnla (RELM-α) expression but only 
partial inhibition of Chi3l3 (YM-1) (Ruckerl et al., 2012). Additionally, although 
alternative activation is a STAT6 dependent process (Gordon and Martinez, 2010), 
the regulation of RELM-α and YM-1 may differ downstream with greater 
dependency of molecular regulation on miR-378 resulting in a more profound effect 
on expression of one over the other in miR-378 deficient mice.  
In the previous study, Ruckerl et al. showed that the most prominent effect of AKT-1 
inhibition (as an indirect measure of the effect of miR-378) is on IL-4 driven 
proliferation of macrophages. In their experiment, mice received vehicle control or 
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triciribine, an AKT-1 specific inhibitor, intraperitoneally 1 hour prior to the injection 
of IL-4c. This pre-treatment with triciribine completely abrogated IL-4 induced 
proliferation. Simultaneously, protein levels of RELM-α were partially reduced 
whereas YM-1 expression remained unaffected. Thus, in our study, to address 
whether miR-378 has a direct primary function in the regulation of IL-4 driven 
proliferation, mice were injected with IL-4c intraperitoneally to induce alternative 
activation and proliferation of tissue resident peritoneal macrophages. As expected, 
delivery of recombinant IL-4 resulted in expansion of the local macrophage 
population (Jenkins et al., 2011, Jenkins et al., 2013). It was predicted that in the 
absence of miR-378, full repression of AKT-1 would not occur as it would in the WT 
mice leading to a higher rate of AAMΦ proliferation in the KO mice. However, no 
difference was observed in the extent of active macrophage proliferation between 
WT, heterozygous or KO animals as measured by BrdU and Ki67hi levels. It is not 
surprising that triciribine treatment did not directly mimic miR-378 deficiency. 
MicroRNAs are well established as key players in the regulation of cell cycle and 
proliferation (Hwang and Mendell, 2006, Zhang et al., 2007, Bueno and Malumbres, 
2011, Wang and Blelloch, 2011). Combinatorial targeting (Hon and Zhang, 2007) 
and microRNA synergistic networks (Xu et al., 2011) are a key feature in microRNA 
repression of gene expression. Often microRNAs (or a single microRNA) do not 
induce complete knockdown of their targets (Xiao and Rajewsky, 2009) and act in 
families targeting an entire signalling pathway rather than individual members 
leading to a general suppression (Guo et al., 2010). Furthermore, competition 
between microRNAs for target sites also shapes post-transcriptional gene regulation 
(Jens and Rajewsky, 2015). Hence, it is highly plausible that the lack of miR-378 is 
compensated for by other microRNAs involved in the regulation of macrophage 
proliferation. This may also be reflected in the fact that a trend towards reduced 
proliferation was noticeable in the KO mice when compared to controls.  
In addition to its effects on proliferation, AKT-1 also influences alternative 
activation. Therefore, the levels of RELM-α and YM-1 were also measured 
following IL-4c injection. RELM-α expression was significantly higher in the KO 
mice compared to both WT and heterozygous animals. Samples obtained from the 
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heterozygous mice also exhibited greater levels of secreted RELM-α compared to 
WT controls. However, these differences were only apparent through quantification 
by ELISA and no changes were seen at the intracellular level in the percentage of 
macrophages expressing RELM-α (Figure 4.4). This can be potentially explained by 
the fact that upon delivery of active rIL-4 at a single dose of 5μg, >80% 
macrophages stain positive for RELM-α. At this dose, intracellular protein 
expression is likely saturated. A dose titration study involving delivery of 
recombinant IL-4 at varying concentrations may help elucidate the role of miR-378 
in intracellular RELM-α protein levels in AAMΦ in vivo. Similarly, the levels of 
secreted YM-1 were also higher in mice lacking miR-378 when compared to control 
animals, although subtle differences were also noticeable at the intracellular level in 
some cases. It is also worth noting that between experimental repeats, the results 
varied with time suggesting that the effect of miR-378 on alternative activation is 
transient and time dependent.  
The next question addressed was whether these subtle changes were a result of an 
initial defect in activation due to improper AKT-1 (and other) responses or a slow 
accumulation of small differences over time. A time course study of the kinetics of 
alternative activation in thioglycollate-elicited macrophages over a course of 24 
hours was conducted. Quantification of secreted RELM-α and YM-1 proteins 
revealed significant differences between the amounts of protein produced by KO 
mice compared to WT controls at 24hr post stimulation with IL-4/IL-13. Expression 
of RELM-α and YM-1 was consistently lower over time, with subtle differences in 
protein quantity apparent from 12-16 hours post stimulation. It still remains to be 
determined if these differences are also reflected at the transcript level and whether 
they are a direct result of miR-378 being absent. To determine whether these 
differences are AKT-1 mediated, and hence, a direct or indirect effect of miR-378, 
AKT-1 expression or activity needs to be quantified and correlated with the changes 
in RELM-α and YM-1 expression over time.  
Lastly, to determine whether the deficiency of miR-378 and the differences observed 
in alternative activation in the KO mice had functional consequences, mice were 
infected with Litomosoides sigmodontis. At day 8 post infection, no differences were 
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observed in macrophage responses between the WT, heterozygous and KO mice. The 
rate of proliferation and the amounts of RELM-α and YM-1 produced, both 
intracellular and secreted, were indistinguishable between the three infected groups. 
Previously in this chapter, we showed differences in alternative activation of pleural 
macrophages upon peritoneal IL-4c injection in mice, with elevated levels of both 
RELM-α and YM-1 in the KO mice in comparison to the WT animals. This is in 
contrast to the lack of differences between the different genotypes during L. 
sigmodontis infection. Infection is much more complex than IL-4c delivery wherein 
other cell types and factors have a much greater influence on the overall response 
generated against the nematode. During L. sigmodontis infection, a robust TH2 
response ensues, marked by leukocyte infiltration and increased levels of IL-5 and 
IL-13 (Babayan et al., 2003b). Early on during infection, ILC2s also expand in the 
pleural cavity and produce IL-5 and IL-13 (Boyd et al., 2015). Secretion of IL-5 
results in the recruitment of eosinophils, which also produce IL-4 besides TH2 cells 
as infection progresses (Al-Qaoud et al., 1997, Babayan et al., 2003b). The presence 
of IL-4 and IL-13 in the cavity results in the alternative activation and proliferation 
of pleural tissue resident macrophages. In parallel, the nematode also elicits a strong 
systemic TH2 response characterised by elevated levels of IgG1, IgE and IL-5 in the 
blood plasma (Babayan et al., 2003b). Exposure to infective L3 larvae also results in 
the rapid recruitment and increase in Treg cells (Taylor et al., 2009) besides other 
immune cell types. Moreover, products such as microRNAs and exosomes 
containing immunomodulatory molecules are also secreted by the parasite (Buck et 
al., 2014). In contrast, delivery of recombinant IL-4 to the peritoneal cavity is 
relatively less complex as the main populations residing in the peritoneal cavity 
comprise mainly B cells and macrophages as evidenced by FACS data (data not 
shown).  
Since microRNAs often act as fine tuners and not master regulators of responses 
(Selbach et al., 2008), it would not be surprising if subtle effects of microRNAs 
induced by IL-4 alone were diluted out with infection.  Furthermore, many signalling 
cascades are activated simultaneously in response to infection or insult. With the 
knowledge that microRNAs exert subtle effects on gene expression (Mourelatos, 
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2008, Hon and Zhang, 2007) along with the fact that several microRNAs are co-
induced during immune responses (Lindsay, 2008, Zhou et al., 2011, Lu and Liston, 
2009, Chen et al., 2013), the probability of compensation for the lack of a single 
microRNA is also high. In this chapter, we have also shown that the effects of miR-
378 on alternative activation were the result of a build up of subtle differences over 
time. Day 8 is a relatively early time point in the course of L. sigmodontis infection. 
It is possible that differences may become more evident at later time points during 
infection, especially when activation and proliferation are at their peak at day 11. An 
infection with incorporation of several time points would help to answer these 
questions.  
In addition to the experiments described in this chapter, additional experiments could 
be envisioned with the miR-378 KO mice to pin down the role of microRNAs in 
regulating macrophage function. Firstly, it is yet to be determined if miR-378 plays a 
concrete role in the regulation of IL-4 driven macrophage proliferation through the 
direct suppression of AKT-1. Through the results described in this study, it is evident 
that miR-378 alone is not responsible for the regulation of AAMΦ proliferation. 
However, the lack of miR-378 does have an effect on alternative activation. In 
chapter 3, we have reported a role for miR-199b-5p in the regulation of macrophage 
proliferation. Additionally, we have shown that microRNA mimics can be delivered 
in vivo and that overexpression of miR-199b-5p significantly affects YM-1 
expression. With microRNAs working in synergy with one another to regulate 
signalling cascades, it would be extremely interesting to inhibit miR-199b-5p in mice 
lacking miR-378 to study their additive contribution in regulating AAMΦ activation 
and proliferation.  
Secondly, besides its role in regulating AAMΦ responses, miR-378 is a known 
regulator of metabolic pathways, including insulin signalling and mitochondrial 
metabolism (Carrer et al., 2012, Liu et al., 2014). We have demonstrated in Chapter 
3 that miR-199b-5p regulates IRS-1 expression; a key component of insulin 
signalling that is also regulated by IL-4. AAMΦ have key functions in regulating 
metabolism and utilise oxidative phosphorylation to fuel their functions (Odegaard 
and Chawla, 2011, Galvan-Pena and O'Neill, 2014, Vats et al., 2006, Schug and Li, 
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2009). Thus, it would be intriguing to address the cumulative effect of these 
microRNAs in regulating AAMΦ responses outwith proliferation and characteristic 
hallmarks of activation.  
Thirdly, a role for miR-378 has been implicated in adipogenesis (Kulyte et al., 2014, 
Gerin et al., 2010, Ortega et al., 2010). AAMΦ are key players during thermogenesis 
and macrophages found in the adipose tissue also display the M2 phenotype (Kang et 
al., 2008, Suganami and Ogawa, 2010, Nguyen et al., 2011). FAT-associated 
lymphoid clusters (FALCs) are a type of lymphoid tissue associated with visceral fat 
that expand in response to inflammation. This FALC formation in response to 
inflammation is IL-4Rα dependent and a role for FALCs has been implicated as a 
centre for differentiation of B cells into plasma cells and germinal centre like B cells, 
indicative of an important function during immune responses (Benezech et al., 2015). 
Thus, it may be interesting to address the role of miR-378 towards FALC 
development during infection in the different miR-378 genotypes. In resting 
conditions, FALCs are composed mainly of IgM+ B cells (Benezech et al., 2015). 
Therefore, as a starting point, IgM levels could be measured in the supernatants 
harvested from the pleural cavity at day 8 post L. sigmodontis infection as an indirect 
indication of any FALC developmental defects.  
In conclusion, the results from this chapter support a role for miR-378 in the 
regulation of alternative activation, with a greater contribution in regulating RELM-α 
expression than YM-1. Of note, only the levels of RELM-α and YM-1 were 
evaluated as characteristic markers of alternative activation. The effects of miR-378 
deficiency on other molecules that are also upregulated during alternative activation 
still remain to be assessed. However, no effect was observed on IL-4 driven 
macrophage proliferation, despite AKT-1 being a direct target of this microRNA. 
Further work to identify whether these differences in RELM-α and YM-1 occur at 
the transcript level underpinning its impact on IL-4R α signalling would provide a 
better understanding of the regulation of the AAMΦ phenotype by miR-378. In the 
context of infection, no significant role for miR-378 could be established. However, 
due to experimental limitations, it is too early to conclusively rule out a role for miR-
378 in helminth infection. 
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A. 




Figure 4.1 Literature validation of mice genetically lacking miR-378/378* 
Peritoneal exudate cells (PEC) were harvested from WT, heterozygous and KO mice. 
Peritoneal macrophages were then adherence purified after incubation at 37C for 4 hours. 
Cells were lysed and RNA extracted. A. MiR-378 levels were quantified by qRT-PCR and 
normalised to RNU6B expression B. CRAT and MED13 transcripts were also quantified by 
qRT-PCR and expression normalised to 18S. Fold changes were calculated relative to the 
WT animals. Data represented are the mean fold change ± SEM and determined using one-
way ANOVA (Kruskal Wallis test) (* P< 0.05, ** P< 0.01, *** P< 0.001). Data are 
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Figure 4.2 Alternative activation in BMDMs derived from WT, heterozygous or miR-
378 KO mice 24 and 48 hours post IL-4/IL-13 stimulation.  
A) Total bone marrow was isolated from mice and cultured in media containing CSF-1 for 7 
days. Cells were harvested on day 7 and seeded overnight before stimulation with 20ng/mL 
of IL-4 and IL-13. Supernatants were harvested at 24 and 48 hours post stimulation and cells 
were stained for FACS analysis. B) Intracellular and secreted RELM-α and YM-1 expression 
in BMDM derived from heterozygous and KO mice. Data are representative of a single 
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Figure 4.2 Alternative activation in BMDMs derived from WT, heterozygous or miR-
378 KO mice 24 and 48 hours post IL-4/IL-13 stimulation.  
C) Levels of intracellular and secreted RELM-α and YM-1 in BMDM isolated from WT and 
KO animals at 24 hours post stimulation. Data are representative of a single experiment 
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Figure 4.2 Alternative activation in BMDMs derived from WT, heterozygous or miR-
378 KO mice 24 and 48 hours post IL-4/IL-13 stimulation. D & E) Experimental repeat 
of BMDMs inclusive of all three miR-378 genotypes, namely WT, heterozygous and KO. 
Intracellular and secreted levels of RELM-α and YM-1 were measured by flow cytometry 
and ELISA at D) 24 hours and E) 48 hours post stimulation respectively. Data are 
represented as mean ± SEM and determined using one-way ANOVA (Kruskal Wallis test) (* 
P< 0.05, ** P< 0.01, *** P< 0.001). Data are representative of measures from two separate 
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Figure 4.3 IL-4 driven proliferation and alternative activation in the peritoneal cavity 
in the absence of miR-378.  
A) WT mice or miR-378 KO mice were injected with either PBS or IL-4c intraperitoneally. 
BrdU was also injected subcutaneously 3 hours prior to culling. Pleural exudate cells (PEC) 
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were harvested at 42 and 72 hours post injection. Cells were utilised either for FACS 
analysis or qRT-PCR and supernatants harvested for protein quantification by ELISA.  
B) Graphs represent FACS analysis of intracellular staining of peritoneal macrophages for 
BrdU, Ki67hi and RELM-α at 42 and 72 hour time points. Results from quantification of 
secreted RELM-α and YM-1 by ELISA at 42 and 72 hours post injection are also displayed. 
Data are represented as mean ± SEM and determined using one-way ANOVA (Kruskal 
Wallis test) (* P< 0.05, ** P< 0.01, *** P< 0.001). Data are representative of a single 
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Figure 4.4 Comparison of IL-4 induced proliferation and alternative activation in the 
peritoneal cavity of WT, heterozygous and miR-378 KO mice.  
A) WT mice, heterozygous mice or miR-378 null mice were injected with either PBS or IL-
4c intraperitoneally. PEC was harvested at 42 and 72 hours and cells were subject to FACS 
analysis and supernatants harvested for ELISA. B) Graphs represent FACS analysis of 
intracellular staining of peritoneal macrophages for Ki67hi, YM-1 and RELM-α at 42 and 72 
hours. C) Results from quantification of secreted RELM-α and YM-1 by ELISA at 42 and 72 
hours post treatment. Data are represented as mean ± SEM and determined using one-way 
ANOVA (Kruskal Wallis test) (* P< 0.05, ** P< 0.01, *** P< 0.001). Data are 
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Figure 4.5 Comparison of IL-4 driven proliferation and alternative activation in the 
peritoneal and pleural cavities of heterozygous and KO mice.  
A) Heterozygous mice or miR-378 deficient mice were injected with either PBS or IL-4c 
intraperitoneally. PEC and PLEC were harvested at 42 and 72 hours. B & D) FACS analysis 
of intracellular staining of peritoneal and pleural macrophages for Ki67hi, RELM-α and 
YM-1 expression at 42 and 72 hours. C & E) Results from quantification of secreted RELM-
α and YM-1 by ELISA from the peritoneal and pleural cavities at 42 and 72 hours post 
treatment. Data are represented as mean ± SEM and determined using one-way ANOVA 
(Kruskal Wallis test) (* P< 0.05, ** P< 0.01, *** P< 0.001). Data are representative of a 
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Figure 4.6 Kinetics of alternative activation in thioglycollate elicited macrophages.  
A) Schematic for isolation of thioglycollate elicited macrophages. WT, heterozygous or KO 
mice were injected with 4% thioglycollate intraperitoneally. PEC was harvested 3 days post 
injection and macrophages adherence purified for 4 hours at 37C. Purified macrophages 
were stimulated with 20ng/mL of IL-4 and IL-13. Samples were harvested at various time 
points ranging from 2hr to 24hr. B) The levels of secreted YM-1 and RELM-α proteins were 
quantified in the PEC supernatant by ELISA. Data are represented as mean ± SEM and 
determined using one-way ANOVA (Kruskal Wallis test) (* P< 0.05, ** P< 0.01, *** P< 
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Figure 4.7 Alternative activation and macrophage proliferation during L. sigmodontis 
infection in WT mice, heterozygous mice and miR-378 KO mice.  
A) Mice were infected with infective larvae subcutaneously and culled at day 8 post 
infection. Pleural lavage (PLEC) was harvested for analysis. B) Analysis of intracellular 
staining for Ki67, RELM-α and YM-1 expression in F4/80+ pleural  macrophages. C) 
Quantification of secreted YM-1 and RELM-α proteins in the PLEC supernatant was carried 
out by ELISA. Data are represented as mean ± SEM and determined using one-way ANOVA 
(Kruskal Wallis test) (* P< 0.05, ** P< 0.01, *** P< 0.001). Data are representative of a 
single experiment (n=6). 
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Chapter 5: Analysis of miR-146 levels in AAMΦ and 
generation of a stable cell line towards the 
biochemical identification of microRNA targets 
 
SUMMARY:  
MiR-146a is a highly studied microRNA that has previously been linked strongly to 
TH1 immune responses, especially classical activation of macrophages. However, a 
role for this microRNA in regulating AAMΦ is yet to be determined. In Chapter 2, 
we have showed that expression of miR-146 is central to a range of alternative 
activation conditions in vitro and in vivo. The central focus of this chapter is to 
examine the role of miR-146 in the regulation of AAMΦ. Expression of miR-146a 
and miR-146b, the two isoforms of miR-146, was found to be opposite in AAMΦ, 
with a decrease in miR-146a and increase in miR-146b expression in response to IL-
4 both in vitro and in vivo. Based on this difference in expression and their known 
functions in suppressing excessive proinflammatory responses, it was hypothesised 
that miR-146a/b serve to regulate proinflammatory molecules (and signals) in a fine 
balance to allow efficient alternative activation to occur. However, a difference of 
just two nucleotides between the sequences of these two miR-146 isoforms proved to 
be a hindrance to test this hypothesis in terms of shared targets. Therefore, the latter 
half of this chapter was devoted to the generation and optimisation of a stable cell 
line for the identification of microRNA targets using CLASH (cross-linking, ligation 
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5.1 Introduction 
The primary aim of this thesis is to identify microRNAs differentially expressed in 
AAMΦ and to study their functional roles in regulating this phenotype. We have 
shown previously in Chapter 2 that the mature forms of miR-146a and miR-146b, 
originating from the 5’ arms of their respective precursor microRNAs, are 
differentially regulated in response to IL-4. MiR-146a and miR-146b are two 
isoforms of miR-146 that are derived from two separate genes located on different 
chromosomes. These mature forms share identical seed regions and differ in their 
sequences by just two nucleotides in the 3’ region. Of these, miR-146a is one of the 
most widely studied microRNAs in the context of immune responses (Pedersen and 
David, 2008, Rusca and Monticelli, 2011). A role for miR-146a has been proposed in 
the regulation of both innate and adaptive immunity (Boldin et al., 2011, Labbaye 
and Testa, 2012).  
The functional properties of miR-146a have been particularly well characterised in 
monocytes and macrophages. The miR-146a promoter contains several binding sites 
for NF-κB and induction of miR-146a is NF-κB dependent (Taganov et al., 2006). 
MiR-146a has been shown to target Interleukin-1 receptor-associated kinase 1 
(IRAK1) and TNF receptor associated factor 6 (TRAF6) both in vitro and in vivo 
(Taganov et al., 2006, Hou et al., 2009) and is involved in a negative feedback loop 
suppressing the expression of genes such as IL-6 (He et al., 2014c), IL-8 (Bhaumik et 
al., 2009), IL-1β (Perry et al., 2008) and TNF-α (Sheedy and O'Neill, 2008). 
Moreover, infection of murine macrophages with vesicular stomatitis virus (VSV) 
induces miR-146a, which negatively regulates the RIG-I antiviral pathway by 
targeting IRAK, IRAK2 and TRAF6, thereby suppressing the production of 
interferons (Hou et al., 2009). In addition to its role in regulating innate immune 
responses, miR-146a is also known to be essential in adaptive immunity. T cells 
deficient in miR-146a are hyperactive in both antigenic and chronic inflammatory 
autoimmune responses, whereas the deficiency of miR-146a in Treg cells results in a 
breakdown of immunological tolerance due to enhanced expression of signal 
transducer and activator transcription 1 (STAT1), otherwise suppressed by miR-146a 
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(Lu et al., 2010, Yang et al., 2012).  MiR-146a is also one of the few microRNAs to 
be differentially expressed in TH1 and TH2 cells, suggesting that miR-146a could 
potentially be involved in fate determination (Curtale et al., 2010, Labbaye and 
Testa, 2012). Furthermore, miR-146a-deficient mice, in addition to autoimmunity, 
develop an exaggerated pro-inflammatory response when exposed to LPS (Boldin et 
al., 2011). The aged knockout mice also develop tumours in secondary lymphoid 
organs and undergo myeloproliferation, suggesting the involvement of miR-146a in 
regulating development and activation of immune cells (Boldin et al., 2011, O'Neill 
et al., 2011, Sonkoly and Pivarcsi, 2011). More recently, a role for miR-146a has 
been implicated in the modulation of inflammatory responses through its transfer 
between cells through exosomes (Alexander et al., 2015, Okoye et al., 2014).  
In contrast to miR-146a, the other isoform of miR-146 i.e. miR-146b, has not been as 
extensively studied. Although both microRNAs are predicted to bind the same 
targets due to identical seed sequences, their transcriptional regulation has been 
shown to be different. Whilst miR-146a expression is NF-κB dependent (Taganov et 
al., 2006), expression of miR-146b is dependent on GATA-1 (Zhai et al., 2014) and 
STAT3 (Xiang et al., 2014). The induction of both microRNAs has been reported 
during proinflammatory responses. However, production of miR-146a has been 
shown to be dependent on IL-1β whereas miR-146b expression is reliant on IFN-γ 
(Kutty et al., 2013). Additionally, induction of miR-146a is regulated 
intracellularly via NF-κB and JNK-1/2 whilst miR-146b expression is thought to be 
MEK-1/2 and JNK1/2 mediated (Perry et al., 2009). Like miR-146a, a role for miR-
146b has also been implicated in regulating proinflammatory responses (Taganov et 
al., 2006, Xiang et al., 2014). A survey of current literature reveals that the function 
of miR-146b is largely associated with several cancers and tumour metastasis, 
particularly in gliomas (Xia et al., 2009, Katakowski et al., 2010, Garcia et al., 2011, 
Katakowski et al., 2013). Dysregulation of miR-146b has also been linked to 
regulation during thyroid carcinomas (Chou et al., 2010, Deng et al., 2015) and a role 
for miR-146b has been implicated in the modulation of Transforming Growth Factor- 
β (TGF- β) signalling via suppression of SMAD4 in thyroid tumorigenesis (Geraldo 
et al., 2012). MiR-146b expression is also altered during obesity (Chen et al., 2014c). 
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Besides the negative regulation of TLR signalling through IRAK1 and TRAF6, miR-
146b is also induced by IL-10 and can display anti-inflammatory properties in 
monocytes through targeting multiple components of the TLR4 pathway (Curtale et 
al., 2012, Renzi et al., 2012). Other than that, the role of miR-146b in immune 
responses still remains largely unknown.  
Based on the existing literature reviewed above, miR-146 has a well-defined role in 
the regulation of CAMΦ and limiting their responses. However, a role for miR-
146 in the regulation of AAMΦ is yet to be determined. A previous study carried 
out by our lab identified miR-146a as being differentially expressed in AAMΦ 
isolated from B. malayi implant in mice (Ruckerl et al., 2012). In this chapter, the 
expression profiles of both miR-146a and miR-146b were explored in detail under 
different conditions of alternative activation to infer potential roles of miR-146 in 
regulating AAMΦ. However, the extent of similarity between the mature sequences 
of miR-146a and miR-146b limits the ability to delineate their targets and functions 
using synthetic inhibitors, which are likely to bind to both forms.  
To overcome this hurdle, a part of this chapter focused on setting up the tools 
required to biochemically identify targets using the “cross-linking, ligation and 
sequencing of hybrids (CLASH)” technique (Helwak et al., 2013). MicroRNA 
binding sites are generally situated in the 3’UTR of mRNAs and target recognition is 
largely mediated through complementarity to the seed region of the microRNA 
(position 2-8nt in the mature microRNA sequence). However, non-canonical binding 
of targets via bulged or centred interactions has gained importance over the past 
years (Shin et al., 2010, Chi et al., 2012, Martin et al., 2014, Cloonan, 2015) but 
these interactions are still difficult to identify. Identification of microRNA targets 
involves a balance between computational and experimental approaches (Thomson et 
al., 2011, Hausser and Zavolan, 2014). As discussed previously in Chapter 3 the false 
positive rate relating to target prediction is relatively high (50-70%) (Thomson et al., 
2011), largely due to the reliance on canonical binding and exclusion of other factors 
that could affect binding affinities such as RNA structures and RNA-binding proteins 
that might affect binding site accessibility (Ameres et al., 2007, Kedde and Agami, 
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2008). A common method to identify direct microRNA targets involves the 
immunoprecipitation of Argonaute (AGO) proteins followed by sequencing of the 
isolated AGO-bound RNAs (Hausser and Zavolan, 2014). CLASH (Helwak et al., 
2013) is a variation of one such high throughput sequencing technique involving 
AGO cross-linking and immunoprecipitation (HITS-CLIP) that can be utilised for 
the identification of direct microRNA targets (Ule et al., 2003, Licatalosi et al., 2008, 
Konig et al., 2011). In CLASH, like other CLIP techniques, following cross linking 
tagged AGO protein bound to microRNAs and their target mRNAs contained within 
the RISC complexes is immunoprecipitated. However, , in an additional step that 
distinguishes CLASH from other similar techniques as shown in Figure 5 below, the 
microRNA is then ligated to its target mRNA, thereby providing physical evidence 
of direct target binding without relying on the assumption of canonical binding site 
interactions (Helwak et al., 2013, Helwak and Tollervey, 2014).  
A secondary aim of this chapter, therefore, was to generate a suitable stable 
macrophage cell line expressing the tagged AGO protein for the identification of 
miR-146 targets using CLASH. In the second half of this chapter, a RAW 264.7 
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Figure 5. A brief simplified overview of the Cross Linking And Sequencing of Hybrids 
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5.2 Results 
5.2.1 Contrasting regulation of miR-146a and miR-146b during 
alternative activation in macrophages across different cell 
types 
As discussed in chapter 2, microarray data identified both miR-146a and miR-146b 
as being differentially regulated in bone marrow derived macrophages in response to 
IL-4. In this section, the expression profiles of these isoforms have been examined in 
detail under varying conditions of alternative activation. 
5.2.2 Macrophage cell lines 
RAW 264.7 and J774A.1 cells were treated with IL-4 and IL-13 for 24 and 48 hours. 
Contrasting expression of miR-146a and miR-146b was observed in both 
macrophage cell lines (Figure 5.1A and 5.1B). Whilst miR-146a levels were reduced, 
expression of miR-146b was enhanced. It has previously been reported that LPS 
induces the expression of both miR-146a and miR-146b (Taganov et al., 2006, 
Curtale et al., 2012, Chen et al., 2014b). Hence, in a repeat experiment, both RAW 
264.7 and J774A.1 cells were also stimulated with 10ng/mL LPS. In agreement with 
the existing literature, qRT-PCR analysis revealed that expression levels of both 
miR-146a and miR-146b were up-regulated nearly 2-3 fold in response to LPS 
treatment compared to untreated controls in both RAW 264.7 (Figure 5.2A) and 
J774A.1 (Figure 5.2B) cells. In line with our previous findings, there was a 2-fold 
reduction in the expression of miR-146a in both the cell lines at 24 and 48 hours post 
stimulation with IL-4/IL-13 (Figure 5.2A and Figure 5.2B). In contrast, miR-146b 
was upregulated in RAW 264.7 cells by 1.5 fold (Figure 5.2A) compared to 
untreated controls in response to IL-4/IL-13. Although a 1.5 fold increase in its 
expression was also observed in J774A.1 cells at 48 hours, no significant change was 
observed at 24 hours (Figure 5.2B). Together, these results from two different 
macrophage cell lines confirm that miR-146a and miR-146b levels are differentially 
altered in macrophages in response to IL-4 and IL-13.  
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Having confirmed that the expression of both these microRNAs was altered in RAW 
264.7 cells in response to a combination of IL-4 and IL-13, we next sought to 
identify the relative contribution of these two cytokines towards altered miR-146a/b 
expression. To this end, cells were left untreated or stimulated with either 20ng/mL 
of IL-4 or IL-13 or a combination of both IL-4 and IL-13. RNA was extracted from 
lysed cells at 24 and 48 hours for qRT-PCR analysis. The altered expression of both 
miR-146a and miR-146b was induced equally by IL-4 or IL-13 alone and the effect 
combining the two cytokines on expression of these microRNAs was not additive 
(Figure 5.3).  This is in contrast to results in chapter 2 that showed alternative 
activation of RAW 264.7 cells was mainly driven by IL-4.    
5.2.3 Primary macrophages 
Having determined the response of both miR-146 isoforms to classical and 
alternative activation of the cell lines, the differences in their expression in primary 
AAMΦ and CAMΦ were determined. BMDMs were generated from bone marrow 
precursors derived from WT C57BL/6 mice and stimulated with either 10ng/mL of 
LPS or 20ng/mL of IL-4/IL-13. Cells were harvested at 24 and 48 hours post 
stimulation. As was observed in the cell lines, both miR-146a and miR-146b were 
significantly up regulated in BMDMs in response to LPS treatment at 24 hours 
(Figure 5.4A). There was a gradual decline in expression of miR-146a in response to 
IL-4/IL-13 treatment over time, with levels being reduced by nearly 2 fold at 48 
hours as shown in Figure 5.4B. In contrast, expression of miR-146b was enhanced 
with time with a 2 fold increase at 48 hours post IL-4/IL-13 stimulation (Figure 
5.4B). These alterations in expressions of both miR-146a and miR-146b were also 
reflected in the copy numbers determined using synthetic standards at 24 and 48 
hours post treatment with IL-4 and IL-13 (Figure 5.4C and 5D). Analysis of the copy 
numbers also revealed that BMDMs that miR-146a levels are 100 fold higher than 
miR-146b levels in these cells: 107 copies/ng of RNA versus 105 copies/ng of RNA 
respectively. 
To extend the analysis to other in vitro conditions of alternative activation, the 
expression of both miR-146 isoforms was investigated in Thio elicited MΦ 
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adherence purified from PEC populations obtained from WT C57BL/6 mice. The 
Thio elicited MΦ were stimulated with 10ng/mL of LPS or 20ng/mL of IL-4 and IL-
13 in vitro for up to 48 hours before RNA was harvested for qRT-PCR. Consistent 
with the previous findings, levels of both miR-146a and miR-146b were significantly 
increased (average of 3 fold) in response to LPS treatment (Figures 5.5A and 5.5B). 
Also consistent with earlier experiments, expression of miR-146a was downregulated 
by >2 fold at 48 hours post stimulation with IL-4/IL-13, whereas expression of miR-
146b was upregulated (Figures 5.5A and 5.5B). Taken together these findings 
suggest similar changes in miR-146a/b expression levels in response to IL-4/13 
treatment of a range of macrophages in vitro.  
5.2.4 IL-4c treatment in the peritoneal cavity of mice 
Having examined the expression profiles of these microRNAs under conditions of 
alternative activation in vitro, we next sought to determine if these changes in miR-
146a and miR-146b expression also occurred in vivo. Peritoneal macrophages sorted 
from PEC cells isolated from WT C57BL/6 mice injected with a single dose of 5μg 
of recombinant IL-4 (24 hours post injection) express significantly lower amounts of 
miR-146a (~2 fold reduction) and higher amounts of miR-146b (~1.5 fold increase) 
when compared to macrophages isolated from mice injected with PBS only (Figure 
5.6A). These changes in the relative expression levels of miR-146a/b were also 
reflected in the copy numbers as measured using synthetic microRNA standards 
(Figure 5.6B). In agreement with the in vitro data obtained from BMDMs, miR-146a 
is expressed at significantly higher copy numbers/ng RNA in macrophages isolated 
from the peritoneal cavity (106-107 copies) when compared to miR-146b expression 
in the same population (105 copies/ng RNA) as shown in Figure 5.6B.  
5.2.5 Litomosoides sigmodontis infection in mice 
Until now we have shown a consistent downregulation in the expression of miR-
146a during alternative activation whilst at the same time showing that levels of 
miR-146b are increased across different conditions. To investigate whether the 
contrasting expression of miR-146a and miR-146b also occurred in an environment 
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with potential functional consequences, we next examined the expression levels these 
microRNA isoforms over the course of L. sigmodontis infection. With the 
progression of infection over time, a statistically non-significant trend towards 
downregulation of miR-146a expression was observed. In contrast, the expression of 
miR-146b was significantly increased over the course of infection (Figure 5.7A).  
Since the transcriptional regulation of miR-146a and miR-146b in response to IL-
4/IL-13 is in opposition, we hypothesised that miR-146b is up-regulated during 
alternative activation to compensate for the reduction in levels of miR-146a through 
suppression of shared targets. Therefore, in the same study, we also analysed the 
change in copy numbers of these microRNAs over the course of infection 
progression as represented in Figure 5.7B. There was a significant difference in the 
levels of miR-146a and miR-146b that are expressed by pleural macrophages during 
infection with L. sigmodontis.. Macrophages isolated from naïve mice expressed ~ 
106 copies of miR-146a per ng of RNA whereas miR-146b was only expressed at 
around 104 copies/ng RNA. Whilst there was significant up-regulation of miR-146b 
by approximately 10 fold with the progression of infection, the levels of miR-146a 
appeared to remain unchanged at ~106 copies/ng RNA (Figure 5.7B).  Although this 
lack of altered miR-146a expression was in agreement with the fold change in its 
expression during L. sigmodontis infection (Figure 5.7A), it is in contrast to the 
consistent downregulation in its expression during other conditions of alternative 
activation. Therefore, with a lack in reduction of miR-146a copy number over the 
course of infection, it seems that a compensatory mechanism may not exist between 
miR-146a/b, at least in this model of infection.  Furthermore it is not clear what 
effect a 10 fold increase in miR-146b would have on the regulation of shared targets, 
since miR-146a was still expressed at ~10 fold higher copy numbers. 
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5.2.6 MiR-146a/b expression profiles over the course of alternative 
activation 
Because miR-146a and miR-146b are isoforms with identical seed sequences that 
differ in their 3’ region by just 2 nucleotides, they are predicted to share targets and 
indeed have been shown to bind some of the same mRNA targets. For example, both 
miR-146a/b are negative regulators of TLR signalling and target the same molecules 
in this pathway (Taganov et al., 2006). Hence, based on their differential regulation 
in AAMΦ along with their known functions in suppressing excessive 
proinflammatory responses, it was hypothesised that miR-146a/b serve to regulate 
proinflammatory molecules (and signals) in a fine balance to allow efficient 
alternative activation to occur. 
To help formulate a hypothesis related to whether miR-146 is important for the 
initiation and/or maintenance of alternative activation, the expression profiles of 
miR-146a/b were studied during a time course of alternative activation in RAW 
264.7 cells. The rationale behind this experiment was to examine the onset of 
changes in miR-146a/b expression in relation to the expression of Chi3l3 (YM-1), a 
characteristic marker of alternative activation. With the known role of miR-146 in 
regulating proinflammatory responses (TLR signalling), classical activation was used 
as a control in this experiment. RAW 264.7 cells were left untreated or stimulated 
with 10ng/mL of LPS or 20ng/mL of IL-4 and IL-13. Cells were harvested at 0hr, 
2hr, 4hr, 6hr, 8hr, 12hr, 18hr, 24hr, 36hr and 48hr post stimulation. Quantification by 
qRT-PCR revealed a gradual increase in Chi3l3 (YM-1) expression over time (Figure 
5.8A). A significant increase in mRNA expression was observed at 4-6hr post IL-
4/IL-13 stimulation and this continued to rise steadily until peak expression at 18-
24hr hours post treatment (Figure 5.8A).  On the other hand, mRNA levels of TNF-α 
(Tnfa) and iNOS (Nos2) were used as a measure of classical activation (Figure 5.8B). 
As expected, both TNF-α and iNOS mRNAs were induced fairly quickly following 
exposure to LPS, with expression significantly increased at 2 hours post treatment. 
Their expression levels peaked at 4 hours with a gradual decline over time as shown 
in Figure 5.8B. Consistent with existing literature, both miR-146a and miR-146b 
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were significantly up-regulated in response to LPS treatment (Nahid et al., 2009, 
Nahid et al., 2011) as is reflected in Figure 5.8C. Expression escalated quickly by 6 
hours post stimulation and continued to rise until 24-48hr. This increase correlated 
with the decrease in TNF-α and iNOS. There was a decline in their expression as 
levels of miR-146a/b continued to rise and this is in agreement with their role as 
regulators of endotoxin tolerance in a negative feedback loop (Nahid et al., 2009, 
Nahid et al., 2011). Following confirmation of miR-146a/b expression during 
classical activation, their expression profiles over the course of alternative activation 
were next examined (Figure 5.8C). Consistent with the previous data obtained from 
RAW 264.7 cells, expression of miR-146a was reduced upon exposure to IL-4 /IL-13 
over time. This reduction was observed from 8 hours post treatment but wasn’t 
significant until 12 hours. This reduction in expression was maintained until 48 hours 
(Figure 5.8C & Appendix 4). In contrast, miR-146b expression was enhanced from 
18 hours post treatment until 48 hours (Figure 5.8C & Appendix 4).  
The primary aim of this experiment was to examine potential correlation between the 
expression of miR-146a/b to Chi3l3 (YM-1) expression. We have shown that miR-
146a expression declined in response to IL-4/IL-13 while expression of Chi3l3 was 
greatly enhanced over the course of alternative activation (Figures 5.8A and 5.8C). 
Correlation of miR-146a expression over time to Chi3l3 mRNA levels revealed a 
moderate negative correlation with a Pearson’s r value of -0.59. However, this 
correlation was not statistically significant with a P value of 0.09 as shown in Figure 
5.8D. Similarly, a correlation was calculated between miR-146b expression and 
Chi3l3 mRNA levels (Figure 5.8E). There was a strong overlap in the induction of 
both miR-146b and YM-1 upon exposure to the cytokines IL-4 and IL-13, with 
expression of both being significantly up-regulated over time. This was reflected in a 
moderately positive correlation of 0.59 as determined by Pearson’s r coefficient. This 
positive correlation was statistically significant with a P value of 0.01 (Figure 5.8E).  
During this time course, levels of miR-146a began to decline at 12 hours post 
stimulation with IL-4/IL-13 whereas expression of miR-146b was significantly 
enhanced from 18 hours onwards. Both miR-146a and miR-146b had moderate 
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negative and positive correlations with alternative activation respectively as 
measured through Chi3l3 (YM-1) levels. Taken together, these results indicate that 
there may be a fine balance between the switching off of miR-146a and induction of 
miR-146b expression, which also coincides with the onset of the peak of alternative 
activation. This would suggest that a compensatory mechanism might exist between 
miR-146a and miR-146b with the suppression of shared proinflammatory targets, 
which would otherwise hinder efficient alternative activation. To further validate this 
hypothesis, experiments involving inhibition of either miR-146a or miR-146b or both 
would help determine whether miR-146 was involved in the regulation of alternative 
activation and if this regulation was based on suppression of shared targets by miR-
146a/b in a compensatory mechanism through differential transcriptional regulation. 
However, due to the high sequence similarity between these two isoforms, with a 
difference of just two nucleotides, synthetic inhibitors would not be specific to one 
form (at least when targeting the mature microRNA). Although this specific 
inhibition was not necessary to study the overall role of miR-146 in regulating 
AAMΦ, it was important to delineate the role of the two miR-146 isoforms and 
testing our specific hypothesis. To overcome this hurdle and to determine whether 
miR-146a/b bind the same targets under conditions of alternative activation, the use 
of the technique cross-linking, ligation and sequencing of hybrids (CLASH) was 
considered. We thus decided to generate a stable RAW 264.7 cell line expressing 
tagged mAGO2 for the identification of microRNA targets 
 
5.2.7 Generation of a stable RAW 264.7 cell line expressing tagged 
mAGO2 for the identification of microRNA targets 
CLASH relies on the co-immunoprecipitation of UV cross-linked complexes 
containing microRNAs and their target mRNAs bound to tagged AGO protein 
(Helwak and Tollervey, 2014). Making use of endogenous AGO protein to 
immunoprecipitate protein-RNA complexes is not an efficient process as the binding 
affinity of the anti-AGO antibody is not strong enough to survive the stringent 
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purification conditions utilised during the process. Therefore, it is essential to have a 
system that is capable of stable expression of the tagged AGO protein. There are four 
Argonaute proteins found in humans and mice (AGO 1-4) that are thought to be 
functionally redundant (Su et al., 2009). However, out of the four only AGO2 is 
known to have slicer activity essential for cleavage of target mRNAs based on near 
perfect complementarity to microRNAs (Karginov et al., 2010, Bracken et al., 2011). 
Furthermore, a role for AGO2 has been implicated in development. Ago2-/- mice are 
embryonic lethal whereas other AGO proteins are dispensable suggesting a crucial 
role for AGO2 in development (Liu et al., 2004a). Therefore, mAGO2 was selected 
for this study. In order to create such a stable macrophage cell line for the 
identification of miR-146a/b (and other microRNA) targets, a lentiviral system of 
transduction was utilised. RAW 264.7 cells were chosen based on their ability to 
both classically and alternatively activate (Chapter 2). We have also shown that 
successful synthetic microRNA transfection can be achieved in RAW 264.7 cells 
enabling microRNA levels to be manipulated in subsequent experiments. A lentivirus 
is a retroviral vector system that has the ability to infect both dividing and non-
dividing cells and can efficiently drive gene expression both in vitro and in vivo 
(Naldini et al., 1996, Lois et al., 2001, Ailles et al., 2002, Scherr et al., 2002). It is an 
advantageous system to use in terms of its low immunogenicity and long-term stable 
expression of the gene of interest.  
Lentiviral expression vectors generally contain large regions of repeated DNA 
sequences from the long terminal repeats (LTRs) of retroviruses from which they are 
derived. These LTRs are the basis for homologous recombination and incorporation 
of the gene of interest, which is cloned in between two LTR regions.  For the 
generation of lentiviruses, three different plasmid constructs were utilised. Two of 
these encoded essential packaging genes encoding the envelope protein (pMD2.5-
VSV-G) and the other packaging protein required for replication (psPAX2). The 
third vector was the transfer vector pLVX-EF1α-IRES-ZsGreen1 containing the LTR 
regions. It is a bicistronic vector that contains an internal ribosomal entry site (IRES) 
that allows the gene of interest and the ZsGreen1 fluorescent protein to be 
simultaneously co-expressed. This vector consists of an EF-1α promoter, derived 
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from the human EEF1A1 gene that expresses the alpha subunit of eukaryotic 
elongation factor 1. This promoter allows robust and constitutive expression of the 
gene of interest in cell types in which CMV promoters are often silenced, such as 
hematopoietic and stem cells (Teschendorf et al., 2002). Additionally, the vector 
allows efficient flow cytometric detection of stably or transiently transfected cells 
through the ZsGreen1 fluorescent protein without the need for other time consuming 
selection processes such as drug and clonal selection.  
A tagged protein construct using the vector pCDNA3 with murine AGO2 (mAGO2) 
fused to a Protein A-TEV protease-Histidine (HTP) tag was available in the lab 
(Figure 5.9A). It was decided that a new tag should be designed for these studies in 
order to eliminate potential issues with specific binding of IgG to Protein A. This 
affinity could be a potential hindrance for performing CLASH in vivo to confirm the 
results obtained in vitro as well as for factoring in processes such as IL-4 induced 
macrophage proliferation that cannot be utilised in vitro. Furthermore previous work 
in the lab suggested that the TEV cleavage site was not functional. Therefore, the 
PTH tag was replaced with a new tag consisting of 3xFLAG residues, a PreScission 
protease site and 6x Histidine residues (FPH). The new tag was cloned into the 
pLVX-EF1α-ZsGreen1 vector as shown in Figures 5.9B and 5.9C. The HTP tag 
DNA sequence was first excised from the pCDNA3 vector by restriction digestion 
with BamHI and EcoRV (Figure 5.9A). The FPH tag was generated through 
annealing and elongation of two overlapping oligos using the Klenow fragment DNA 
polymerase. BamHI and ExoRV restriction sites were designed at the end of these 
oligos, which were then used to digest and clone the tag into pCDNA3 upstream of 
mAGO2 (Figure 5.9B). For cloning the FPH-mAGO2 into the pLVX-EF1α lentiviral 
construct, the BamHI site in pCDNA3 was replaced with an SpeI digestion site 
through PCR amplification (Figure 5.9C). This amplified PCR product was then 
digested with SpeI and NotI and cloned into the lentiviral vector (Figure 5.9D).  
Prior to lentiviral packaging, the expression of the tagged protein was examined 
based on CaCl2 transfection. RAW 264.7 cells were left untreated or transfected with 
pLVX-EF1α-ZsGreen1 empty vector or the pLVX-EF1 α-ZsGreen1 vector 
Chapter 5: miR-146 and CLASH  
  197 
containing the FPH-mAGO2 sequence. Protein lysates were harvested at 48 hours 
post transfection and analysed by Western blot using antibodies against the FLAG 
tag and mAGO2 protein. As shown in Figure 5.10A and 5.10B, cells transfected with 
pLVX-EF1α-ZsGreen1-FPH-mAGO2 and the control vector pCDNA3-FPH-
mAGO2 expressed high levels of FLAG tag and mAGO2 whereas the tagged protein 
was absent in untreated cells or cells transfected with the control empty vectors 
pLVX-EF1α-ZsGreen1 and pCDNA3.  Cells transfected with the vectors containing 
FPH-mAGO2 also expressed high levels of mAGO2 and no bands were observed for 
endogenous mAGO2 in the control wells. This may be attributed to the fact that the 
exposure for the blots shown was a mere 10 seconds which may not have been 
enough for quantification of endogenous levels. This would indicate that upon 
transfection there was a substantial over-expression of the protein compared to the 
endogenous level.  
Following verification of tagged mAGO2 expression, the pLVX-EF1α-ZsGreen1-
FPH-mAGO2 construct was co-transfected with pMD2.5-VSV-G and psPAX2 into 
HEK293T cells to generate lentiviral particles. The viral supernatant was harvested 
and concentrated by ultracentrifugation (~100 fold) before being used for 
transduction of RAW264.7 cells. The protocol has previously been established in the 
lab and it was determined that the viral supernatant contains ~108 particles/mL prior 
to ultracentrifugation (Dr. Shatakshi Sood). This was determined based on lentiviral 
titering of the freshly harvested supernatant using HEK293T cells. Following 
concentration of the lentiviral stock, a previously determined optimal volume of 
25μL for 3T3 and HEK293T cells (unpublished data) was used for the generation of 
a stable cell line. To do this, RAW 264.7 cells were left untreated or transduced with 
the concentrated viral supernatant. 48 hours post transduction, cells were harvested 
for analysis of ZsGreen1 expression by flow cytometry. FACS analysis of ZsGreen1 
expression revealed successful transduction of a very small percentage of RAW 
264.7 cells (8.2%) with the empty pLVX-EF1α-ZsGreen1 vector and the percentage 
of cells transduced with the pLVX-EF1α-ZsGreen1-FPH-mAGO2 construct was 
only 6% as shown in Figure 5.11. Although the actual percentage of transduced cells 
was minute, these results suggested that the lentiviral generation, transduction and 
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the analysis of transduction through ZsGreen1 expression worked as a system 
overall.  
It is well established that macrophages are a difficult cell type to transfect or 
transduce. To ensure the lentiviruses are capable of efficient transduction NIH-3T3 
cells were transduced with lentivirus containing either the empty vector pLVX-
EF1α-ZsGreen1 or the pLVX-EF1α-ZsGreen1-FPH-mAGO2 construct. NIH-3T3 
cells were chosen because a high level of lentiviral transduction efficiency has 
previously been achieved with this cell line in our lab. Similar to the previous 
experiment described above, cells were transduced with 25μL of concentrated 
lentiviral stock and harvested at 48 hours for FACS analysis. Analysis of ZsGreen1 
expression showed that 97.7% of NIH-3T3 cells transduced with the empty pLVX-
EF1α-ZsGreen1 vector were positive for ZsGreen1 expression. Cells transduced with 
pLVX-EF1α-ZsGreen1-FPH-mAGO2 also showed high percentage positivity for 
ZsGreen1 (90.9%) as shown in Figure 5.12. In comparison, untreated cells did not 
express any ZsGreen1 protein as expected (Figure 5.12). Thus, these results confirm 
that the lentiviral system works well for transduction and that the poor transduction 
efficiency seen in RAW 264.7 cells (Figure 5.11) is related to the cell type rather 
than the protocol involved.  
Following concentration by ultracentrifugation, the lentivirus stock is usually frozen 
at -80C. For transduction, this stock is then thawed for use. It has been suggested that 
each freeze thaw cycle might reduce the viability and activity of the virus by as much 
as 30%. Therefore, in an effort to improve transduction efficiency of RAW 264.7 
cells, the supernatant harvested from HEK293T cells following lentiviral packaging 
was centrifuged to remove any HEK293T cells and cellular debris and transferred 
directly to RAW 264.7 cells for 48 hours. Cells were then analysed for ZsGreen1 
expression by FACS. Analysis showed a marked improvement in the percentage of 
cells successfully transduced as measured by ZsGreen1 expression (Figure 5.13). 
37.2% cells transduced with pLVX-EF1α-ZsGreen1 empty vector lentivirus were 
positive for ZsGreen1 whereas 24.8% cells transduced with pLVX-EF1α-ZsGreen1-
FPH-mAGO2 containing lentivirus expressed ZsGreen1 (Figure 5.13). These results 
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suggest that direct transfer of freshly harvested supernatant containing lentiviruses 
results in greater transduction efficiency in RAW 264.7 cells than virus that has been 
frozen after concentration by ultracentrifugation.  
Although freshly harvested supernatant resulted in a better transduction efficiency of 
the RAW cells, only ~30% of the cells were successfully transduced. Therefore, in 
an effort to improve the transduction efficiency in RAW cells, the transduction 
protocol was further optimised. Using HEK293T cells and serial dilutions of the 
lentiviral stock, the lentiviral titre was determined through percentage positivity of 
cells for ZsGreen1 using flow cytometry (data not shown). Based on the viral titre, 
RAW 264.7 cells were either left untreated or transduced with lentivirus containing 
the empty pLVX-EF1α-ZsGreen1 construct at various MOIs ranging from 10.8 to 
172.8 (Figure 5.14). Additionally, existing literature states that an MOI of 10-25 is 
ideal for macrophage transduction with lentiviruses (Leyva et al., 2011). Therefore, 
RAW264.7 cells were also transduced with pLVX-EF1α-ZsGreen1-FPH-mAGO2 
containing lentivirus at an MOI of 16.2 (Figure 5.14). Due to limited amounts of 
lentivirus containing the tagged mAGO2 construct and the involvement of a longer 
procedure to generate this construct, the empty pLVX-EF1α-ZsGreen1 construct was 
utilised in this experiment for optimisation of transduction at different MOIs. As 
shown in Figure 5.14, increased transduction efficiency was observed with 
increasing MOIs (MOI-10.8-86.4) ranging from 4.3% to 34.9% of ZsGreen1 
expression in cells transduced with the empty vector containing lentivirus. Cells 
transduced with pLVX-EF1α-ZsGreen1-FPH-mAGO2 containing lentivirus at MOI 
16.2 showed a comparable 7.2% positivity for ZsGreen1 in comparison to the empty 
vector (Figure 5.14).  
Although an increase in ZsGreen1 expression was observed with increasing MOIs of 
lentivirus (Figure 5.15A), the percentage viability of cells was also profoundly 
affected with higher lentivirus doses as shown in Figure 5.15B. Maximal 
transduction was observed at MOI 43.2 as reflected in the mean fluorescence 
intensity of ZsGreen1 (Figure 5.15A) but at the same time, only ~ 10% of the cells 
were intact following transduction. Similar trends were observed with an inverse 
Chapter 5: miR-146 and CLASH  
  200 
correlation between transduction efficiency and cell viability at the higher MOIs of 
86.4 and 172.8. Although transduction was the lowest at MOI 10.8 and MOI 16.2, 
the cells in these samples were in fact the healthiest with nearly 50% of the 
population intact (Figures 5.15A and 5.15B).  
Although lentiviral vectors are non infectious, the envelope proteins may still be 
recognised by pathogen recognition receptors and induce a proinflammatory 
response. Besides Type-1 interferons, TNF-α production is induced relatively 
quickly in macrophages upon viral contact and can result in cell death depending on 
the accumulated concentrations (Willeaume et al., 1995). To investigate this inverse 
correlation between MOI and cell viability, the levels of TNF-α were quantified 
(range 0.001-2ng/mL) in the supernatants harvested from RAW 264.7 cells 
transduced at varying MOIs for 24hr, 48hr and 72hr respectively. As represented in 
Figure 5.16A, TNF-α levels were indeed elevated in cells transduced at MOIs greater 
than 21.6 at 24 hours following transduction. Interestingly, the viability of cells 
transduced with the lentivirus containing the FPH-mAGO2 construct was the lowest 
(<5%) and TNF-α expression was the highest (beyond the detection limit) in this 
sample (Figure 5.16A and 5.16B) at 24 hours post transduction. The elevated TNF-α 
levels returned to baseline levels from untreated cells by 48 hours (Figure 5.16A). 
Overall these results suggest that the loss of cell viability with increased transduction 
is associated with the production of proinflammatory molecules in response to viral 
recognition.  
To address this issue and to improve cell viability as well as transduction efficiency, 
RAW 264.7 cells were transduced with freshly harvested viral supernatant and 
centrifuged for 1 hour at an increased temperature of 32C to enhance viral entry. 
Thereafter, the supernatant was aspirated and the culture medium replaced every 
hour for 10-12 hours post transduction. Cells were then harvested 48 hours post 
transduction and FACS analysed for ZsGreen1 expression. Cell viability was 
improved from <10% to greater than 30% for cells transduced with both empty 
vector and FPH-mAGO2 containing lentiviruses (Figure 5.17). At the same time, 
transduction efficiency was also profoundly increased to >50% as shown in Figure 
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5.17. These cells positive for ZsGreen1 were then sorted using flow cytometry and 
cultured for 48 hours to repopulate numbers. After 48 hours, a small proportion of 
the cells was reanalysed by FACS to confirm percentage positivity for ZsGreen1 
before further analyses. FACS analysis revealed an enrichment in cells positive for 
ZsGreen1 from 56.5% to 74.6% in cells transduced with pLVX-EF1α-ZsGreen1 
containing lentivirus. The cell viability was also improved from 30% to 60.7% as 
predicted due to cell recovery in the absence of any external stimuli (Figure 5.18). In 
contrast, the percentage positivity for ZsGreen1 in cells transduced with pLVX-
EF1α-ZsGreen1-FPH-mAGO2 lentivirus was decreased to 38.7% compared to an 
earlier 50%. However, cell viability was improved from 30% to 57.5% (Figure 5.18). 
The cells were incubated for a further 5 days to allow maximal growth and recovery 
before being FACS analysed again to resort the populations and exclude any 
ZsGreen1 negative cells. As shown in Figure 5.19, cells transduced with pLVX-
EF1α-ZsGreen1 lentivirus that expressed ZsGreen1 was significantly lower at  at day 
7 compared to day 2 (30.6% versus 74.6%) although the viability had further 
increased to 69%. Similarly, cells transduced with pLVX-EF1α-ZsGreen1-FPH-
mAGO2 lentivirus had completely lost ZsGreen1 expression but viability was greatly 
improved at 75.5% (Figure 5.19). Taken together, these results imply that either 
transduction of RAW 264.7 cells is transient with expression being lost by day 7 or 
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5.3 Discussion 
MicroRNAs tend to be highly redundant, with multiple individual microRNAs 
converging upon the same target mRNAs. Some of this redundancy owes to different 
microRNAs sharing identical or highly similar seed sequences. The focus of this 
chapter was two such microRNA isoforms that share the same seed sequence but 
differ by two nucleotides in their 3’ regions: miR-146a and miR-146b. MiR-146 has 
a well-established role in regulating CAMΦ and their responses (Taganov et al., 
2006, Curtale et al., 2012, He et al., 2014c). However, a functional role for miR-146 
in regulating alternative activation is yet to be determined and the relationship 
between the two isoforms in this context is unknown. Thus, in conjunction with 
Chapter 2, the expression profiles of these two isoforms were studied in AAMΦ in 
detail. It was found that both miR-146a and miR-146b are differentially expressed 
during alternative activation; however, their expression patterns differed: there was a 
reduction in miR-146a levels and an enhancement of miR-146b expression. This 
differential regulation was observed under various conditions of alternative 
activation including cell lines, BMDMs, Thio elicited MΦ and following IL-4c 
delivery in vivo suggesting a consistent alteration of miR-146 expression in AAMΦ. 
Based on their contrasting expression during alternative activation and their known 
role for negatively regulating proinflammatory responses, it was hypothesised that 
miR-146a/b contribute to efficient alternative activation through the suppression of 
shared proinflammatory targets in a compensatory mechanism.  
Although a significant increase was observed in miR-146b expression in AAMΦ 
isolated from L. sigmodontis infection at various time points, no significant changes 
were observed in miR-146a expression over the course of infection. This could be 
attributed to two reasons -1) All quantification was carried out by qRT-PCR. With 
high sequence similarity between the two isoforms and a difference of just two 
nucleotides, it was probable that the primer specificity was not sensitive enough to 
differentiate between miR-146a and miR-146b. To investigate this further, synthetic 
microRNA standards of known concentrations for both miR-146a and miR-146b 
were tested at various dilutions for primer specificity (Appendix 5). A high degree of 
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cross talk was observed with primers binding efficiently to both isoforms implying 
that the changes in expression quantified by qRT-PCR may not be valid. However, 
besides fold changes, copy numbers of miR-146a/b were quantified per ng of RNA 
for each of the alternative activation conditions that were studied. These also 
reflected significant differences in miR-146a and miR-146b expression with miR-
146a expressed at a much higher copy number (106-107 copies/ng RNA) compared to 
miR-146b (105 copies/ng RNA). These results would suggest that although primer 
specificity may be a concern, the large difference between miR-146a and miR-146b 
expression levels in macrophages reduced our concern. 2) During L. sigmodontis 
infection, macrophages were isolated by adherence purification. In all the other 
conditions of alternative activation that were studied, the populations were relatively 
homogeneous, either cell lines or BMDMs, or FACS sorted after IL-4c injection. 
Although adherence purification is an efficient technique to distinguish macrophages 
from other cell types, it does not result in a population that consists purely of 
macrophages. We found that these populations were 60-80% pure as analysed by 
FACS (data not shown). Thus, there are likely other cell types within the well that do 
not get washed away and may contribute to the quantification of miR-146 in the 
samples. MiR-146a especially is differentially expressed in different T helper cell 
subsets and is involved in fate determination (Monticelli et al., 2005, Rusca and 
Monticelli, 2011). Significant differences in miR-146b expression during the 
infection were only detectable day 11 onwards. By this time, other immune cell types 
are already present in the cavity and the adaptive immune responses are well initiated 
(Babayan et al., 2003a, Graham et al., 2005b). Thus, it is plausible that some of these 
cell types might have contributed to the levels of miR-146 detected and the reason 
why a reduction in miR-146a was not observed. It is also worth mentioning that 
besides IL-4Rα signalling, infection with a nematode creates a complex environment 
with simultaneous cues and external stimuli that may also affect microRNA 
expression. In all the other conditions studied, especially the in vitro models of 
alternative activation, this complex network of signals did not exist. Furthermore, 
changes in microRNA expression are subtle. Hence, it is possible that significant 
changes at the individual cell level may get masked in an infection environment and, 
therefore, cannot be detected.  
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Finally, the expression of miR-146a/b was correlated to the expression of YM-1, a 
marker characteristic of alternative activation. Whilst a non-significant negative 
correlation was observed for miR-146a, a moderately positive and significant 
correlation existed between miR-146b and YM-1 expression. Additionally, as levels 
of miR-146a began to decline, a rise in miR-146b expression was observed 
suggesting there may exist a compensatory mechanism to suppress shared targets. 
Expression of miR-146a is NF-κB dependent (Taganov et al., 2006) whereas miR-
146b expression is STAT3 induced (Xiang et al., 2014). NF-κB is a nuclear factor 
considered to be a prototypical signal for the expression of several proinflammatory 
molecules and a well-known regulator of classical activation (Lawrence, 2009, 
Martinez, 2011). Although IL-4 can induce NF-κB processing, it is able to do so only 
in B cells and not in T cells or macrophages (Thieu et al., 2007). Contrastingly, both 
IL-4 and IL-13 are potent activators of STAT3 (Wery-Zennaro et al., 1999, 
Umeshita-Suyama et al., 2000, Bhattacharjee et al., 2013). Thus, the downregulation 
of miR-146a expression and induction of miR-146b with the progression of/during 
alternative activation may be explained through differential regulation at the 
transcriptional levels.    
With the predicted/hypothesised role of miR-146a/b in regulating alternative 
activation through the suppression of shared proinflammatory targets, the next 
obvious step was to inhibit these microRNAs together and individually to assess their 
effect on alternative activation and to identify shared targets. The most commonly 
used microRNA inhibitors are chemically modified antisense oligonucleotides that 
sequester mature endogenous microRNA (Stenvang et al., 2012). Due to the high 
sequence similarity between miR-146a/b, it is likely not possible to inhibit one 
microRNA alone – the key to delineating functions and shared targets of miR-146a 
vs. miR-146b during alternative activation as a compensatory mechanism. In Chapter 
3 synthetic microRNA delivery in vivo was achieved. MiR-146a KO mice exist and 
it may be possible to inhibit miR-146b in these mice to study their targets and effect 
on activation. However, delivery in vivo is not restricted to macrophages and thus, in 
the absence of two important microRNAs may result in outcomes not related to 
macrophage activation.  
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Another common approach used for the identification of microRNA targets involves 
the cross-linking of RNA-protein complexes followed by immunoprecipitation of 
tagged AGO protein and sequencing of associated RNAs (Ule et al., 2003, Licatalosi 
et al., 2008, Hausser and Zavolan, 2014). Several modifications of this method exist. 
One such modification termed CLASH (Helwak et al., 2013, Helwak and Tollervey, 
2014) has been established for use in our lab. CLASH differs from other cross 
linking and immunoprecipitation (CLIP) techniques in that it involves an additional 
ligation step to join microRNAs to their mRNA targets, thus providing evidence for 
direct physical interaction. The latter half of this chapter focused on the generation of 
a stable cell line expressing tagged mAGO2 protein for the identification of miR-146 
(and other microRNA) targets using CLASH.  
For the generation of the tagged mAGO2 cell line, RAW 264.7 cells and a lentiviral 
system of transduction were utilised. FPH tagged mAGO2 was successfully cloned 
into an EF-1α promoter driven bicistronic vector containing an IRES site that allows 
the gene of interest and the ZsGreen1 fluorescent protein to be simultaneously co-
expressed. RAW 264.7 cells were then transfected with this vector and 
overexpression of FPH tagged mAGO2 was confirmed. Next, RAW 264.7 cells were 
transduced with lentiviral particles containing this vector with and without FPH-
mAGO2. Transduction of RAW 264.7 cells resulted in a very low level of ZsGreen1 
expression (~8-10%) compared to control NIH-3T3 cells, which showed a near 
perfect 100% transduction efficiency. It was thought that low transduction efficiency 
in macrophages might be due to too low of a MOI, as this parameter was optimised 
for NIH-3T3 and HEK293T cells, both with different cell origins. The requirements 
for efficient transduction may vary with different cell types. An existing study that 
evaluated transduction efficiency in primary macrophages using lentiviral vectors 
states that an MOI of 10-50 depending on the vector used is ideal (Leyva et al., 
2011). Thus, the lentivirus was titred using HEK293T cells and RAW 2647 cells 
were transduced with varying MOIs ranging from 10 to 175. Although increased 
transduction up to 30% was observed with increasing MOIs, this also led to a 
significant decrease in cell viability. This was attributed to the production of TNF-α 
by the macrophages in response to the lentivirus. TNF-α is one of the first molecules 
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to be produced by macrophages in response to viruses besides interferons 
(Malmgaard, 2004, Malmgaard et al., 2004, Paludan et al., 2001, Paludan and 
Mogensen, 2001). TNF-α signalling is a key player in inducing cell death (Nagata 
and Golstein, 1995, Boldin et al., 1996, Wajant et al., 2003). Hence, it was not 
surprising that transduction with increasing MOIs of lentivirus resulted in rapidly 
rising TNF-α production that correlated with increased cell death. Of note, TNF-α 
levels were particularly elevated in response to lentivirus containing the FPH-
mAGO2 protein compared to the empty vector without the protein, even when the 
cells were transduced at comparable MOIs.  The cause of this difference is unclear as 
the lentiviral particles are identical except for the presence of FPH-mAGO2. The 
mAGO2 sequence is unlikely to be the cause of the elevated TNF-α levels as the 
sequence is identical to endogenous mAGO2 protein. Thus, it is possible that the 
FPH tag may be responsible for this difference, potentially due to a conformational 
change that might increase endogenous recognition resulting in inflammation. 
However, it may very well be an artefact of the experiment and needs to be repeated 
to confirm the variations between the empty vector and protein containing lentivirus. 
It is also worth mentioning that macrophages compared to other cell types are highly 
autofluorescent when analysed by FACS. When cell death occurs or cells are 
stressed, the autofluorescence increases many-fold.  Hence, it is also possible that the 
increasing ZsGreen1 expression observed with increasing MOIs may have been the 
result of increased autofluorescence.  
Studies in this chapter have also provided evidence that utilisation of frozen 
concentrated lentiviral stock may negatively affect transduction efficiency. However, 
whether this is due to loss of viral activity would require measurement of viral 
recovery in fresh vs. frozen samples. The use of freshly harvested supernatant along 
with replacement of culture media every hour to remove proinflammatory molecules 
such as TNF-α resulted in a RAW 264.7-FPH-mAGO2 cell line expressing ZsGreen1 
with improved viability. Unfortunately, expression was reduced 48 hours after 
sorting of the ZsGreen1 positive population and completely lost after 7 days. The 
cause and mechanisms behind this loss are still unknown. As professional 
phagocytes, macrophages are endowed with many potent degradation enzymes that 
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can disrupt nucleic acid integrity and make gene transfer into these cells an 
inefficient process. This is especially true of activated macrophages, which undergo a 
dramatic change in their physiology following exposure to immune or inflammatory 
stimuli (Zhang et al., 2009). Thus, it is probable that the transduction did not result in 
integration of FPH-mAGO2 in the genome and was in fact, only transient.  
Several possibilities exist to overcome problems associated with a transiently 
transfected cell line for CLASH. Utilising FACS, single cells expressing ZsGreen1 
could be sorted into individual wells and cultured in an effort to obtain a clone that 
may have a successfully integrated copy of FPH-mAGO2 and could give rise to a 
healthy population expressing the tagged protein. Another option would be to utilise 
large numbers of these transiently transfected cells for CLASH 48 hours after sorting 
as 30% of the cells are still positive for ZsGreen1 at this stage. However, this would 
utilise expensive reagents and be extremely time consuming. An easier solution 
would be to change the lentiviral construct (pLVX-EF1α-ZsGreen1) to one 
specifically designed for macrophage expression. A macrophage restricted 
expression system involving the use of Csf1r and the highly conserved Fms-intronic 
regulatory element (FIRE) has previously been used for the expression of transgenes 
(Pridans et al., 2014). Pridans et al. have developed a lentiviral construct comprising 
mouse FIRE and Csf1r promoter elements that are capable of directing macrophage 
restricted gene expression in several species. Csf1r promoter is constitutively and 
uniquely expressed in macrophages. This construct is readily available and may be 
an extremely useful tool to overcome the problems faced in this chapter. Lastly, our 
lab has very recently generated a transgenic mouse expressing FPH tagged mAGO2 
in all cells, thus, overcoming the problems associated with successful and efficient 
transduction of macrophages. This mouse will be a tremendously advantageous tool 
to identify microRNA targets with physiological levels of endogenously tagged AGO 
protein using CLASH for studies conducted both in vitro and in vivo. It will be 
particularly interesting for microRNAs such as miR-199b-5p discussed in Chapter 3 
that are not expressed highly or induced in vitro.  
In summary, we cannot yet draw conclusions about the role of miR-146 in the 
regulation of AAMΦ from the results generated from the studies in this chapter. 
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Although it is clear that miR-146a/b are differentially and regulated during 
alternative activation, further experiments and optimisation need to be carried out to 
successfully identify whether they share the same targets or different ones and how 
this fits with regulation of the AAMΦ phenotype. Thus, as a starting point a stable 
cell line expressing tagged mAGO2 should be generated utilising the Csf1r-FIRE to 
progress with the identification of miR-146a/b targets using CLASH. Critically 
because both microRNAs and targets are sequenced during CLASH and any 
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Figure 5.1 Contrasting changes in miR-146a and miR-146b levels in response to 
alternative activation A) RAW 264.7 cells and B) J774A.1 cells.  
Cells were left untreated or stimulated with 20ng/mL of IL-4 and IL-13 for 24hr and 48hr 
respectively. Quantification was carried out by qRT-PCR and transcripts were normalised to 
RNU6B. Data represented are the mean fold change ± SEM and representative of two 
separate experiments (n=3). Statistical significance for differences between treated and 
untreated samples were calculated based on unpaired two-tailed Student’s t-test (* P< 0.05, 
** P< 0.01, *** P< 0.001, ****P<0.0001).  
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Figure 5.2 Expression profiles of miR-146a and miR-146b in classically and 
alternatively activated A) RAW 264.7 cells and B) J774A.1 cells.  
Cells were left untreated or stimulated with either 10ng/mL of LPS or 20ng/mL of IL-4 and 
IL-13 for 24hr and 48hr respectively. Quantification was carried out by qRT-PCR and 
transcripts were normalised to RNU6B. Data represented are the mean fold change ± SEM 
and representative of a single experiment (n=3). Statistical significance for differences 
between treated and untreated samples were calculated based on one-way ANOVA (* P< 
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Figure 5.3 MiR-146a and miR-146b expression in RAW 264.7 cells following 
stimulation with IL-4 or IL-13 alone or in combination.  
Cells were left untreated or stimulated with either 20ng/mL of IL-4 or IL-13 alone or IL-4 & 
IL-13 for 24hr and 48hr respectively. Quantification was carried out by qRT-PCR and 
transcripts were normalised to RNU6B. Data represented are the mean fold change ± SEM 
and representative of two separate experiments (n=3). Statistical significance for differences 
between treated and untreated samples were calculated based on one-way ANOVA (* P< 
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Figure 5.4 Quantification of miR-146a and miR-146b expression in classically and 
alternatively activated BMDM.  
Bone marrow precursors derived from WT C57BL/6 mice were cultured in CSF-1 
containing medium for 7 days to generate BMDMs. Cells were left untreated or stimulated 
with either 10ng/mL of LPS or 20ng/mL of IL-4 and IL-13 for A) 24hr and B) 48hr 
respectively. Quantification was carried out by qRT-PCR and transcripts were normalised to 
RNU6B. Data represented are the mean fold change ± SEM and representative of two 
separate experiments (n=3). 
 
miR-146a 24hr miR-146b 24hr 
miR-146a 48hr miR-146b 48hr 
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Figure 5.4 Quantification of miR-146a and miR-146b expression in classically and 
alternatively activated BMDM.  
Copy number per ng of RNA of C) miR-146a and D) miR-146b in untreated or IL-4/IL-13 
stimulated BMDMs as determined using synthetic microRNA standards. Statistical 
significance for differences between treated and untreated samples were calculated based on 
one-way ANOVA or unpaired two tailed Student’s t-test where appropriate (* P< 0.05, ** 
P< 0.01, *** P< 0.001, ****P<0.0001) and representative of two pooled experiments (n=5).  
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Figure 5.5 Changes in expression of miR-146a and miR-146b in Thio elicited MΦ 
stimulated with LPS or IL-4/IL-13.  
WT C57BL/6 mice were injected with 4% thioglycollate intraperitoneally. On day 3, PEC 
populations were harvested and adherence purified for 4 hours at 37C to obtain Thio elicited 
MΦ. Cells were left untreated or stimulated with either 10ng/mL of LPS or 20ng/mL of IL-4 
and IL-13 for 24hr and 48hr. Expression of A) miR-146a and B) miR-146b was quantified 
by qRT-PCR and transcripts were normalised to RNU6B. Data represented are the mean fold 
change ± SEM compared to untreated controls and representative of two separate 
experiments (n=3). Statistical significance for differences between treated and untreated 
samples were calculated based on one-way ANOVA (* P< 0.05, ** P< 0.01, *** P< 0.001, 
****P<0.0001). 
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Figure 5.6 Expression profiles and quantification of miR-146a/b following IL-4c 
delivery in the peritoneal cavity.  
WT C57BL/6 mice were injected with either PBS or 5μg of IL-4c intraperitoneally. PEC 
cells were harvested 24 hours post injection and macrophages sorted by FACS. A) MiR-146a 
and miR-146b levels as measured by qRT-PCR. Sorted macrophages were lysed and RNA 
extracted. Transcripts were normalised to RNU6B and fold changes calculated in comparison 
to PBS injected samples. B) Copy number/ng RNA of miR-146a and miR-146b in 
macrophages following IL-4c delivery. Data represented are the mean fold change ± SEM 
compared to untreated controls and representative of two separate experiments (n=5). 
Statistical significance for differences between treated and untreated samples were calculated 
based on two tailed unpaired Student’s t-test (* P< 0.05, ** P< 0.01, *** P< 0.001, 
****P<0.0001).  
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Figure 5.7 Relative expression levels and copy numbers of miR-146a and miR-146b 
during L. sigmodontis infection.  
Pleural macrophages were isolated from pleural exudate cells through adherence purification 
on days 4, 6, 8, 11, 14, 18 and 28 post infection. RNA was extracted and A) microRNA 
expression quantified by qRT-PCR, normalised to RNU6B and fold changes calculated in 
comparison to a pool of naïve animals (day 4, 11 and day 28) from various time points. B) In 
the same samples, copy number/ng of RNA was determined using synthetic microRNA 
standards. Data represented are the mean fold change ± SEM compared to untreated controls 
and representative a single experiment (n=5). Statistical significance for differences between 
treated and untreated samples were determined using one way or two-way ANOVA where 
appropriate (* P< 0.05, ** P< 0.01, *** P< 0.001).  
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Figure 5.8. Expression kinetics of miR-146a and miR-146b during alternative 
activation time course in RAW 264.7 cells.  
Cells were left untreated or stimulated with either 10ng/mL of LPS or 20ng/mL of IL-4/IL-
13 for various time points ranging from 0hr to 48hr. RNA was extracted and microRNA or 
mRNA expression was quantified by qRT-PCR A & B) YM-1, TNF-a and iNOS expression 
was normalised to Gapdh and fold changes calculated in comparison to untreated samples at 
respective time points stated. C) MiR-146a and miR-146b expression was normalised to 
RNU6b and fold changes calculated in comparison to untreated samples at respective time 
points stated. D & E) miR-146a and miR-146b expression was correlated to YM-1 
expression using Pearson’s correlation and r-value.. Data represented are the mean fold 
change ± SEM compared to untreated controls and representative an individual experiment 
(n=3). Statistical significance for differences between treated and untreated samples were 
determined using two-way ANOVA where appropriate (* P< 0.05, ** P< 0.01, *** P< 
0.001).  
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Figure 5.9 Generation of pLVX-EF1α-ZsGreen1-FPH-mAGO2 construct for lentiviral 
transduction of RAW 264.7 cells.  
A) Map of pCDNA3 plasmid containing mAGO2 fused to ProteinA-TEV-Histidine (HTP) 
tag B) HTP tag in pCDNA3 was cleaved through restriction digestion with BamHI and 
EvoRV and replaced with the FPH tag. C) FPH-mAGO2 was amplified by PCR and SpeI 
site introduced to replace the BamHI site at the N terminus. The PCR product was digested 
with SpeI and NotI and inserted in pLVX-EF1α-ZsGreen1 lentiviral vector containing LTR 
regions for recombination. D) Map of the pLVX-EF1α-ZsGreen1 lentiviral vector. The 
vector was digested with SpeI and NotI for the introduction of FPH-mAGO2 downstream of 
the EF-1α promoter.  
Chapter 5: miR-146 and CLASH  





Figure 5.10 Expression of FLAG-PreScission-Histidine tagged mAGO2 in RAW 264.7 
cells transfected with pLVX-EF1α-ZsGreen1-FPH-mAGO2 lentiviral vector.  
 RAW 264.7 cells were seeded at a density of 1x106 cells/well in a 6 well plate. Cells were 
left untreated or transfected with either pLVX-EF1α-ZsGreen1 empty vector or pLVX-
EF1α-ZsGreen1-FPH-mAGO2 lentiviral plasmid construct using Lipofectamine-2000 and 
incubated for 48 hours. Cells were also transfected with pCDNA3 empty vector or pCDNA3 
containing FPH-mAGO2. 25μg of total protein was loaded onto 12% SDS-PAGE gels. 
Western blot analysis (ECL detection) was carried out using A) Anti-FLAG M2 antibody 
and B) anti-mAGO2 antibody. Data are representative of two separate experiments (n=3 
pooled).  
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Figure 5.11. ZsGreen1 expression in RAW 264.7 cells following lentiviral transduction.  
RAW 264.7 cells were left untreated or transduced with 25μl of concentrated lentivirus 
containing either pLVX-EF1α-ZsGreen1 empty vector or pLVX-EF1α-ZsGreen1-FPH-
mAGO2 construct for 48 hours before being FACS analysed. Histograms display percentage 
positive cells for ZsGreen1 expression based on gating using the untreated sample. Data 
were analysed using FlowJo software and are representative of two separate experiments 
(n=3 pooled).  
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Figure 5.12 ZsGreen1 expression in NIH-3T3 cells following lentiviral transduction.  
NIH-3T3 cells were left untreated or transduced with lentivirus containing either pLVX-
EF1α-ZsGreen1 empty vector or pLVX-EF1α-ZsGreen1-FPH-mAGO2 construct for 48 
hours. Histograms display percentage positive cells for ZsGreen1 expression based on gating 
using the untreated sample. Data were analysed using FlowJo software and are representative 
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Figure 5.13 ZsGreen1 expression in RAW 264.7 cells following lentiviral transduction 
with freshly harvested supernatant.  
RAW 264.7 cells were left untreated or transduced with freshly harvested supernatant from 
HEK293T cells containing lentivirus without ultracentrifugation. Cells were transduced with 
either pLVX-EF1α-ZsGreen1 empty vector or pLVX-EF1α-ZsGreen1-FPH-mAGO2 
construct lentiviruses for 48 hours. Histograms display percentage positive cells for 
ZsGreen1 expression based on gating using the untreated sample. Data were analysed using 
FlowJo software and are representative of two separate experiments (n=3 pooled).  
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Figure 5.14. ZsGreen1 expression following transduction of RAW 264.7 cells with 
increasing MOIs of lentivirus.  
RAW 264.7 cells were left untreated or transduced with pLVX-EF1α-ZsGreen1 empty 
vector lentivirus at varying MOIs of 10.8, 16.2, 21.6, 43.2, 86.4 or 172.8 for 48 hours. Cells 
were also transduced with lentivirus containing pLVX-EF1α-ZsGreen1-FPH-mAGO2 
construct for 48 hours at MOI 16.2. Histograms display percentage positive cells for 
ZsGreen1 expression based on gating using the untreated sample. Data were analysed using 
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Figure 5.15 ZsGreen1 expression and percentage cell viability following transduction of 
RAW 264.7 cells with increasing MOIs of lentivirus.  
RAW 264.7 cells were left untreated or transduced with pLVX-EF1α-ZsGreen1 empty 
vector lentivirus at varying MOIs of 10.8, 16.2, 21.6, 43.2, 86.4 or 172.8 for 48 hours. Cells 
were also transduced with lentivirus containing pLVX-EF1α-ZsGreen1-FPH-mAGO2 
construct at MOI 16.2. Graphs represent A) mean fluorescence intensity for ZsGreen1 
expression based on gating using the untreated sample and B) percentage viability of singlets 
based on propidium iodide staining Data were analysed using FlowJo software and are 
representative of an individual experiment (n=3 pooled).  
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Figure 5.16 Expression levels of secreted TNF-a following transduction of RAW 264.7 
cells with increasing MOIs of lentivirus.  
RAW 264.7 cells were left untreated or transduced with pLVX-EF1α-ZsGreen1 empty 
vector lentivirus at varying MOIs of 10.8, 16.2, 21.6, 43.2, 86.4 or 172.8 up to 72 hours. 
Cells were also transduced with lentivirus containing pLVX-EF1α-ZsGreen1-FPH-mAGO2 
construct at MOI 16.2. Supernatants were harvested at 24hr, 48hr and 72hr post transduction. 
Graphs represent A) TNF-a levels as measured by ELISA at 24hr, 48hr and 72hr after 
transduction and B) Comparison of TNF-a levels as measured by ELISA 24hr post 
transduction in untreated cells or cells transduced with lentivirus containing empty vector or 
FPH tagged mAGO2 at MOI 16.2. Data were analysed using FlowJo software and are 
representative of an individual experiment (n=3 pooled).  
Chapter 5: miR-146 and CLASH  




Figure 5.17 ZsGreen1 expression in RAW 264.7 cells following lentiviral transduction 
with freshly harvested supernatant.  
RAW 264.7 cells were left untreated or transduced with freshly harvested supernatant from 
HEK293T cells containing lentivirus without ultracentrifuation. Cells were transduced with 
either pLVX-EF1α-ZsGreen1 empty vector or pLVX-EF1α-ZsGreen1-FPH-mAGO2 
lentiviruses for 1 hour with centrifugation at 500xg. The medium was aspirated and replaced 
with fresh culture medium every hour for 10-12 hours. Histograms display percentage 
positive cells for ZsGreen1 expression based on gating using the untreated sample. Data 
were analysed using FlowJo software and are representative of an individual experiment 
(n=3 pooled).  
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Figure 5.18 ZsGreen1 expression in RAW 264.7 cells 48 hours after FACS sorting. 
 RAW 264.7 cells were left untreated or transduced with freshly harvested supernatant from 
HEK293T cells containing lentivirus without ultracentrifuation. Cells were transduced with 
either pLVX-EF1α-ZsGreen1 empty vector or pLVX-EF1α-ZsGreen1-FPH-mAGO2 
construct lentiviruses for 1 hour with centrifugation at 500xg. Medium was aspirated and 
replaced with fresh culture medium every hour for 10-12 hours. 24 hours post transduction, 
cells were FACS sorted based on ZsGreen1 expression and cultured for a further 48 hours 
before being FACS analysed. Histograms display percentage positive cells for ZsGreen1 
expression based on gating using the untreated sample. Data were analysed using FlowJo 
software and are representative of an individual experiment (n=5 pooled).  
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Figure 5.19. FACS analysis of ZsGreen1 expression in RAW 264.7 one week (7 days) 
after FACS sorting.  
RAW 264.7 cells were either left untreated or transduced with freshly harvested supernatant 
from HEK293T cells containing lentivirus without ultracentrifuation. Cells were transduced 
with either pLVX-EF1α-ZsGreen1 empty vector or pLVX-EF1α-ZsGreen1-FPH-mAGO2 
construct lentiviruses for 1 hour with centrifugation at 500xg. Medium was aspirated and 
replaced with fresh culture medium every hour for 10-12 hours. 24 hours post transduction, 
cells were FACS sorted based on ZsGreen1 expression and cultured for a further 7 days 
before being FACS analysed. Histograms display percentage positive cells for ZsGreen1 
expression based on gating using the untreated sample. Data were analysed using FlowJo 
software and are representative of an individual experiment (n=3 pooled).  
Chapter 6: Concluding Remarks  
  234 
Chapter 6: Concluding remarks and future direction 
 
6.1 Rationale and objectives of thesis 
Diversity and plasticity are hallmarks of macrophages, which display a wide range of 
phenotypes dictated by environmental cues they encounter. Amongst this broad 
spectrum of highly distinct functional phenotypes, macrophages have been usefully 
classified as being classically or alternatively activated depending on their exposure 
to TH1 or TH2 stimuli respectively (Mosser and Edwards, 2008, Martinez and 
Gordon, 2014). Specifically, the concept of a distinct state of alternative macrophage 
activation induced by TH2 cytokines IL-4 and IL-13 has gained considerable ground 
in recent years. AAMΦ have been implicated in a range of physiological and 
pathological processes including homeostasis, helminth infections, chronic diseases 
& inflammation, wound healing, metabolic functions and tumour progression 
(Gordon, 2003, Gordon and Martinez, 2010, Martinez and Gordon, 2014). Thus, to 
avoid functional dysregulation and to maintain the balance and efficiency of the 
immune response, it is crucial that AAMΦ responses are tightly regulated. 
Furthermore, with great diversity in their function, macrophages are an attractive 
therapeutic target, but this requires a greater understanding of the systemic, cellular 
and molecular processes involved in the regulation of the different phenotypes.  
The substantial progress of microRNAs as therapeutics has been demonstrated by the 
development of a miR-122 inhibitor as an anti-viral agent – the first microRNA 
targeted drug currently in clinical trials (Janssen et al., 2013). Over the past decade, 
cellular microRNAs have also gained importance as immunomodulatory regulators 
and have been reported to be involved in regulating macrophage function (Graff et 
al., 2012a, Liu and Abraham, 2013a, Squadrito et al., 2013). Although microRNAs 
are well-established fine tuners of macrophage responses, the majority of the existing 
literature focuses on CAMΦ (Alam and O'Neill, 2011, O'Neill et al., 2011, Quinn 
and O'Neill, 2011, He et al., 2014a).  Previously, research in the Allen lab 
demonstrated that microRNAs are also differentially expressed and involved in the 
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regulation of AAMΦ (Ruckerl et al., 2012). Besides work from our lab, studies 
delineating the involvement of microRNAs in alternative activation are sparse, 
thereby necessitating further investigation in the regulation of this phenotype. Thus, 
the central hypothesis of this thesis focused on the functional role of microRNAs in 
the induction, maintenance and proliferation of AAMΦ.  
The studies presented in this thesis aimed to: 
1. Identify and validate differential expression of microRNAs during alternative 
activation. 
2. Examine specific targets and cellular pathways regulated by these 
microRNAs.  
3. Generate a stable macrophage cell line for the biochemical identification of 
direct microRNA targets. 
 
6.2 Conclusions 
At the time of carrying out the work presented in this thesis, no published data 
suggesting a role for microRNA regulation of AAMΦ existed beyond the study 
carried out by Ruckerl et al. (2012) from our lab. Thus, the first aim of this thesis 
was to utilise existing microarray datasets (provided by D. Ruckerl and A.Buck, 
involving a collaboration with Thermofisher) to identify and validate ten microRNAs 
differentially expressed during alternative activation. We demonstrated that these 
microRNAs were highly regulated in response to IL-4 (and also IL-13 in some cases) 
both in in vitro and in vivo models of alternative activation. The validation of the 
expression profiles of these microRNAs as being associated with alternative 
activation provided a framework for the selection of three microRNA candidates for 
further studies presented in the later chapters of this thesis. Additionally, some of the 
microRNAs examined in our study, for example, miR-223 and miR-125a-5p, have 
subsequently been identified as regulators of AAMΦ (Zhuang et al., 2012, Banerjee 
et al., 2013b, Squadrito et al., 2014, Ying et al., 2015). Due to time constraints, the 
roles of only a select few microRNAs were investigated further in this study. 
However, these new findings linking some of our shortlisted microRNAs to 
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alternative activation validate our approach and open up exciting new avenues to 
further investigate the roles of microRNAs not addressed in this thesis.  
The second aim of this thesis was to examine the potential of selected microRNA 
candidates as regulators of AAMΦ responses. These included miR-199b-5p, miR-
378-3p and miR-146a/b on the basis of the consistency in their expression under a 
range of conditions of alternative activation. Two of the microRNAs that we selected 
for further study, miR-199b-5p and miR-378-3p, have previously been identified as 
being IL-4Rα dependent (Ruckerl et al., 2012). Roles for both miR-146 and miR-
199b-5p have previously been proposed in macrophages as regulators of TLR 
signalling (Taganov et al., 2006, Lin et al., 2014) and monocyte/macrophage 
differentiation (Lin et al., 2014) respectively. However, no reports of their 
association with alternative activation have been published. Although miR-378-3p is 
known to directly target AKT-1, which is essential for IL-4 induced macrophage 
proliferation (Ruckerl et al., 2012), the direct impact of this microRNA on AAMΦ 
was previously unknown.   
In Chapter 3, we showed that miR-199b-5p was expressed at high copy numbers and 
induced in response to IL-4 in vivo and that these numbers and changes were not 
reflected in vitro. MiR-199a-5p, an isoform of miR-199b-5p that is generated from 
another chromosomal locus but is identical in the mature sequence, is a well-known 
regulator of proliferation in other cell types (Alexander et al., 2013, Song et al., 
2014, Hashemi Gheinani et al., 2015, Zhang et al., 2015). Macrophages, on the other 
hand, are known to proliferate in response to IL-4, for example, during infection with 
the nematodes Litomosoides sigmodontis and Heligomosoides polygyrus (Jenkins et 
al., 2011, Jenkins et al., 2013) and are key contributors to the progression of fibrosis 
(Murray and Wynn, 2011, Wynn and Barron, 2010) and tumours (Gordon and 
Martinez, 2010) during resolution phases. Thus, it is plausible that this IL-4 induced 
proliferation may be important in conferring these pathologies. We, therefore, 
investigated the effect of overexpression of this microRNA on macrophage 
proliferation both in vitro and in vivo. We showed that miR-199b-5p reduced 
macrophage proliferation in vitro but its effect in vivo was inconclusive. This can 
potentially be attributed to different macrophage origins and the lack of consistency 
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in the expression of miR-199b-5p targets in these populations. For example, miR-
199b-5p was shown to affect IRS-1 expression, a critical molecule in the 
insulin/IGF-1 signalling axis. Peritoneal macrophages highly upregulate IR and IGF-
1 signalling in response to IL-4 treatment, however, the same is not true for alveolar 
macrophages. Since miR-199b-5p could only be delivered to the lung without 
disrupting the natural immune population balance and macrophage disappearance, no 
concrete conclusions could be drawn regarding the in vivo action of this microRNA. 
Thus, it is still necessary to confirm if the effect of miR-199b-5p on macrophage 
proliferation is restricted to macrophages of specific origins and whether this effect is 
mediated via insulin signalling or other targeted pathways.  
Successful delivery of the microRNA in vivo without disruption of the natural 
immune balance, however, is advantageous to examine the functionality of not just 
this microRNA, but also others and especially in the context of disease models. At 
the same time, a caveat to this approach is restricted delivery to specific organs and 
not knowing which cell types take up the microRNA containing lipid complexes 
other than macrophages in the absence of cell sorting.  Even though Chapter 3 was 
focused on the role of miR-199b-5p in regulating macrophage proliferation, we have 
also shown that introduction of a miR-199b-5p synthetic mimic in combination with 
IL-4 results in the reduction of YM-1, a marker characteristic of alternative 
activation. Although the functions of CLPs still remain largely unknown, our lab has 
recently shown that YM-1 promotes IL-17 induced neutrophilia, which is important 
for limiting parasite survival in a nematode infection model (Sutherland et al., 2014). 
Whilst it is yet to be determined if this effect on YM-1 expression is at the 
transcriptional level or a secretion defect, these data provide a starting point for 
further research on the potential of miR-199b-5p as a mediator of negative feedback 
loops for both macrophage proliferation and activation.  
In this thesis (Chapter 4), we have also provided new and direct evidence of the 
impact of miR-378-3p deficiency on the regulation of AAMΦ. The ability of 
macrophages isolated from WT and miR-378 KO mice to alternatively activate was 
studied in various systems both in vitro and in vivo. The influence of miR-378 
deficiency on IL-4 induced proliferation was also addressed in vivo. Although AKT-
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1 is a direct target of miR-378-3p and essential for IL-4 induced proliferation 
(Ruckerl et al., 2012), data from these studies demonstrated that miR-378 did not 
solely impact macrophage proliferation. Instead, a greater effect was observed on 
RELM-α and YM-1 expression as measures of alternative activation, with an 
increase in protein expression in miR-378 KO mice. These experiments reflect the 
complexity and interdependency of biological networks that exist in vivo. It would be 
of great interest to understand the functional consequences of the miR-378 mediated 
regulation of alternative activation over the course of an entire infection time course 
using a TH2-inducing pathogen like Litomosoides sigmodontis. MicroRNAs can 
regulate a large number of genes involved in diverse or similar cellular pathways and 
therefore, it is logical to speculate that other microRNAs might also be involved in 
the regulation of AAMΦ in the absence of miR-378. Hence, it would be of interest to 
inhibit other IL-4Rα dependent microRNAs such as miR-199b-5p in the miR-378 
KO mice. Multiple targeting of microRNAs may reveal microRNA combinations 
that determine macrophage proliferation and activation dynamics.  
In chapter 5 we characterised the opposing expression profiles of the miR-146 
isoforms, miR-146a and miR-146b, during alternative activation and hypothesised a 
role for miR-146a and miR-146b in promoting efficient AAMΦ responses through 
shared targets. However, a difference of just 2 nucleotides in the sequences of these 
mature microRNAs proved to be a hindrance in delineating their specific roles during 
alternative activation. This involved overcoming the challenges of specific individual 
inhibition of these microRNA isoforms and the consequent generation of a stable 
macrophage cell line expressing tagged mAGO2 for the biochemical identification of 
miR-146a/b (and other microRNA) targets. Using a lentiviral transduction system, 
we were able to generate a cell line expressing tagged protein, however, this 
expression was only transient. The issue of transient transduction may potentially be 
resolved through the use of a different lentiviral construct comprising a Csf1r 
promoter region that is constitutively expressed by macrophages. However, the 
existence of the recently developed FLAG tagged-AGO2 mouse is an extremely 
useful tool to overcome these challenges and for characterisation of microRNAs and 
their direct targets in different in vivo models of alternative activation.  
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6.3 Future directions 
The findings presented in this thesis provide a strong foundation for further studies of 
the functional role of microRNAs in regulating AAMΦ and their responses. The data 
presented provide insight into the complex regulatory microRNA networks that exist 
and can result in similar outcomes through targeting of different pathways by 
different microRNAs. Nevertheless, a number of questions based on the data 
obtained from this thesis merit further investigation. 
 
Chapter 2: 
 What is the functional significance of other shortlisted microRNAs that are 
altered in response to IL-4 such as miR-99 and miR-223? 
 Do certain microRNAs such as miR-125b-5p, miR-221 and miR-222 play 
significant roles that are specific to the origin of macrophages i.e. tissue 
resident vs. blood monocyte derived? 
 Does dependency on IL-4Rα for induction of microRNA expression define a 
stronger link for microRNAs to regulate AAMΦ and their responses? 
 
Chapter 3: 
 The expression of miR-199b-5p was induced in response to IL-4 only in vivo 
and not in vitro. Besides IL-4Rα signalling, which other factor or cell type is 
necessary for the induction of miR-199b-5p? 
 
 Given that miR-199b-5p enhances IRS-1 expression, does it contribute to the 
regulation of proliferation in peritoneal macrophages that express InsR and 
IRS-1 in response to IL-4? Would this suggest that macrophages employ 
varying mechanisms of proliferation depending on origin and location? 
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 Is the reduction of YM-1 expression by miR-199b-5p specific to alveolar 




 Does the regulation of alternative activation markers RELM- α and YM-1 by 
miR-378 have functional consequences in the context of infection? 
 Does this increase in RELM- α and YM-1 expression also translate at the 
transcriptional level? 
 Do miR-199b-5p and miR-378 have an additive or synergistic function in 
regulating macrophage proliferation and activation?  




 Do miR-146a/b play a significant role in promoting alternative activation 
through suppression of shared proinflammatory molecules? 
 Do these two miRNAs target the same genes because of sequence identity or 
do they target different genes since their transcriptional regulation appears to 
be highly distinct?  
 Will the utilisation of a constitutively expressed Csf1r-FIRE lentiviral 
construct overcome challenges of transient macrophage transduction? 
 Will the FLAG tagged mAGO2 expressing mouse overcome all the technical 
hurdles and provide both microRNA and target information during alternative 
macrophage activation and proliferation? 
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Chapter 7: Materials and methods 
 
7.1 Mice  
All mouse strains used were maintained and bred under specific pathogen-free 
conditions at the University of Edinburgh animal facilities, in accordance with the 
U.K. Home Office and local ethically approved guidelines. Wild type BALB/c and 
C57BL/6 mice were bred in house. 
 
For the microarray datasets generated by D. Ruckerl (described in Chapter 2), WT or 
IL-4Rα -/- animals on a BALB/c background bred in house were utilised for the B. 
malayi implants and thioglycollate treatment. For the bone marrow derived 
macrophage (BMDM) microarray, bone marrow precursors were obtained from 6-10 
week old WT BALB/c mice. For all other experiments, the mice were 6-8 weeks old 
and were sex matched at the start of each experiment.  
 
7.1.1 MiR-378/378* KO mice  
MiR-378/378* KO animals described and utilised in Chapter 4 were obtained from 
the Olson lab. The targeting vector used to generate the null allele of miR-378 and 
miR-378* contained a neomycin resistance gene driven by the pGK promoter and 
flanked by loxP sites. The plasmid also contained a diphtheria toxin gene cassette. 
The neomycin resistance cassette flanked by loxP sites was designed to replace the 
pre-miR miR-378/378* sequence.  To this end, the 5’ and 3’ arms of homology were 
generated using Taq PCR amplification from 129SvEv genomic DNA. The targeting 
vector was electroporated into 129SvEv embryonic stem cells. Five hundred ES 
clones were analysed for homologous recombination by Southern blot. Three 
successful clones targeting the miR-378/378* allele were injected into 3.5 days old 
C57BL/6 blastocysts. High percentage chimeric male mice were crossed with 
C57BL/6 female mice to achieve germline transmission of the targeted allele. 
Subsequently, heterozygous mice containing the neomycin cassette were crossed 
with CAG-Cre transgenic mice to remove the neomycin cassette. These mice were 
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initially on a mixed C57BL/6 and SV129 background and backcrossed with WT 
C57BL/6 mice for several generations before all the experiments were performed in 
Chapter 4, unless otherwise stated.  
 
7.2 In vivo procedures 
7.2.1 Litomosoides sigmodontis infection 
L. sigmodontis life cycle was maintained and infective third stage larvae (L3) were 
obtained from infected gerbils as described by Le Goff et al (2002). Female C57BL/6 
mice aged 6-8 weeks were infected with 25-30 L3 larvae suspended in 100μl 
Roswell Park Memorial Institute-1640 (RPMI) medium by subcutaneous injection. 
Naïve controls received no treatment. Mice were sacrificed by terminal anaesthesia 
by administration of 100μL of 1:1 Domitor/Vetalar, injected subcutaneously. Mice 
were bled by brachial bleeding and pleural exudate cells (PLEC) were harvested as 
described later under macrophage purification. 
 
 
7.2.2 IL-4 complex injection 
IL-4 anti-IL-4 murine antibody complex (IL-4c) was prepared by mixing 5μg of 
recombinant IL-4 (13.5kDa; Peprotech) with 25μg of anti-IL-4 antibody [clone 
11B11 (Bio X Cell)]. The complex was incubated on ice for 15 minutes and made up 
to a final desired volume of 100μl per mouse with Phosphate Buffered Saline (PBS). 
To assess peritoneal and pleural macrophage proliferation, mice were injected 
intraperitoneally with a single dose of either PBS only control or IL-4c, followed by 
100μL subcutaneous injection of 10mg/mL BrdU 3 hours prior to sacrifice. Mice 
were culled and Peritoneal Exudate Cells (PEC) or PLEC were harvested at 42 hours 
and 72 hours post injection. For obtaining proliferation of alveolar macrophages, 
mice were injected with either PBS or IL-4c on day 0 and day 2 and macrophages 
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7.2.3 MicroRNA delivery 
Synthetic microRNA mimic (Dharmacon; 20μg per mouse) was complexed with in 
vivo JetPEI (Polyplus) at an appropriate N:P ratio (6 or 8 as described in Chapter 3) 
in 5% glucose. Calculations were based on a final volume of 40μl or 100μl per 
mouse for intranasal or intraperitoneal delivery respectively. The mixture was 
incubated for 15 minutes at room temperature. For intranasal delivery, mice were 
anaesthetised briefly with 3-5% isoflurane and the complex was delivered using a 
micropipette. The   control mice were administered with 5% glucose only. PEC cells 
were harvested 48 hours after intraperitoneal injection. For intranasal microRNAs 
delivered to the lung, Bronchoalveolar lavage (BAL) fluid and lungs were harvested 
either 48 hours post delivery. In experiments wherein two doses of IL-4c were 
injected, harvests were carried out 72 hours post microRNA delivery. 
 
 
7.2.4 Thioglycollate elicited macrophages 
Mice were injected intraperitoneally with 400μl of thioglycollate matured for 3 
months at room temperature in the dark. 72 hours post injection, PEC cells were 
harvested and processed for analysis either by flow cytometry or adherence purified 
for assessing in vitro activation and/or RNA extraction. 
 
 
7.2.5 Bone marrow derived macrophages (BMDM) 
The tibia and femur were retrieved from the hind legs of mice (WT C57BL/6 or miR-
378/378* genotypes). The marrow was flushed using Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 10% foetal calf serum and 2mM L-glutamine, 0.25 
U/mL penicillin and 100mg/mL streptomycin using a 26G needle. Clumps were 
disrupted by aspiration and dispensing through a 19G needle. Cells were centrifuged 
at 1200RPM for 10 minutes at 4°C. The medium was discarded and the cell pellet 
was resuspended in 2-3mL of Red Blood Cell (RBC) lysis buffer (Sigma) and 
incubated on ice for 5 minutes. Consequently, the solution was made isotonic by 
addition of 20mL complete DMEM. Cells were centrifuged at 1200RPM for 10 
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minutes at 4°C and the cell pellet resuspended in Plutznik medium (DMEM, 25% 
FCS, 25% L-929-conditioned-medium as a source of CSF-1/M-CSF, 1% L-
Glutamine, 1% P/S, 0.1% b-Mercaptoethanol). Cells were counted and seeded at 7.5 
x 106 cells in 10mL media in 10cm2 bacterial grade petridishes. The cells were 
incubated at 37°C with 5% CO2 for 7-9 days. The medium was changed on days 2, 4 
and 6 (and 8 if necessary). On day 7 (or 9), the culture medium was removed and 
cells were washed with pre-warmed PBS. 10mL detachment buffer [1xPBS + 0.144g 
glucose + 4.8ml EDTA (0.5M); 800mL final volume, filter sterilised before use] was 
added to each petridish and cells were incubated at 37°C with 5% CO2 for 10-15 
minutes. Detached cells were collected, FACS stained for confirmation of 
differentiation as assessed by their surface expression of F4/80 and CD11b markers, 
and utilised for further experiments.  
 
 
7.3 Macrophage isolation and purification 
7.3.1 Peritoneal exudate cells (PEC)  
PEC cells were obtained by washing the peritoneal cavity of euthanised mice first 
with 3mL of RPMI containing 1% penicillin and streptomycin and 0.2% neonatal 
mouse serum (NMS) followed by two subsequent washes with 5mL media, which 
was collected in a separate tube. The first 3mL of PEC wash, the cells were 
centrifuged and 1mL of supernatant was transferred to eppendorfs for quantification 
of proteins by ELISA. The remaining 10mL of liquid obtained from the peritoneal 
washes was mixed with the cell pellet and centrifuged at 1200RPM for 5 minutes at 
4°C and resuspended in 2mL fresh medium. The cells were counted with an 
automated Cellometer T4 (Peqlab) and 5 x 105 cells (or 2 x 105 cells for naïve 
samples) were used for FACS analysis. For experiments involving adherence 
purification, PECs were seeded at 5 x 106 cells/well in 6 well cell culture plates 
(NUNC) in RPMI media containing 5% FCS and 2mM L-glutamine, 0.25 U/mL 
penicillin, and 100mg/mL streptomycin. For naïve mice, cells were seeded at 1 x 106 
cells/well in 12 well plates. Following incubation at 37°C with 5% CO2 for 4 hours, 
non-adherent cells were washed off and the adherent cell population detached with a 
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rubber policeman. In some experiments where indicated, following IL-4c injection, 
peritoneal macrophages were purified (>90%) by sorting on a FACS Aria cell sorter 
(BD Biosciences) based on their expression of surface molecules (F4/80+, CD11b+, 
SiglecF-, CD11c-, CD19-, CD3-, Ly6G-; all antibodies were purchased from 




7.3.2 Pleural exudate cells (PLEC) 
PLECs were obtained by washing the pleural cavity of euthanised mice 9 times with 
1mL of RPMI containing 1% penicillin and streptomycin and 0.5% neonatal mouse 
serum (NMS) for each wash. The first two 1mL washes were collected separately  in 
a 15 mL Falcon tube (Greiner). The first 2mL obtained from the washes were 
centrifuged at 1200RPM for 5 minutes at 4°C and the supernatant was harvested for 
ELISAs. Like PECs, the remaining cells were either counted and stained directly for 
FACS analysis or seeded in 6 or 12 well plates for adherence purification and lysed 
for RNA extraction and qRT-PCR.   
 
 
7.3.3 Alveolar macrophages 
Alveolar macrophages were analysed by flow cytometry or qRT-PCR as part of the 
BAL fluid or total lung. The BAL fluid was obtained by cannulation of the trachea 
with plastic tubing and washing of the alveolar spaces four times with 400μL of PBS 
containing 1% BSA. Cells were centrifuged at 1200RPM for 5 minutes at 4°C and 
the supernatant was harvested for ELISAs. Cells were resuspended in 200μL PBS 
containing 1% BSA and used directly for FACS analysis according to the protocol 
described later. For the lung, whole lung tissue was immersed in RNA Later solution 
(Ambion). Single-cell suspensions of the right lung lobe were prepared by digestion 
for 25 minutes at 37°C with 0.2 U/mL Liberase TL (Roche) and 80 U/mL DNase 
(Life Tech) in Hank's balanced-salt solution, followed by forcing of tissue 
suspensions through a 70μM filter. Cells were centrifuged at 1200RPM for 5 minutes 
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at 4°C and red blood cells were lysed in 3mL of RBC buffer (Sigma) for 5 minutes 
on ice. Total cells were counted with an automated Cellometer T4 (Peqlab) and 5 x 
105 cells/sample were used for FACS. The remaining cells were lysed for RNA 
extraction and qRT-PCR.   
 
7.4 Cell culture 
Two macrophage cell lines, RAW 264.7 (ATCC-TIB71) and J774A.1 were used. 
RAW 264.7 cells were obtained from American Type Culture Collection (Manassas, 
VA). J774A.1 cells were obtained from liquid nitrogen stocks of the Allen lab. The 
source and passage of these cells was unknown. Both RAW 264.7 and J774A.1 cells 
were cultured in DMEM (Sigma) containing 10% heat-inactivated FCS (Sigma), 
2mM L-glutamine, 0.25 U/mL penicillin, and 100mg/mL streptomycin (Gibco, Life 
Tech).  
 
NIH 3T3 fibroblasts (ATCC CRL1658) are mouse cells generated from a NIH Swiss 
mouse embryo. The cells were obtained from American Type Culture Collection 
(Manassas, VA). The cells were grown in DMEM (Sigma) containing 10% heat-
inactivated calf serum [HI-CS (Sigma)], 2mM L-glutamine, 0.25 U/mL penicillin, 
and 100mg/mL streptomycin (Gibco, Life Tech).  
 
Human embryonic kidney 293T cells, HEK293T (ATCC CRC 3216) were 
maintained in complete Iscove's Modified Eagle Medium [IMEM (Sigma)] 
containing 10% HI-FBS, 2mM L-glutamine, 0.25 U/mL penicillin, 100mg/mL 
streptomycin and 25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
[HEPES (Invitrogen)]. 
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7.5 Macrophage activation 
Cells were cultured in either DMEM (for BMDMs, RAW 264.7 and J774A.1 cells) 
or RPMI (for thioglycollate elicited macrophages) supplemented with 5% FCS, 2mM 
L-glutamine, 0.25 U/mL penicillin and 100mg/mL streptomycin overnight prior to 
activation with external stimuli in 96 or 24 well plates. Cells were either left 
untreated or stimulated with 20ng/mL of recombinant IL-4 and IL-13 (Peprotech) 
and incubated for various periods of time as appropriate at 37°C with 5% CO2. For 
classical activation, cells were exposed to 100ng/mL of LPS (Escherichia coli 
0111:B4; Sigma Aldrich) or medium alone for the desired time period. Following 
treatment, supernatants were harvested for ELISA and cells washed with cold PBS 
before being processed for FACS analysis and/or lysed for RNA extraction.  
 
 
7.6 Flow Cytometry 
Cells were seeded at a density of 5x105 cells/well in V bottomed 96 well plates 
(Greiner) and centrifuged at 1200RPM for 5 minutes at 4°C. Cells were washed 
twice with 200μL of D-PBS with centrifugation at 1200RPM for 5 minutes at 4°C. 
The  cells were incubated with Aqua live/dead stain (Thermofisher) made up in D-
PBS for 10 minutes at room temperature. Subsequently, cells were incubated on ice 
for 15 minutes with Fc block (CD16/CD32 and neonatal mouse serum) made in 
FACS buffer (PBS supplemented with 2mM EDTA and 0.5% BSA).  Cells were then 
stained on ice for 30 minutes with fluorescence-conjugated antibodies (in FACS 
buffer) of interest that bind to surface markers. The lab has previously determined 
the optimal dilutions of these antibodies. Details of staining panels and antibodies 
utilised to identify different macrophage populations of interest are detailed below. 
For permeabilisation and intracellular staining, cells were washed with 200μL of 
FACS buffer prior to overnight fixation with 2% paraformaldehyde (eBioscience) at 
4°C. Cells were stained with antibodies of interest conjugated to the relevant 
fluorophore in permeabilisation buffer for 45 minutes at room temperature. When 
using biotinylated antibodies, an additional step involving the incubation of cells 
with fluorochrome conjugated streptavidin beads was performed. The cells were then 
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washed twice with permeabilisation buffer wash (eBioscience) followed by a final 
wash in FACS buffer. Finally the samples were resuspended in 50-300µL of FACS 
buffer and acquired on either  LSR  II  (BD Biosciences, USA),  Canto  II  (BD  
Biosciences, USA) or MacsQuant (Miltenyi, Germany) flow cytometers using BD 
FACS Diva software. All data was analysed using the FlowJo software.  
 
Table 7.1 Macrophage populations and surface markers utilised for gating on FlowJo 
software:  





CD11bhi/+ F4/80hi Tim4+ CD11clo/- MHCIIlo/- 





CD11bhi/+ F4/80+ Tim4+ CD11clo/- MHCIIlo/- 
CD11bhi/+ F4/80+ Tim4- CD11clo/- MHCIIhi/+ 
Alveolar macrophages CD11blo/- F4/80+ CD11chi/+ SiglecF+ 
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Table 7.2 Details of antibodies utilised for FACS staining: 
 
Antigen Conjugate Supplier Clone 
BrdU PE Biolegend BU20a 
CD11b AF780 eBiosciences M1/70 
CD11b AF488 BioLegend M1/70 
CD11b Pacific Blue BioLegend M1/70 
CD11b PECy7 BioLegend M1/70 
CD11c APC BioLegend N418 
CD11c APC eBiosciences N418 
CD11c APCCy7 BioLegend N418 
CD11c BV421 BioLegend N418 
CD11c FITC BioLegend N418 
CD11c PE BioLegend N418 
CD11c PECy7 eBiosciences N418 
CD19 PE Biolegend 6D5 
CD19 BV421 Biolegend 6D5 
CD19 PE Biolegend 6D5 
CD4 FITC BioLegend GK1.5 
CD4 PB BioLegend GK1.5 
CD4 PercP BioLegend GK1.5 
CD45.2 PerCP BioLegend 104 
F4/80 PE eBiosciences BM8 
F4/80 PECy7 BioLegend BM8 
F4/80 PECy7 eBiosciences BM8 
Gr1 FITC eBiosciences RB6-8C5 
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Gr1 PercP BioLegend RB6-8C5 
Ki67 AF488 BioLegend Ki-67 
Ki67 FITC BD Pharm B56 
Ki67 PE BD Pharm BV56 
Ly6C Biotin BioLegend HK1.4 
Ly6C FITC BioLegend HK1.4 
Ly6G AF647 BioLegend 1A8 
Ly6G APC/Cy7 BioLegend 1A8 
Ly6G BV421 BioLegend 1A8 
Ly6G PE BD Pharm 1A8 
Ly6G PercP/Cy5.5 BioLegend 1A8 
MHC class II (I-A/I-
E) 
BV421 BioLegend M5/114.15.2 
MHCII AF780 eBiosciences M5/114.15.2 
MHCII PercP BioLegend M5/114.15.2 
MHCII (I-A/I-E) Pacific Blue Biolegend M5/114.15.2 
Streptavidin AF780 eBiosciences x 
Streptavidin APC BioLegend x 
Streptavidin PercP BioLegend x 
TCR beta Pacific Blue Biolegend H57-597 
Tim4 PE BioLegend RMT4-54 
Zenon Rabbit IgG AF488 Molecular Probes x 
Zenon Rabbit IgG AF647 Molecular Probes x 
Zenon Rabbit IgG Pacific Blue Molecular Probes x 
Zenon Rabbit IgG PE Molecular Probes x 
Ym1 Biotin RnD Labs x 
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7.7 Extraction of RNA 
For whole lung tissue stored in RNA Later, tissue was transferred to a 2mL 
eppendorf containing a stainless steel bead (Qiagen) and 500μL of TRIzol 
(Thermofisher)/Qiazol (Qiagen). The lung tissue was subsequently homogenised 
using a TissueLyser (Qiagen) followed by addition of 500μL of TRIzol/Qiazol. For 
in vitro cell culture and PEC, PLEC and BAL, cells were washed twice with ice cold 
PBS before the addition of 500μL of TRIzol/Qiazol. Cells were incubated with the 
lysing reagent for 10 minutes at room temperature and transferred to 1.5mL 
eppendorfs. Subsequently, 100μL of chloroform was added to the tube and the 
samples were mixed by inversion followed by incubation at room temperature for 2-
3 minutes. Samples were then centrifuged at 11,400RPM for 20 minutes at 4°C. 
Next, the aqueous phase was transferred into fresh eppendorf tubes containing 300μL 
of isopropanol and 2μL of 15mg/mL of GlycoBlue (Ambion). The samples were 
mixed by inversion and incubated at room temperature for 15 minutes followed by 
centrifugation at 11,200RPM for 10 minutes at 4°C. The supernatant was discarded 
and the pellet was washed twice with 70% ethanol. Following the final wash, the 
pellet was air dried at room temperature for 15-20 minutes and finally resuspended in 
30-50μL of RNase and DNase free water (Gibco, Invitrogen). The tubes were 
incubated at 56°C for 10 minutes for the pellet to completely dissolve. The extracted 
RNA was placed on ice immediately or stored at -70°C.  RNA was quantified and 
assessed for purity and quality using NanoDrop ND-1000 (ThermoScientific). In 
some instances, RNA integrity was also determined by urea based polyacrylamide 
gel electrophoresis (PAGE).  
 
7.8 Reverse transcription (RT) and quantitative Real-Time 
Polymerase Chain Reaction (qRT-PCR) 
For experiments involving comparison of RAW 264.7 and J774A.1 cell line 
activation (detailed in Chapter 2), 200ng of total RNA was treated with 50 U Tetro 
reverse transcriptase (Bioline), 40 mM dNTPs (Promega), 0.5μg primers (Roche) and 
RNasin inhibitor (Promega) for synthesis of cDNA for qRT-PCR. This method was 
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used for cDNA synthesis from mRNAs only. The completed reaction was stored at 
4°C to prevent cDNA degradation. Prior to quantification by qRT-PCR, the newly 
synthesised cDNA was diluted 1:5 with RNase and DNase free water. 
 
For all other experiments, reverse transcription was carried out using miScript II RT 
kit (Qiagen). 200ng of RNA in a volume of 6μL (in H2O) from each sample was 
added to a final reaction volume of 10μL containing 2μL of 5x miScript HiFlex 
buffer, 1μL of 10x miScript Nucleics mix and 1μL of miScript Reverse Transcriptase 
enzyme. This method synthesised cDNA from both mRNAs and microRNAs. The 
RT reaction was incubated at 37°C for 1 hour followed by inactivation of the RT 
enzyme at 95°C for 5 minutes. The completed reaction was stored at 4°C to prevent 
cDNA degradation. Prior to quantification by qRT-PCR, the newly synthesised 
cDNA was diluted 1:10 with RNase and DNase free water.  
 
The abundance of transcripts from the genes of interest was measured by real-time 
PCR with the Lightcycler 480 II system (Roche) with a SYBR Green I Master kit 
(Roche) or Brilliant III SYBR Master Mix kit (Agilent) for mRNAs. Kits were used 
according to manufacturer’s instructions. For microRNAs, the miScript SYBR Green 
PCR kit (Qiagen) was utilised. A total reaction volume of 5μL containing 2μL of 2x 
QuantiTect SYBR Green PCR Master mix, 0.5μL of 10x miScript universal primer, 
0.5 μL of 10x miScript specific primer and 0.5 μL of cDNA template and 1.5μL of 
RNase/DNase-free water was used in 384 well plates (Roche). Specific primer pairs 
that were utilised for quantification of microRNAs and mRNAs are described in the 
Table 7.3 below. Primer pairs for mRNA quantification were generated using the 
online Roche Universal Probe Library primer design tool (http://www.roche-applied-
science.com) and purchased from Invitrogen. For microRNAs, custom-made primers 
available at Qiagen were purchased as forward primers. A universal reverse primer 
(Qiagen) for microRNA quantification was used for all reactions.  
 
The temperature profile used for quantification of mRNAs comprised a pre-
denaturation step for 5 minutes at 95°C followed by 45 cycles consisting of 
denaturation for 10 seconds at 95°C, annealing for 10 seconds at 60°C and 
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elongation for 10 seconds at 72°C. For microRNA quantification, a standard protocol 
designed by Qiagen with a longer annealing time of 30 seconds and 55 cycles was 
used. Fluorescence data collection was performed at the end of each elongation step. 
All samples were tested in duplicates and nuclease free water was used as a non-
template control.  
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7.8.1 qRT-PCR data analysis  
PCR amplification was analysed using the second-derivative maximum algorithm 2-
ΔΔCt method (Livak and Schmittgen, 2001). Fold change was calculated as the ratio of 
the relative change between a treated sample and the average of the relative change 
values of naïve/untreated samples. For quantification of mRNAs in some instances, 
relative expression was calculated using a standard curve generated through serial 
dilutions of a pool of all samples. In each instance, expression of the gene of interest 
was normalised to housekeeping genes described in the relevant sections for mRNAs 
and RNU6B for microRNAs. 
 
Absolute quantification of microRNAs was carried out using synthetic single 
stranded RNA oligonucleotides corresponding to the exact mature microRNA 
sequence under consideration (IDT). Synthetic microRNAs were reverse transcribed 
using the Qiagen miScript II RT kit in a manner similar to that described above. A 
standard curve was generated for each microRNA using a dilution series of known 
input amount of the synthetic oligonucleotide. Ct values obtained using a SYBR 
Green based detection system were then plotted against the known logarithmic copy 
numbers of the synthetic microRNA and a standard curve linear equation was 
generated, where Ct = a (Log copy number) + b. An example of the standard curves 
generated is shown in Appendix 6.  
 
Statistical analysis for qRT-PCR (and other) data was carried out using GraphPad 
Prism (Version 6) software. Depending on the group sizes and number of parameters 
in question, the relevant statistical tests such as one-way or two-way ANOVA, 
unpaired two-tailed Student’s t-Test were applied and P-values <0.05 were 
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7.9 Protein Quantification 
7.9.1 Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA kits were utilised for the measurement of RELM-α (Peprotech) and YM-1 
(DuoSet; R&D Systems) proteins in the supernatants.  
 
7.9.1.1 RELM-α 
Carbonate Buffer:  
Solution A: 8.5g NaH2CO3 (or NaHCO3) in 100ml distilled water (1M) 
Solution B: 10.6g Na2CO3 in 100ml distilled water (1M) 
Add 45.3ml of A and 18.2ml of B to 936.5ml distilled water = Carbonate Buffer. 
Check pH and adjust to pH 9.6 if required 
 
Wash Buffer: 
 1x PBS / 0.05% Tween-20 (500 μL tween / litre PBS) 
 
96 well flat bottomed plates (NUNC Maxisorp) were coated with 50μL/well of 
1μg/mL rabbit anti-mouse RELM-α capture antibody (Peprotech) diluted in 
carbonate buffer and incubated overnight at 4°C. The plates were then washed thrice 
with the wash buffer and blocked with 200μL/well of blocking buffer (PBS 
containing 10% FCS) for 2 hours at room temperature. Plates were inverted to 
remove the blocking buffer and samples at appropriate dilutions and standard (0.1-
100ng/mL; Peprotech) were added to the relevant wells. The plates were then 
incubated overnight at 4°C. Subsequently, the plates were emptied and washed thrice 
with wash buffer and 50μL/well of 0.25 μg/mL of rabbit anti-mouse RELM-α biotin 
antibody was added followed by an incubation at room temperature for 2 hours. 
Next, the plates were emptied and washed 6 times with the wash buffer before the 
addition of 50μL/well of 0.5mg/mL streptavidin-peroxidase (KPL) to each well and 
incubation at 37°C for 30 minutes. The plates were then washed 8 times with the 
wash buffer prior to addition of 50μL TMB MicroWell Peroxidase substrate system 
(KPL). Once the reaction developed, it was stopped by the addition of 50μL of 
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96 well flat bottomed plates (NUNC Maxisorp) were coated with 50μL/well of 
1μg/mL rat anti-mouse ECL-F capture antibody diluted in PBS (DuoSet; R&D 
Sytems) and incubated overnight at 4°C. The plates were then washed thrice with the 
wash buffer and blocked with 200μL/well of blocking buffer (PBS containing 10% 
FCS) for 2 hours at room temperature. Plates were inverted to remove the blocking 
buffer and samples at appropriate dilutions and standard (0.01-20ng/mL; Allen lab) 
were added to the relevant wells. The plates were then incubated overnight at 4°C. 
Subsequently, the plates were emptied and washed thrice with wash buffer and 
50μL/well of 0.1μg/mL of goat anti-mouse ECL-F biotin antibody was added 
followed by an incubation at room temperature for 2 hours. Next, the plates were 
emptied and washed 6 times with the wash buffer before the addition of 50μL/well of 
0.5mg/mL streptavidin-peroxidase (KPL) to each well and incubation at 37°C for 30 
minutes. The plates were then washed 8 times with the wash buffer prior to addition 
of 50μL TMB MicroWell Peroxidase substrate system (KPL). Once the reaction 
developed, it was stopped by the addition of 50μL of 0.18M H2SO4. The plate was 
then read at 450nm using a spectrophotometer (Varioskan).  
 
7.9.1.3 Arginase assay 
50µL sample was combined with 50µL 25mM Tris-HCl and 10µL of MnCl2 and 
incubated at 56°C for 10 minutes. Samples were transferred on ice and 100µL of L-
Arginine (pH 9.7) was added before incubating at either 4°C or 37°C for 2 hours. 
Urea was used as the standard (0-20mM). Following incubation, samples and 
standard were placed on ice and 40µl from each transferred to a tube containing 
160µL stop solution (10% H2SO4, 30% H3PO4) and 8µl of Isonitrosopropiophenone 
(ISPF) dye. Samples were boiled at 97°C for 30 minutes and cooled down to 10°C. 
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200µL of each sample was transferred to a 96 well plate and the absorbance 
measured at 540nm using spectrophotometer (Varioskan).  
 
7.9.2 Western Blot 
4x SDS-PAGE loading buffer:  
50mM Tris-Cl (pH 6.8), 12.5mM EDTA, 2% SDS, 10% glycerol, 1% β-
mercaptoethanol and 0.02% bromophenol blue 
 
NP-40 lysis buffer:  
50mM Tris-Cl (pH 7.5), 100mM NaCl, 1% NP40 (IGEPAL), protease inhibitors and 
phosphatase inhibitors (Roche) 
 
10% Ammonium Persulfate (APS): 1gm of APS in 10mL dH2O 
 
Laemmli running buffer (10x), pH 8.3:  
30.3gm Tris, 144.2gm Glycine, 10gm SDS in 1 litre of dH2O 
 
Transfer buffer (10x):  
29gm Tris, 144gm Glycine, 3.7gm SDS in 1 litre of dH2O 
1X buffer prepared with 10% transfer buffer (10X), 20% methanol and 70% dH2O 
 
1M Tris-HCl, pH 6.8: 120gm of Tris dissolved in total volume of 1 litre with dH2O 
 
1.5M Tris- HCl, pH 8.8: 181gm of Tris dissolved in total volume of 1 litre with 
dH2O 
 
Tris-buffered saline-Tween (TBS-T): 10mM Tris-HCl, 100mM NaCl, 0.2% 
Tween-20 
 
Blocking buffer: 5% skimmed milk powder in TBS-T 
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Protein lysates were prepared on ice by washing cells once with cold PBS followed 
by cell lysis using NP-40 lysis buffer containing protease and phosphatase inhibitors 
(Roche). Cell lysates were transferred into eppendorf tubes and placed on ice for 30 
minutes with intermittent mixing by inverting. Cell debris was removed by 
centrifugation at 12,000 x g at 4°C for 15 minutes and transfer of supernatant to new 
tubes. The protein was quantified by BCA assay (Thermofisher) following the 
manufacturer’s protocol. Briefly, a standard curve was generated using bovine serum 
albumin (BSA) with concentrations ranging from 0 to 2,000ng/μL and the protein 
concentrations of samples were calculated using the standard curve as the reference. 
The protein lysates (25-50μg) were mixed with 4x SDS loading buffer and boiled at 
95°C for 5 minutes followed by loading onto a sodium dodecyl sulfate 
polyacrylamide (SDS-PAGE) gel comprising a 12% resolving gel and 5% stacking 
gel. To prepare 30 mL of the resolving gel, 9.9 mL of dH2O was mixed with 12mL 
of 30% polyacrylamide, 7.5mL of 1.5M Tris (pH 8.8), 300μL of 10% SDS, 300μL of 
10% APS and 12μL of TEMED. The gel mixture was poured between the glass slabs 
and immediately overlaid with isopropanol for an even surface. Once the gel 
solidified, the isopropanol was removed and the gel was washed with dH2O. 10mL of 
the stacking gel was prepared with 6.8mL of d dH2O, 1.7ml of 30% polyacrylamide, 
1.25mL of 1M Tris (pH 6.8), 100μL of 10% SDS, 300μl of 10% APS and 10μL of 
TEMED and poured on top of the resolving gel. 
 
Samples were loaded onto the polyacrylamide gel along with a marker [Fermentas 
PageRuler Plus Prestained Protein Ladder (ThermoScientific)]. The gel was run at 
120 Volts for 2 hours at room temperature. The separated proteins on the gel were 
transferred onto a nitrocellulose Hybond EC membrane (Biorad) by wet blot 
procedure. This transfer was carried out at 35 Volts at 4°C overnight. Following 
protein transfer, the membrane was incubated with 5% skimmed milk in TBS-T at 
room temperature to block the membrane. After 2 hours, the blocking buffer was 
replaced with primary antibody diluted in 5% skimmed milk (or 5% BSA where 
relevant) in TBS-T and incubated at 4°C overnight. The membrane was washed three 
times with TBS-T for 10 minutes each and incubated with the secondary antibody 
conjugated to HRP (Horseradish Peroxidase) and diluted in blocking buffer at room 
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temperature for 2 hours. The unbound antibody was removed by washing the 
membrane three times with TBS-T for 10 minutes each. The protein was detected 
using an ECL (Enhanced Chemiluminescent Substrate) based western blotting 
detection system (Pierce, ThermoScientific), X-ray films (Fuji) and a film developer 
(Konica Minolta) in a dark room. 
 
7.10  Transfection with synthetic oligonucleotides 
All procedures carried out involved the reverse transfection of cells wherein cells 
were mixed with the transfection complex prior to seeding in plates designed for 
tissue culture at densities detailed in Table 7.4. RAW 264.7 cells were transfected 
with synthetic mature microRNA mimics or control oligonucleotides (Dharmacon) 
using Lipofectamine-2000 (ThermoFisher).  The constituents of the transfection 
mixture were  based on different well sizes and are described in Table 7.4. Briefly, 
4% lipid mixture was prepared by diluting Lipofectamine-2000 with Opti-MEM 
(ThermoFisher) followed by incubation at room temperature for 5 minutes. This lipid 
mixture was subsequently added drop wise to a new tube containing the 
microRNA/Opti-MEM mixture (1:1). The mixture was incubated at room 
temperature for a further 20 minutes to allow complexing before the addition of cells 
at a desired concentration in antiobiotic-free culture medium to the same tube. This 
mixture containing the synthetic oligos at a final concentration of 25nM was then 
pipetted into each well at a desired volume and concentration in accordance with 
3before being incubated at 37°C with 5% CO2 for 24 hours. The medium was then 
replaced with complete culture medium containing antibiotics for a further 24 hours 
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Table 7.4. Volumes of different reagents utilised (per well) for transfection of 
RAW264.7 cells with synthetic microRNAs depending on plate formats.  
 
 
7.11 Measurement of cell expansion with Carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE) and alamarBlue 
RAW264.7 cells were stained with 5μM of Vybrant CFDA-SE cell tracer dye 
(Invitrogen) according to manufacturer’s guidelines followed by reverse transfection 
with synthetic oligonucleotides (25nM) as described previously. Cells were 
incubated at 37°C with 5% CO2 and analysed for proliferation at 24 hours and 48 
hours post transfection. 4 hours before the end of the incubation period, alamarBlue 
(ThermoFisher) was added to the culture medium (1:10 dilution). Cell expansion was 
analysed by measuring alamarBlue conversion in a FluoStar (BMG Labtech) 
fluorescence plate reader and Vybrant CFDA-SE dilution as a measure of cell 
proliferation by FACS analysis. Data are presented as percentage of control (RISC-
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7.12  3xFLAG-PreScission-6xHistidine (FPH) tag generation  
The FPH tag was generated utilising the annealing and extension of two partially 
overlapping oligonucleotides of ~100nt each. The sequences of these 
oligonucleotides are as follow: 
  
Table 7.5 Oligonucleotides used for the generation of 3xFLAG-PreScission-Histidine 
tag 













3xFLAG – PreScission – 6 x Histidine – S-G-G-G-G-S alpha 
















BamHI – Kozak – Start codon - 3xFLAG-PreScission – 6 x 
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The oligonucleotides were reconstituted in nuclease free water at a stock 
concentration of 100μM. The oligonucleotides were then mixed with New England 
Biolabs Buffer 4 and nuclease free water to achieve a final working concentration of 
25μM in 87μL reaction volume. The mix was incubated at 94ºC for 5 minutes and 
gradually cooled down to 65ºC and incubated at this temperature for 5 minutes to 
anneal the oligonucleotides. Subsequently, the mixture was cooled to a final 
temperature of 37ºC and 2μL Klenow fragment 3’-5’ DNA exo-polymerase (New 
England Biolabs) was added to the tube. 11μL of dNTPs (0.25mM each) were then 
added to the tube, mixed by inversion and incubated at 37ºC for 1 hour.  After 1 hour, 
the polymerase was inactivated by heating the mixture to 75ºC for 20 minutes.  
 
 
7.13 Generation of plasmid constructs 
Restriction sites for BamHI and EcoRV were designed within the oligonucleotides 
and the tag was successively digested with a purification step in between using filter 
columns as outlined by the manufacturer (New England Biolabs). Simultaneously, a 
pCDNA3 construct containing mAgo2 fused with a ProteinA-TEV protease-
Histidine (HTP) tag was digested with the same restriction enzymes and the HTP tag 
was replaced with the new FPH tag with overnight ligation at a molar ratio of 3:1 
(insert:vector) with T4 ligase (New England Biolabs) at 16ºC.  
 
Successful clones were sequenced and subsequently for cloning the FPH-mAgo2 
sequence into the pLVX-EF1α lentiviral construct, the BamHI site upstream of the 
FPH tag in the pCDNA3 plasmid was replaced with an SpeI site through PCR 
amplification. The cycling conditions consisted of the initial denaturation at 95°C for 
2 minutes followed by amplification for 30 cycles comprising 95°C for 30 seconds, 
65°C for 30 seconds and elongation at 72°C for 3 minutes. A final extension step 
consisted of elongation at 72°C for 5 minutes. The PCR product was held at 4°C. 
This was followed by digestion of both the PCR amplified tag containing the SpeI 
site and the pLVX-EF1α vector with SpeI and NotI. The digested fragment was then 
cloned into pLVX-EF1α tag with overnight ligation at a molar ratio of 3:1 
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(insert:vector) with T4 ligase (New England Biolabs) at 16ºC. Successful clones were 
sequenced and transformed into DH5α competent cells to generate glycerol stocks.  
 
7.14 Generation of lentivirus 
 
HEK293T cells were transfected with the pLVX-EF1α-FPH-mAGO2 vector or the 
control pLVX-EF1α vector using calcium chloride transfection. The reagents used 
for this method are as follow: 
 
2x HBS [Hexadimethrine Bromide (Polybrene)] Stock (for 50 ml):  
281mM NaCl (2.81mL from 5M)  
100mM HEPES (1.19 gm) 
1.5 mM Na2HPO4 (weigh 0.1065 gm dissolve in 1 mL and add 100μL)  
Adjust final pH to 7.12, filter sterilize through a 0.22μm filter and store at -20ºC. 
 
2.5M CaCl2 (50 ml):  
13.875gm of anhydrous tissue culture grade, 0.22μm filtered and stored at -20ºC. 
 
1x TE buffer:  
10 mM Tris (pH 8.0, 0.5 mL from 1 M Tris) 
1 mM EDTA (pH 8.0, 0.1 mL from 0.5 M EDTA)  
Dilute 1:10 with dH2O (0.1x TE buffer), 0.22μm filtered and stored at 4
ºC. 
 
Na Butyrate: make a 1000x stock solution (10mM, 0.011gm in 10mL of dH2O) 
0.22μm filter aliquot and store at -20ºC. 
 
pMD2.G-VSV-G (http://www.addgene.org/12259/) envelope vector 
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HEK293T cells were seeded in 10cm2 petridishes at a density of 4.5x106 cells/dish 24 
hours prior to transfection with 16μg of pLVX-EF1α-FPH-mAGO2 vector, 4.5 μg of 
pMD2.GVSV-G (envelope plasmid) and 11.5 μg of psPAX2 (packaging plasmid) 
using the calcium chloride transfection method. The cells were ~90% confluent 
before proceeding with transfection. The plasmid solution was made up to a final 
volume of 562.5μL with 0.1x TE/dH2O in a 2:1 ratio in accordance with the 
reference table above. 62.5μL of 2.5M CaCl2 was then added to this mixture 
followed by drop wise addition of 625μL of 2x HBS solution to the DNA-TE-CaCl2 
mixture while vortexing at full speed under sterile conditions. The petridishes were 
then incubated at 37°C with 5% CO2. 18 hours post transfection, the culture medium 
was replaced with 11mL complete medium  [IMDM supplemented with 2mM L-
Glutamine, 25mM of HEPES, 10% FBS, Penicillin (25 U/mL) and Streptomycin (25 
U/mL)] containing 10μM sodium butyrate. The supernatant was harvested 30 hours 
after media changing (48 hours post transfection) and filtered through 0.22μm filter 
followed by ultracentrifugation at 19,500 rpm at 4°C for 2 hours to concentrate the 
generated lentiviruses. Pellets were resuspended in complete IMEM and stored at -
70°C. 
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7.15 Lentiviral transduction 
Polybrene (1000x solution): Polybrene is a polycation that neutralises charge 
interaction to increase binding between pseudoviral capsid and cellular membrane. 
 
For initial experiments, RAW264.7 cells were seeded 3x105 cells per well in a 6 well 
plate 24 hours prior to transduction. The culture medium was aspirated and cells 
were infected with 1mL of complete DMEM medium containing 4μg/mL polybrene 
(1:1000) and 25μL of the concentrated lentivirus. Alternatively, the lentivirus was 
tittered and cells were transduced with the desired MOI.  Where indicated, RAW 
264.7 cells were seeded in 10cm2 petridishes at 5x106 cells/dish and freshly 
harvested supernatant from HEK293T cells containing the lentivirus was centrifuged 
at 4000 RPM for 10 minutes to remove cellular debris and transferred onto RAW 
264.7 cells following addition of polybrene. The petridishes/plates were centrifuged 
at 500xg for 1 hour at 32°C to enhance transduction. Cells were incubated at 37°C 
with 5% CO2. The media was changed following centrifugation and fresh culture 
medium (complete DMEM) was added. Where appropriate, cells were washed and 
fresh medium was added every hour for 9-12 hours post transduction to remove pro-
inflammatory death inducing molecules. Cells were analysed for ZsGreen1 
expression 24 hours and 48 hours post transduction by flow cytometry.  
 
7.16 Genotyping of miR-378/378* mice 
The REDExtract-N-Amp PCR ReadyMix (Sigma-Aldrich) was utilised for 
genotyping of mice. Ear clips were immersed in 100μL of the Extraction Buffer 
followed by the addition of 25μL Tissue Preparation solution. Samples were mixed 
by inversion and incubated at room temperature for 10 minutes and subsequently 
heated at 95°C for 3 minutes and cooled down to 10°C. 100μL of the Neutralisation 
B solution was added to each sample and mixed by inversion. Samples (DNA 
template) were stored at 4°C or used straightaway for PCR amplification. In a fresh 
tube, 5μL of the REDExtract-N-Amp PCR reaction mix was mixed with 2μL of 
DNA template, 0.5μL each of the forward and reverse primers (listed in Table 7.3) 
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and 2μL of nuclease free water. The samples were then subject to a PCR comprising 
an initial denaturation step at 96°C for 3 minutes followed by 30 cycles of 
denaturation at 95°C for 30 seconds, annealing at 56°C for 30 seconds and 
elongation at 72°C for 30 seconds. This was followed by a final extension at 72°C 
for 4 minutes and samples were stored at 4°C or run on a 2% agarose gel. The 





7.17 Statistical data analysis 
The statistical approach utilised for individual experiments was dependent on the 
parameters under consideration. All statistical analysis was carried out using 
GraphPad Prism (Versions 5 and 6) software. 
For a simple comparison between two groups involving a single parameter such as 
treatment or time, a two-tailed unpaired Student’s T-test was utilised (Mann-Whitney 
test for non-parametric data).  
For analysis involving three or more groups and a single parameter such as treatment 
or time, a one-way ANOVA using means of replicates (biological or technical) was 
utilised (Kruskal-Wallis H test for non-parametric data).  
For analysis involving multiple groups and parameters such as treatment and time, a 
two-way ANOVA using means of replicates (biological or technical) was utilised. 
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Chapter 8: Appendices 
 
8.1 Appendix 1: Expression profiles of other markers associated with 
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8.3 Appendix 3: Expression profiles of ten shortlisted microRNAs in 
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8.4 Appendix 4: Expression profiles of miR-146/b up to 48 hours post 
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8.5 Appendix 5: Specificity of primers for the real time quantification of miR-

























































































































































































































































Taqman miR-146a primer assay
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8.6 Appendix 6: Examples of standard curves generated using synthetic 
microRNA dilutions for the determination of microRNA copy numbers 
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